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PTEN is a tumour suppressor gene on chromosome 10, which has a central role in 
regulation of the phosphatidylinositol-3-kinase (PI3K) cell signalling pathway which 
has been linked to cell proliferation and apoptosis. Previous studies have shown that 
loss of PTEN induces leukaemogenesis by generating leukaemia stem cells and 
depleting haematopoietic stem cells. Phosphoinositide-dependent kinase-1(PDK1) is 
considered as a critical kinase in the PI3K signalling pathway and is responsible for 
mediating the phosphorylation of AKT and a wide range of other kinases that inhibit 
apoptosis. Given the important role of PI3K signalling in proliferation and apoptosis, 
we hypothesized that targeting of key components in this pathway such as PDK1 
might be of therapeutic value in the treatment of loss of PTEN driven AML, ALL and 
other cancers. The main objective of this study is to investigate the role of PTEN and 
PDK1 in leukaemogenesis and normal haematopoiesis. We generated conditional 
knockout mice (PTEN fl/fl Rosa-cre-ERT), PDK1 (PDK1 fl/fl Rosa-cre-ERT) and 
PTEN-PDK1 (PTEN fl/fl PDK1 fl/fl Rosa-cre-ERT) where gene deletion can be 
mediated by tamoxifen treatment. To restrict the deletions to the haematopoietic 
compartment, bone marrow cells from the KO mice were transplanted to recipient 
mice and then treated with tamoxifen.  Using these mouse models, we compared the 
impact of PTEN, PDK1 or both deletions on haematopoietic development from early 
HSCs to restricted progenitors. Further analysis using two specific knock-in (KI) mice 
(PDK1 L155e MG and PDK1 K465e) was carried out to further elucidate the activity 
of PDK1. In these models, PDK1 L155e MG mice have disrupted PDK1-PIF pocket 
domain whereas the PDK1 K465e have a defective PDK1-PH domain. These two 
domains are critical for the distinctive function of PDK1. Consistent with previously 
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published data, our data showed that loss of PTEN perturbed the normal 
haematopoietic development. Simultaneous deletion of PTEN and PDK1 rescued 
some of the abnormalities caused by PTEN deficiency suggesting that PDK1 may play 
a crucial role in haematopoiesis.  We further demonstrate that loss of PTEN in the 
haematopoietic compartment results in the development of AML or ALL and in some 
cases both AML and ALL consistent with previous published data. In addition, we 
demonstrate that simultaneous deletion of PTEN and PDK1 does not completely 
reverse the leukaemogenesis induced by PTEN deletion; however it was able to 
significantly delay the onset of AML. Moreover, deletion of PDK1 in PTEN deficient 
haematopoietic cells rescued the mice from developing ALL in both PTENfl/fl 
PDK1fl/fl Rosa-26cre-ERT mice and PTEN fl/fl PDK1 fl/fl Vav-cre mice. PDK1 
MGK465 and PDK1L155 mutation did not have any effect on the phenotype of the 
leukaemia mediated by loss of PTEN, however both mutants significantly reduced the 
leukemic stem cell frequency of PTEN null ALL stem cells. Our data further suggest 
that the mechanism of leukaemia in the compound PTEN PDK1 KO might be due the 
ability to bypass the normal activation of Akt through PDK1 when PTEN is deleted. 
Further studies need to be carried out to identify the mechanism or cross talk that by 
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Chapter 1 Introduction 
1.1 Normal haematopoiesis and haematopoietic stem cells 
 
Haematopoiesis is a process that generates and sustains all the blood cells of different 
lineages in the body. It is hierarchically organised with the haematopoietic stem cells 
(HSCs) at the apex possessing self-renewal properties and the ability to give rise to all 
progenitors and mature blood cells (Quesenberry et al., 2014).  The self-renewal 
ability of HSCs may be achieved by undergoing an intrinsically asymmetric cell 
division whereby cell fate determinants are segregated into only one of the two 
daughter cells. While one daughter cell remains an HSC, the other daughter cell will 
proliferate to produce immature progenitors that gradually further differentiate into 
progenitor cells that are more lineage restricted and have lost self-renewal capability 
(Blank et al., 2008). However during developmental stage or injury additional self-
renewal strategies that forcefully control the number of stem cells may permit them to 
undergo symmetric cell division to produce two daughter cells destined to the same 
fate, ie two HSCs or two differentiated cells (Morrison and Kimble, 2006) . The 
lineage restricted progenitors further proliferate and differentiate into mature 
functional blood cells (Yeung and So, 2009).  
Several technological advances over the last few decades including the generation of 
monoclonal antibodies and fluorescent activated cell sorting (FACS) were 
instrumental to isolate phenotypically different haematopoietic cell populations. 
Functional characterization of the different cell types in the adult haematopoietic 
system (Fig 1.1) are based on results from in-vivo transplantation assays that 
demonstrated the ability of HSC’s but not committed progenitors to fully reconstitute 
a lethally irradiated mouse. In addition, several in vitro differentiation assays were 
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made possible to further characterise haematopoietic cells by the discovery of 
haematopoietic growth factors (Robert-Moreno et al., 2008, Morgan et al., 2008). 
These studies demonstrated that Notch induction by adding soluble Jagged1 ligand to 
ex vivo cultures of human CD34+CD38−Lin− cord blood or incubating murine BM 
Lin−Sca1+cKit+ (LSK) cells with a fusion protein containing the Dll1 ligand can 
expand haematopoietic progenitors as well as stem cells. In vitro expansion of these 
progenitor populations resulted in gain of function that allowed short-term 
hematopoietic reconstitution in mice following transplantation. The HSCs which 
possess unique combination of self-renewal and multi-lineage potential can be 
classified into long term or short term HSCs depending on their functionality. Long 
term HSCs (LT-HSCs) are characterised by their ability to provide long term multi-
lineage reconstitution in a lethally irradiated mouse and reconstitute a secondary 
recipient mouse upon serial transplantation whereas short term HSCs (ST-HSCs) 
provide a short term reconstitution for many months after transplantation but cannot 
reconstitute a secondary recipient mouse (Yeung and So, 2009). All HSCs reside in 
the LSK (Lin- Sca1+ c-Kit+) compartment in the murine (Fig 1.2)  bone marrow and 
do not express mature cell surface markers such as CD19 and B220 found on B 
lymphoid cells, CD4, CD3 and CD8 found on the T lymphoid cells, Mac1 and CD15 
expressed on the macrophages and Gr1 found on the granulocytes (Doulatov et al., 




Figure 1.1: Schematic diagram of murine haematopoiesis 
The HSC is located at the apex of the haematopoietic system and is the origin of all haematopoietic 
cells. Mature and functional blood cells are produced through a series of progressive proliferative and 
differentiation steps of the haematopoietic stem cells. All these proliferation and differentiation steps 
in normal haematopoiesis are tightly controlled and disturbances to this balance may result in 
haematological malignancies 
 
Further functional analysis of the LSK population not only revealed the refinement of 
HSCs into LT-HSCs and ST-HSCs (see Table 1.1), but also identified non self-
renewing multipotent progenitors (MPPs) downstream of HSCs (Fig 1.2). Signalling 
lymphocytic activation molecule (SLAM) family markers can be used to enhance the 
purification of mouse HSCs. SLAM family markers CD150 (also known as Slamf1) 
and CD48 (Slamf2)  showed that LT-HSCs and ST-HSCs were enriched in the 
CD150+CD48-  and CD150-CD48- fraction respectively while the MPPs are found in 
the CD150-CD48+ within the LSK compartment (Cai et al., 2011). More recently, 
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another population known as the LMPPs (lymphoid primed multipotent progenitors) 
has been found in the LSK compartment downstream of the MPPs (Yang et al., 2005, 
Doulatov et al., 2012). The LMPP population was identified as a more restricted 
progenitor within CD150-CD48+ population (Yilmaz et al., 2006a) that was positive 
for the surface marker FLT3 (Iwasaki and Akashi, 2007) (see table 1). LMPPs were 
able to give rise to cells of the myeloid and lymphoid lineages but had little or no 
potential to produce megakaryocytes and erythrocytes (Adolfsson et al., 2001).  
Table 1.1 HSC and progenitor population in a normal adult mouse 
 
 





Figure 1.2: Classification of subpopulation of HSC 
The HSCs are contained in the Lin-/lo Sca1+c-Kit+ (LSK) fraction of the bone marrow. Forward scatter 
(FSC-A) and side scatter (SSC-A) gates are set to remove debris. The PI gate is set to select live cells 
from dead cells. Sca1 and c-Kit positive cells are gated from the Lin- cells fraction. LSKs are further 
classified into LT-HSCs and ST-HSCs MMPs and LMPPs by CD150 and CD48 expression. LT-HSCs 
to be enriched in the CD150+CD48- and ST-HSCs enriched within CD150-CD48- while the MPPs are 
found in the CD150-CD48+ within the LSK compartment. 
 
The haematopoietic hierarchy branches to CMP (common myeloid progenitors) and 
CLP (common lymphoid progenitors) while CMPs give rise to 
megakaryocyte/erythrocyte progenitors (MEPs) or GMPs (Granulocyte macrophage 
progenitor); GMPs can also be derived from LMPPs.  These progenitor populations 
are found in the lineage negative, Sca-1 negative and c-Kit positive fraction of the 
mouse bone marrow and make up to 20% of the total bone marrow cells (Yeung and 
So, 2009). Further classification of CMPs, GMPs and MEPs can be differentiated 
using CD34 and CD16/32 cell surface markers (Fig1.3). While CMPs are 
CD34+CD16/32lo, GMPs are CD34+CD16/32hi and MEPs are CD34-CD16/32lo (Table 
1.1). On the other hand CLPs give raise to lymphoid restricted lineages known as pro-
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B lymphoid cells and pro-T lymphoid cells. These will subsequently give rise to 
mature T cells, B cells and natural killer (NK) cells. CLPs constitute about 0.28 % of 
the total bone marrow cells and are enriched within the Lin-/lo IL-7Rα+Sca-1lo c-Kit lo 
compartment (Fig 1.4).  
 
 
Figure 1.3: Classification of myeloid progenitor populations 
The progenitor population is found in the lineage negative, Sca-1 negative and c-Kit positive fraction 
of the mouse bone marrow and make up to 20% of the total bone marrow cells (Yeung and So, 2009). 
Further classification of the progenitor population into CMPs, GMPs and MEPs can be made using 
CD34 and CD16/32 cell surface markers. While CMPs are CD34+ CD16/32lo, GMPs are CD34+ 







Figure 1.4. Classification of common lymphoid progenitors (CLP).   
CLPs can be classified  as Lin–/lo IL-7Rα+Scaloc-Kitlo cells and constitute 0.02% of the bone marrow 
(Yeung and So, 2009)         
           
1.1.1 Pathways critical for haematopoiesis 
 
Haematopoiesis is a tightly regulated process in which self-renewal, cell proliferation, 
differentiation and cell survival are maintained by several pathways and master 
regulators such as Bmi-1, Hox, p53 and p21, Wnt, Notch, Hedgehog, Raf/MEK, ERK 
and PI3 kinase pathways. Consistently, mutations in these pathways and master 
regulators may perturb the normal haematopoiesis process leading to various 
haematopoietic malignancies.  Bmi-1 protein belongs to Polycomb Group (PcG) 
family and it is expressed mainly in the immature HSC population (Raaphorst, 2003, 
Park et al., 2003). Bmi-1 is necessary for the self-renewal of HSCs and it has been 
shown that Bmi1- knockout mice have defective haematopoiesis and develop 
hypocellular bone marrow (Park et al., 2003).  In mammals, clustered homeobox 
(Hox) genes are organised in 4 clusters (HoxA to HoxD) and are tightly regulated in 
the haematopoietic system at each stage in lineage differentiation. Hox genes have 
been found to be frequently mutated and deregulated in haematopoietic malignancies 
(Eklund, 2011, Alharbi et al., 2013). Individual Hox genes seem to have diverse effect 
on haematopoiesis. For instance over expression of HoxA10 in mice results in 
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selective expansion of megakaryocytic cells with reduced monocytic and B-lymphoid 
progenitors (Borowitz et al., 1997), whereas over expression of hoxb4 results in the 
expansion of HSCs (Antonchuk et al., 2002). 
The Wnt/β-catenin signalling pathway has been implicated in the regulation of 
haematopoiesis, however, different approaches by different laboratories yielded 
controversial and sometimes contradictory data, resulting in an incomplete picture of 
the actual role of Wnt/β-catenin in haematopoiesis (Staal and Luis, 2010). Wnt 
proteins fall under a large family of 19 soluble glycoproteins that have a wide range 
of effects on haematopoietic progenitors and haematopoietic stem cells. Although the 
Wnt/β-catenin pathway regulates self-renewal of various tissue stem cells and is active 
in HSCs (Perry et al., 2011), β-catenin itself is not required for self-renewal of adult 
HSCs (Cobas et al., 2004, Jeannet et al., 2008). Conversely, over-expression of β-
catenin has also been associated with increased HSC frequency and prevention of 
differentiation (Reya et al., 2003), and was shown to predispose to T-cell lineage ALL 
(Guo et al., 2007).  Moreover, WNT signalling is activated in AML cells by certain 
oncogenic fusion molecules such as PML-RARA or AML1-ETO (Kindler et al., 
2005).  A role for Notch signalling has also been proposed in the regulation of 
haematopoiesis and other tissues. While loss of Notch signalling pathway proteins 
Notch1 and Jagged-1 have been shown to result in defective HSC development at the 
embryonic stage in mice (Robert-Moreno et al., 2008, Kumano et al., 2003), over 
expression of intracellular Notch increased the number of HSCs, HSC self-renewal 
and favoured lymphoid over myeloid development (Stier et al., 2002). Moreover, 
Notch mutation has been suggested to be the main oncogenic lesion in T-ALL 
(Maillard et al., 2004).  
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The phosphotidyl-inosital-3 kinase (PI3K)/AKT pathway has also been linked with 
the regulation of haematopoiesis. The PI3K pathway is normally activated by the 
binding of ligands to receptor tyrosine kinases such as Fms-like tryrosine 3 (FLT3), 
c-Kit and is constitutively activated (without the need of ligand binding) by mutations 
of e.g. FLT3 such as FLT3-ITD. Consequently, FLT3 is one of the most frequent 
mutations in AML (Zeisig et al., 2012). Moreover, loss of PTEN, a negative regulator 
of the PI3K pathway leads to the generation of leukemic cells while depleting normal 
HSCs. It has also been speculated the PTEN might play a role in keeping the HSCs in 
a quiescent state (Zhang et al., 2006, Yilmaz et al., 2006b) as well as affecting the 
lineage selection. Furthermore, deletion of other components of the PI3K pathway 
such as AKT1/2, TSC1/2 as well as FOXa1, 2 and 3 in mouse HSCs has been shown 
to cause defects in HSC development (Warr et al., 2011).  
 
1.2 Leukaemia and Leukemic stem cells  
 
Leukaemia, generally classified as myeloid or lymphoid depending on the lineage 
involved and as acute or chronic based on the stage of differentiation of the malignant 
cells. Hematopoietic stem cells have self-renewal properties that allow them to persist 
throughout life. These self-renewal mechanisms are controlled by a system of master 
regulators that are often proto-oncogens and tumour suppressors (Zhang et al., 2009). 
Cancer cells hijack these mechanisms allowing them to transform into immortal cells 
that are able to self-renew just like HSCs. Interestingly, not all cancer cells within a 
cancer are equal. Data from several investigations has provided evidence suggesting 
that in any given cancer there is a variable fraction of phenotypically distinctive cell 
populations (e.g. AML 1/540 to Melanoma 1/3) that are more primitive compared with 
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the bulk of the tumour cells and exhibit properties similar to stem cells, i.e. self-
renewal and differentiation (Grove and Vassiliou, 2014). Moreover, these rare and 
more primitive cells are often enriched for leukaemia initiating cells and are thus 
called leukemic stem cells (LSC).  
In general, leukaemia is characterised by unrestrained proliferation of white blood 
cells in the bone marrow and these cells can be arrested at different stages of 
differentiation. Furthermore, LSC were first functionally identified and characterized 
in leukaemia by  separating LSCs from the bulk of acute myeloid leukaemia (AML) 
cells and demonstrating that these cells resided only in the CD34+CD38- population 
(Bonnet and Dick, 1997). While CD34+CD38- fractionated patient cells  were able to 
engraft into lethally irradiated non-obese diabetic-severe combined immunodeficient 
(NOD-SCID) mice and proliferate to repopulate the bone marrow of recipient mice 
with leukemic cells, mice injected with other CD34 CD38 populations failed to 
develop leukaemia (Dick, 2008). Although the exact LSC fraction may differ from 
patient to patient and may also depend on the mouse model used (Bonnet and Dick, 
1997), these studies provide evidence of the existence of LSCs as the leukaemia 
initiating cells. The LSC model is clinically relevant as it can help to understand the 
high rates of both incomplete remission and more importantly relapses seen in the 
majority of leukaemia patients.  While current chemotherapeutic agents target highly 
dividing cells both normal and cancerous, it has been shown that the LSCs may reside 
in the bone marrow microenvironment where they  remain quiescent at G0 stage 
(Guan, Gerhard et al. 2003; Ishikawa, Yoshida et al. 2007) and thus evading the 
treatment and cause relapse after treatment(Sauer et al., 2015). Indeed, a better 




While LSC clearly share properties with normal HSC such as self-renewal and the 
ability to generate differentiated progeny, the cellular origin of LSC is unknown. 
Murine studies suggest that HSCs as well as myeloid restricted progenitors that have 
lost self-renewal capability can be transformed by chimeric proteins found in patients 
(So et al., 2003, Cozzio et al., 2003, Huntly et al., 2004, Sauer et al., 2015) to initiate 
leukaemia in lethally irradiated recipient mice. However, this is not a universal 
property, as not all oncogenic fusion proteins have the capacity to transform myeloid 
restricted progenitors to LSCs. For instance, BCR-ABL, the result of the t(9:22) 
translocation can only transform murine HSCs but not myeloid progenitors (Fig 1.5). 
 
 
Figure 1.5: Schematic diagram of leukaemia stem cell origins.  
Some oncogenic fusion proteins are able to transform normal HSC to LSC. Interestingly some other 
oncogenic fusion found in AML such as the MLL-Gas7 and MLL-ELL are transform HSC as well 
progenitors to LSCs. In general leukaemia can be viewed as haematological events initiated by a 







1.2.1 Acute Leukaemia   
 
In contrast to chronic leukaemia that develops slowly over a number of years, acute 
leukaemia progresses rapidly and aggressively thus making early diagnosis and 
immediate treatment imperative. Acute leukaemia can be further classified into three 
subgroups: acute lymphocytic leukaemia (ALL), acute myeloid leukaemia (AML) and 
acute biphenotypic leukemia (ABL) depending on the expression of surface markers 
from the lymphoid and myeloid lineages.  
 
1.2.2 Acute lymphoblastic leukaemia (ALL)  
 
Acute lymphoblastic leukaemia (ALL) affects both children and adults, but 60% of 
cases occurs at ages < 20 with a peak at ages between 2 and 5 years (Inaba et al., 
2013).  ALL can be separated into two categories depending on the cells involved: T-
ALL (T cell origin) or B-ALL (B cell origin). Advances in immunophenotyping, 
molecular cytogenetics and histology have contributed to a much more precise 
diagnosis and classification of ALL (see next section). More than 50 genetic 
alterations have been identified in ALL patients and gene deletions are among the 
most frequent aberrations (Mullighan et al., 2008). Several other mutations have been 
associated with ALL such as activating mutation in the PI3K pathway as well as the 
Notch1 signalling.   In addition to mutations and deletions, ALL also results from 
chromosomal rearrangements that disrupt genes controlling normal haematopoiesis 
and lymphoid development such as MLL, AML1, MYC. Interestingly, these 
rearrangements result not only in the creation of fusion genes such as TEL-AML1 or 
32 
 
MLL fusions but also in translocations in which a gene (e.g. MYC or BCl-2) is brought 
under the control of immunoglobulin heavy locus or the T-cell antigen receptor gene 
locus in the case of TAL1, TLX1, TLX3 and LYL1 (Inaba et al., 2013). 
 
1.2.3 Classification of ALL 
 
The classification of ALL was first established on the bases of morphologic, 
immunologic and cytogenetic (MIC) presentation of the leukaemia (Szczepanski et 
al., 2003).  It was later revised by the FAB (French, American and British) which 
made recommendation to classify ALL into sub-groups of ALL 1, 2 and 3. The 
inclusion of B- and T-lineage surface marker expression further refined the 
classification of ALL.  While the morphological classification by FAB helped to 
distinguish different types of ALL, it has little clinical or prognostic relevance. Thus 
the WHO advocates, as an alternative, a classification that recognises clinically 
relevant molecular genetic characteristics of these lesions in addition to the 



















Table 1.2 FAB and MIC classification of ALL 
 
 
+, positive ; -, negative; no symbol, not specified by MIC  
Abbreviations; TdT  terminal deoxynucleotidyl transferase 
 
Table1.3. World Health Organization (WHO) Classification of Acute 





1.2.4 Acute Myeloid Leukaemia (AML) 
 
AML occurs at any age accounting for approximately 20% of childhood leukaemia 
(Faulk et al., 2014) with increasing incidence in older adults. Both de novo as well as 
secondary AML (sAML) resulting from either the progression of other myeloid 
proliferative disorder such as myelodysplasia or the treatment of an unrelated 
neoplasm with topoisomerase II inhibitors has been described (Kumar, 2011). With 
the exception of t(15;17) PML-RARA subtype of AML for which overall survival 
rates of more than 5 years can be achieved for up to 80% of patients, the survival rates 
for all other subtypes is far worse. Chromosomal aberrations are found in about half 
of the AML patients and often involve transcription factors such as MLL, RARA and 
core binding factors (CBFs). In contrast to ALL, the recurrent translocations in AML 
result exclusively in the generation of chimeric fusion genes. While the other half of 
AML patients appears to possess a normal or complex karyotypes, next generation 
sequencing has identified aberrations in these patients that could not have been 
identified using karyotyping and banding, including mutations in signalling genes, 
transcription factors and epigenetic modifiers (Zeisig et al., 2012). Interestingly, 
receptor tyrosine kinases such as FLT3 and c-Kit upstream of the PI3 kinase pathway 







1.2.5 AML classification 
 
Similar to the FAB classification of ALL, the FAB morphological classification in 
AML is only partially useful as it does provide common vocabulary and classification 
of the disease but has little clinical or prognostic relevance. Using the FAB 
classification, AML is confirmed when primitive blast cells are found in excess of 
more than 20% in the bone marrow. More recently, the WHO introduced a 
classification combining cytogenetics and molecular characteristics (Table 1.4). 
Chromosomal translocations leading to a gain or loss of function that affects normal 
haematopoiesis have been identified in over a third of AML patients (Look, 1997) and 
in most cases chromosomal translocation occur on genes that encode for transcription 
factors. In fact, the four most common translocations t(15;17) PML-RARA, t(8,21) 
AML1-ETO, inv(16) CBF-MYH11 and t(x;11) MLL fusions make up to 35% of all 
AML cases and have prognostic value. These and other mutations of prognostic 
relevance including mutations in the FLT3, NPM or CEBPA genes have been included 
in the WHO classification. Given that mutations in FLT3, C-Kit and PTEN, a negative 
regulator of the PI3K pathway, are found in over 30% of AML patients (Zeisig et al) 
and mutations of PTEN in over 20% of T-ALL (Palomero et al.). Deregulation of the 
PI3K pathway is a common event in AML and ALL.  Indeed multiple PI3K inhibitors 



















1.3 Overview of the PI3K signalling pathway  
 
The PTEN/PDK1/PI3K signalling pathway, controlling cell proliferation, growth and 
survival has been directly linked with cancer in several studies (Engelman, 2009, He 
et al., 2014, Hashimoto et al., 2014, Elkabets et al., 2013). PI3K pathway is often 
under normal circumstances activated by binding of ligands such as insulin, or platelet 
derived growth factor (PDGF) which will trigger the activation of the corresponding 
receptor tryrosin kinases (RTKs) (Fig 1.6). Likewise, other abundant receptors such 
as the insulin receptor (IR), FLT3 and c-Kit can also trigger the activation of the PI3K 
pathway.  Genetic alterations in the upstream signalling molecules such as the RTK, 
FLT3,IR or c-Kit as well loss of PTEN have been associated with cancers including 
AML (McCubrey et al., 2012). The most critical PI3K proteins implicated in 
tumorigenesis and cell division are those that belong to class 1A which is formed by 
the catalytic subunit p110α and its associated regulating subunit p85 (Hafsi et al., 
2012).  Upon binding of a ligand to the tyrosine receptor kinases or associate receptor, 
a conformational change that allows the binding of p85 via its SH2 domain (Rous-
sarcoma SRC oncogene homology 2 domain) will occur resulting in activation of the 
regulatory subunit. Once active p110α is released from its inhibitor (p85α), it is 
recruited to the plasma membrane (Vogt et al., 2006). Activated p110α phosphorylates 
Phosphotidylinisitil 4,5- biphosphate (PIP2) to Phosphatidylinisitol 3,4,5 triphosphate 
(PIP3) (Hales et al., 2013). PIP3 recruits adaptor and effector proteins 
phosphoinositide-dependant kinase 1 (PDK1) and protein kinase B (PKB/AKT) 
(McManus et al., 2004, Lawlor et al., 2002) . Interaction of PI3K with PDK1 results 
in a conformational change that allows PDK1 to phosphorylate AKT at Thr308 via 
the PH domain. To fully activate AKT, the mammalian target of rapamycin 2 
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(mTORC2) complex (Fig 1.6) is required to  phosphorylate AKT at Ser473 (Hafsi et 
al., 2012) . 
 
Figure 1.6: Schematic diagram of the PI3K pathway 




In addition to AKT, PDK1 has been shown to phosphorylate a wide range of proteins 
known as AGC family kinases. These kinases include isoforms of protein kinase B, 
p70 ribosomal S6 kinase (S6K), p90 ribosomal S6 kinase RSK (Lawlor et al., 2002, 
Carracedo and Pandolfi, 2008).  Activated AKT promotes cell cycle progression and 
cell proliferation through the phosphorylation of targets involved in protein synthesis, 
glycogen metabolism and cell cycle regulation (Kaul et al., 2012). Inhibition of GSK3 
(glycogen synthase kinase 3) by AKT induces cell cycle progression by preventing 
the phosphorylation and degradation of -catenin. GSK3  promotes the translocation 
of -catenin into the nucleus where it forms a complex with different transcription 
factors such as TCF/LEF-1 to drive the expression of several genes that induce cell 
cycle progression such as Cyclin D1 and Myc (Perry et al., 2011).  Inactive GSK3, 
phosphorylated by AKT, also increases glucose transporter Glut4 translocation to the 
plasma membrane by blocking AS160 (a160-kDa AKT substrate that has Rab-
GTPase activity) (Karunanithi et al., 2014) and inhibiting phosphoenolpyruvate 
carboxykinase as well as glucose-6-phosphatase through inactivation of forkhead box 
O (FOXO) resulting in elevated glucose metabolism rate (Burgering, 2008).  Most 
importantly, AKT activates mTOR which plays a critical role in regulating translation 
of proteins and ribosomal biogenesis (Kalaitzidis et al., 2012) by phosphorylating and 
blocking PRAS40 (proline-rich AKT substrate of 40 KDa) that inhibits the activity of 
mTOR. mTOR is a serine/threonine (Ser/Thr) protein kinase with important functions 
in haematopoiesis (Kalaitzidis et al., 2012).The mTOR kinase can be found in two 
multi-protein complexes named mTORC1 and mTORC2 (Fig 1.7).  The mTORC1 
complex is composed of 3 associated proteins, Raptor, PRAS40, and mLST8/GβL 
together with the mTOR catalytic subunit (Kalaitzidis et al., 2012, Harris and 
Lawrence, 2003). The mTORC2 complex however, contains mTOR and 
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mLST8/GβL, but instead of Raptor and PRAS40, it contains the proteins Rictor, 
mSin1, and Protor (Hung et al., 2012, Guertin and Sabatini, 2007). Both complexes 
are thought to be negatively regulated by DEPTOR (Wang et al., 2012). The mTORC2 
is generally associated with the phosphorylation of Akt at S473 (Sarbassov et al., 
2005).  Conversely, Akt phosphorylates mTORC1 after its phosphorylation and 
activation by PDK1 at T308. An alternative activation of mTORC1 is through the 
inhibition of Tuberous sclerosis 1 (TSC1) and Tuberous sclerosis complex  2 (TSC2) 
(Fig 1.6) either by Akt itself or through the Ras/Erk pathway (Manning and Cantley, 
2007) as well as activation by Rheb (Ras-homolog enrichedin brain) through the 
inhibition of FKBP38 which is also known to inhibit mTOR activity (Carracedo and 
Pandolfi, 2008).  
Activated mTORC1 affects translation by phosphorylation of S6 kinase 1 and 2 as 
well as  phosphorylation of 4E-binding protein 1 (4E-BP1) leading to the inhibition 
of eukaryotic translation initiating factor 4E (e1f4E) which has also been 
demonstrated to inhibit apoptotic (Glaysher et al., 2014).  Hyper activation of 
mTORC1 in HSCs can evoke myeloid proliferative neoplasia (MPN) that may 
progress to AML. Mutations that lead to loss of function in the PTEN or TSC1 alleles 
(known inhibitors of mTORC1) or gain of function mutation in Akt and Rheb2 
(known activators of mTORC1) in mouse HSC have resulted in HSC cycling and 
depletion of HSCs while generating leukemic stem cells (LSC) (Kalaitzidis et al., 
2012). In mouse models where  the function of mTOR1 complex was disrupted by 
deleting Raptor  in the bone marrow, the mice developed a persistent and rapid 
pancytopenia, splenomegaly with extramedullary haematopoiesis and disrupted 




In addition, loss of Raptor led to increase frequency of both BM CD48+CD150+-, and 
CD48+CD150− cells, while CD48−CD150+FLT3−CD34−-LT-HSC were largely 
unaffected.  Interestingly mTORC1 loss via homozygous Raptor ablation is sufficient 
to extend survival in mouse models of PTEN loss evoked leukemogenesis in a cell-
autonomous manner (Kalaitzidis et al., 2012). In mouse models where loss of mTOR2 
was induced by ablation of Rictor all mice did not develop any signs of illness over 
the given period of time and showed no significant differences in bone marrow 
cellularity, HSC frequency, or absolute HSC numbers  (Magee et al., 2012). While 
inhibitors of mTORC1 have been shown to be promising in cancer therapy (Guertin 
and Sabatini, 2009), it has also been demonstrated that substances such as rapamycin 
inhibiting mTORC1 have little or no effect on mTORC2, suggesting that mTORC1 
and mTORC2 might be independently regulated.  
 
Figure 1.7: Schematic representation of mTOR 2 and mTOR 1 complexes 
The mTORC1 complex is composed of 3 associated proteins, Raptor, PRAS40, and mLST8/GβL 
together with the mTOR catalytic subunit. The mTORC2 complex however, contains mTOR and 
mLST8/GβL, but instead of Raptor and PRAS40, it contains the proteins Rictor, mSin1, and Protor 




1.3.1 Regulators of the PTEN/PDK1/PI3-Kinase signalling pathway 
 
The prominent role of the PI3K pathway in cancer development strongly suggests that 
it is regulated by proteins with proto-oncogene or tumour suppressor functions. One 
of the most important tumour suppressors in this pathway is PTEN which is perhaps 
the main negative regulator of this signalling cascade. Loss of PTEN leads to 
uncontrolled PI3 kinase pathway signalling. PTEN itself is regulated at the 
transcriptional and post-translational level. Interestingly, part of its transcriptional 
regulation involves a negative feedback loop in which the transcription factors NF-κB 
and PPARβ/δ repress PTEN mRNA transcription and are themselves downstream of 
PI3 kinase signalling (Han et al., 2008, Barber et al., 2006). On the other hand, PTEN 
is also regulated at the post-translational level through ubiquitinlation- dependant 
degradation induced by the NEDD4-1, the only known ubiquitin E3 ligase for PTEN 
(Trotman et al., 2007). Moreover, NEDD4-1 mediated ubiquitination of PTEN allows 
it also to shuttle to the nucleus, whereas PI3K promotes the exclusion of PTEN from 
the nucleus (Shi et al., 2012), suggesting that PTEN activity is also regulated by its 
subcellular localization.  
Another critical regulator of the PI3 kinase pathway is the tumour suppressor protein 
PML (promyelocytic leukaemia). PML was first identified as a component of PML-
RARα fusion protein, the dominant initiating cytogenetic abnormality in acute 
promyelocytic leukaemia (Nakahara et al., 2014, Gamell et al., 2014). Recent studies 
have shown that PML is  involved in various cell processes including  regulating the 
DNA-damage response, apoptosis, senescence, and angiogenesis (Maarifi et al., 
2014). In addition, PML has been reported as a regulator of metabolic pathways in 
stem cell compartments, including the hematopoietic system (Nakahara et al., 2014). 
44 
 
PML has been shown to affect apoptosis by recruiting PP2A phosphatase to the 
nucleus where it dephosphorylates and inactivates Akt residing in the nuclear bodies 
(Mazza and Pelicci, 2013). Inactivation and nuclear expulsion of Akt, has a 
considerable effect on functional properties of many tumour suppressor proteins such 
as FOXO3a.  Absence of Akt allows for normal function of FOXO3a which is 
otherwise phosphorylated (at multiple serine and threonine residues) and deactivated 
by active nuclear Akt subjecting FOXO3a to degradation (Chatterjee et al., 2013). 
Repressed activity of FOXO3a results in the uncontrolled cellular proliferation 
coupled with reduced apoptosis.  Deletion of PML gene by homologous 
recombination is not embryonic lethal and mice survive normally. However PML null 
HSCs have defective cell growth and differentiation (Nakahara et al., 2014). The PI3K 
pathway is also regulated through negative feedback from downstream effectors.  The 
most well-known feedback regulating the PI3K pathway is triggered downstream of 
the mTORC1. Constant stimulation of the PI3K pathway has been shown to induce 
the phosphorylation of adaptor protein IRS 1 (insulin receptor substrate) leading to its 
proteasomal degradation. IRS is one of the adaptor proteins recruited to the RTKs 
during activation of the PI3K pathway.  IRS1 transmits various key extracellular 
signals such as insulin and insulin-like growth factor (IGF) to downstream factors, 
subsequently activating intracellular signalling including the PI3 kinase pathway 
(Shen et al., 2014). IRS 1 is also regulated by S6K1 phophorylation, as phosphorylated 




Figure 1.8: Feedback mechanism that counteract stimulation of PI3K.  
An mTORC1/S6K-dependent negative feedback loop restraining IRS1-PI3K signalling.  
1.3.2 Role of PTEN in tumorigenesis  
 
While truncation, deletions or transcriptional silencing resulting in the loss of function 
of the tumour suppressor gene PTEN have been reported in several cancers (Dean et 
al., 2014, Ciuffreda et al., 2014, Cordes et al., 2013, Seront et al., 2013, Shuch et al., 
2013, Chowdhury et al., 2013), specific mutations affecting the catalytic domain or 
ubiquitinlation site have also been associated with the development of malignant 
tumours (Trotman et al., 2007). Loss of PTEN leads to cell cycle check point failure 
therefore altering cell cycle kinetics as well as stimulating growth through the 
activation of the PI3K/Akt cascade (Gupta et al., 2009) . On the other hand over 
expression of PTEN can lead to reduced cell proliferation by arresting the cell cycle 
during the G1 to S phase transition and also by inducing apoptosis due to reduced Akt 
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activity (Steelman et al., 2004) . PTEN mutations have been associated with various 
diseases including cancers. While PTEN mutation has been reported in more than 80% 
of patients with Cowden syndrome, a rare autosomal dominant inherited disease 
characterized by tumour-like growths and an increased risk of breast, thyroid, and 
endometrial cancer (Steelman et al., 2008), a pivotal role for PTEN has also been 
described in asthmatic bronchial inflammations (Kwak et al., 2003). PTEN is one of 
the most commonly lost tumour suppressors in human cancer with mutations rates of 
up to 50% in ovarian and endometrial cancers, up to 20% in endohyperplasia cancers 
(Steelman et al., 2004).  
Recently, loss of function of PTEN has also been linked to leukaemogenesis. PTEN 
has been found to be mutated in human adult leukaemia but rarely in early childhood 
leukaemia (Magee et al., 2012).   Deletion of PTEN from adult mouse hematopoietic 
cells has been shown to activate the PI3 kinase pathway leading to hematopoietic cell 
proliferation, depletion of HSC and leukaemogenesis (Zhang et al., 2006, Yilmaz et 
al., 2006b). Loss of function of PTEN has been frequently associated with T-ALL and 
albeit less often also with AML due to mutations or promoter methylation (Medyouf 
et al., 2010, Gutierrez et al., 2009), but is rarely seen in B-ALL which commonly 
presents in children. Given the contrasting role of PI3K pathway in various 
haematological malignancies and age of the patient, it has been speculated that the 
PI3K pathway may be differentially regulated during the course of life. Indeed, Magee 
and colleagues (Magee et al., 2012) demonstrated that PTEN is required for normal 
adult haematopoiesis but not for neonatal haematopoiesis using conditional knockout 
mice PTEN fl/fl Mx1–Cre in which PTEN was conditionally deleted after a single 
dose of pIpC at various time points after birth. PTEN deletion did not affect in vivo 
BrdU incorporation at 2 weeks after birth, PTEN- deficient HSCs showed a drift 
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towards increased BrdU incorporation at 3 weeks after birth which was further 
significantly enhanced at 4 and 5 weeks after birth.  Furthermore, PTEN deletion 
induced in 2 week old mice resulted in a >40 fold increase in the number of mobilised 
HSCs in the spleen of mice compared to mice that were 6 weeks old when PTEN 
deletion was induced. On the other hand, when pIpC was administered to 2 days old 
neonate and 6 weeks old adult mice, histological signs of myeloproliferative disorder 
were observed in adult but not in neonatal spleen or liver 2 weeks after injection.   
 
1.3.3 Role of PDK1 in tumogenesis 
 
It has been shown that the interaction of PDK1 with its target proteins occurs at two 
main sites, the PH domain and the PIF domain (Fig 1.8). While the ability of PDK1 
to phosphorylate S6K, SGK and RSK is dependent on the PIF-pocket (Biondi et al., 
2001, Biondi et al., 2000, Collins et al., 2003, Najafov et al., 2012), phosphorylation 
of PKB and Akt is dependent on interaction with the PH domain (Bayascas et al., 
2008, McManus et al., 2004). Activated Akt phosphorylates up to 100 substrates some 
of which inhibit apoptosis such as BAD, procaspase-9 and member of the fork head 
family of transcription factors (FOXO) (Brunet et al., 1999).  Concurrently, Akt has 
been associated with increased resistance to apoptosis induced by TRAIL/APO-2L 
(TNF-Related Apoptosis-Inducing Ligand) (Xu et al., 2010). Furthermore, AKT also 
phosphorylates the transcription factors cyclic AMP response element-binding protein 
(CREB) and IB (IKK) which regulate the expression of genes antagonising cell death 
(Caravatta et al., 2008). The importance of PDK1 in activating certain AGC kinase 
members was demonstrated by findings that mouse embryonic stem cells lacking 
48 
 
PDK1 failed to activate Akt, S6K and RSK whereas these enzymes were fully 
activated in wild type embryonic stem cells in response to stimulation with insulin 
like growth factor (Balendran et al., 2000).  Due to the number and diversity of 
pathways regulated by PDK1, it has been proposed as a key oncogenic driver in some 
cancers (Ferro and Falasca, 2014, Tan et al., 2013). PDK1 has been found to be over 
expressed together with other effectors of PI3K pathway in PTEN deletion induced 
tumours (Chin et al., 2014, Tan et al., 2013).  In addition, PDK1 has been shown to 
be essential for anchorage-independent and xenograft growth of breast cancer cells 
harbouring either PIK3CA or KRAS mutations (Gagliardi et al., 2012). Recently it 
has been reported that PDK1 directly phosphorylates the Polo-like kinase 1 (PLK1) 
which consequently leads to phosphorylation of MYC resulting in cell growth. MYC 
has been shown to be involved in pathways that control of self-renewal. Most 
importantly PDK1 directly activate Akt and mTOR complex 1, which have been 
directly linked to leukaemogenesis and depletion of normal haematopoietic stem cells 




Figure 1.9: Structure and function of PDK1 
The PIF pocket interacts with SGK, RSK and PKC whereas the PH domain interacts with Akt. 
 
1.4 Targeting PTEN and PDK1 in cancer treatment 
 
PTEN and PDK1 are major regulators of the PI3-kinase pathway and mutations or de-
regulation of these proteins are frequently found in cancers. PDK1 contributes to 
cancer cell growth due to its ability to activate a series of signal transducers that are 
involved in promoting cell proliferation and survival. Because of its role, PDK1 has 
been identified as a promising cancer therapy target particularly in PTEN null cancers 
(Bayascas et al., 2005, Khan et al., 2013). Moreover, it has been demonstrated that 
conditional deletion of PDK1 rescues many effects of PTEN deletion in the brain 
(Chalhoub et al., 2009).  In this study conditional deletion of PTEN alone in the brain 
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of mice resulted in macrocephaly, increased neuronal cell size and abnormal 
cerebellar neuron migration and layering, whereas PDK1 single knockout mice 
developed microcephaly (Iwanami et al., 2009). However, when both PTEN and 
PDK1 were knocked out, the mice had normal brain development with normal neuron 
cell size but still showed abnormal cerebellar migration, suggesting that PDK1 can 
rescue some but not all PTEN effects in normal murine brain development.  
Using transgenic mice with the Lck-Cre system which allows PTEN deletion only in 
lymphocytes (Finlay et al., 2009) it was demonstrated that PTEN null mice die of 
lymphoma between 13 and 14 weeks.  These mice had increased levels PDK1-Akt 
signalling indicated by elevated levels of threonine 308 and serine 473 phosphorylated 
Akt in comparison to the wild type mice. To address the importance of PDK1 in 
lymphoma caused by deletion of PTEN, mice that were genetically engineered to 
simultaneously delete floxed PTEN and PDK1 alleles in the T-cell progenitors were 
employed. While all PTEN null mice died of lymphoma, only a few mice with deletion 
of both PTEN and PDK1 developed lymphoma with a longer latency and the majority 
survived without any clinical symptoms of lymphoma, suggesting that PDK1 might 
be essential for the lymphomagenesis caused by PTEN deletion. Taken together, 
although these results show that loss of PDK1 does not entirely inhibit the whole 
spectrum of the aberrant pathology induced by PTEN loss of function, it can 
effectively prolong PTEN null lymphoma in mice, suggesting that PDK1 inhibition 
may be potent therapeutic strategy in PTEN null cancers. Given the involvement of 
PTEN in normal and malignant haematopoiesis, we propose to further dissect the role 




1.4.1 PI3K pathway inhibitors   
 
The PI3K-Akt pathway plays a vital role in cell proliferation and survival. 
Deregulation of this pathway has been reported in many cancers including colon, 
breast, lung and blood malignancies. Targeting this pathway has been shown to be of 
therapeutic value in the treatment of cancer. The first generation inhibitors of the 
PI3kinase LY294002 and wortmannin act as ATP inhibitors. Wortmannin binds to a 
conserved lysine residue in the ATP binding site of the enzyme PI3K therefore inhibits 
its activity (Wymann et al., 1996). LY294002 is a flavonoid derivative which acts as 
a ATP-competitive inhibitor that is also reversible (Wetzker and Rommel, 2004). 
LY294002 can effectively target other enzymes including the serine /therionine 
protein kinase (PIM1), protein-like kinase 1 (PLK1), casein kinase II (CK2) as well 
as ataxia-telangiectasia mutant (ATM) (Ogita and Lorusso, 2011).  Both LY294002 
and wortmannin have be shown to be highly effective PI3kinase inhibitors with anti-
proliferative and apoptotic effect in vivo as well in vitro (Wetzker and Rommel, 2004). 
Moreover treatment of primary AML blasts with LY294002 has been show to induce 
apoptosis in vitro and also impaired engraftment in NOD/SCID mice (Xu et al., 2003).  
However due to the instability, poor solubility and toxic side effects the use of these 
two compounds has only been limited to preclinical application.   
 
Recently other PI3K inhibitors are being studied by a number of academic institutions 
and pharmaceutical companies. Some of these inhibitors include pan-PI3K inhibitors 
targeting all four isoform of class 1 PI3K as well as isoform-selective  inhibitors 
PI3Kα , PI3Kβ , PI3Kγ and PI3Kδ (Massacesi et al., 2016). Although all the four PI3K 
class 1A isoforms are known to be essential for the activation of AKT, p110δ has been 
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shown to be particularly consistently over expressed in AML.  Interestingly, p110δ 
specific inhibitor IC87114 was able to repress the activation of AKT similarly to the 
effect of LY294002 and moreover impaired the proliferation of AML blasts (Billottet 
et al., 2006, Sujobert et al., 2005). Inhibitors targeting AKT directly have also been 
developed and some are already in pre-clinical or early phase clinical trials. AKT 
inhibitors are classified as either alkylysophospholipis (APLs) or small molecule 
inhibitors. (Barrett et al., 2012). APLs mainly act on the cellular membrane of actively 
dividing cells by blocking the recruitment of AKT to the cell membrane where it gets 
activated.  A few AKT small molecule inhibitors have been used in clinical trials 
including GSK2141795, MK-2206 and triciribine (Barrett et al., 2012). Other small 
molecular inhibitors targeting PDK1 which is responsible for the activation of AKT 







Tissue homeostasis and regeneration are tightly controlled processes and their 
disruption contributes to the development of malignancies. Several pathways and key 
molecules such as Bmi-1, Hox, Wnt, Notch, Hedgehog, and the PI3 kinase contribute 
to the regulation of haematopoiesis. The PI3 kinase pathway is frequently found up-
regulated in cancers including acute leukaemia, where mutations in upstream RTKs 
and loss of PTEN have been identified as the main causes for aberrant activation of 
the pathway. Given the crucial role of PDK1 in mediating PTEN functions, we 
hypothesize that PDK1 which relay upstream signals to downstream kinases and 
effector proteins might be a therapeutic target in the treatment of AML and other 
cancers which display activated PI3K pathway activity. Thus we will investigate the 
consequences of loss of PDK1 in the development of PTEN loss mediated leukaemia 
using various genetic mouse models. The main objective will be to define the 
contribution and critical pathways mediated by PDK1 in the establishment of LSCs 
induced by loss of PTEN.  
The aims of my PhD project are 
• To investigate the role of PTEN and PDK1 in leukaemogenesis and normal 
haematopoiesis  
• To explore the origin of the leukaemia stem cells generated by loss of PTEN. 





Chapter 2 Materials and Methods 
 
2.1 Rosa-26cre-ERT mice 
 
The Rosa-26cre-ERT mice carry a cre recombinase (Cre-ERT2) allele inserted into 
the universally expressed Rosa26 locus. Cre is a 38kDa enzyme that belongs to the 
integrase family of site specific recombinase that catalysis the site specific 
recombination event between two DNA recognition sites (loxP sites). The estrogen 
receptor T2 moiety fused to cre (CRE-ERT2) is retained in the cytosol and suppressed 
by binding with the heat shock protein 90 (hsp90) until tamoxifen administration 
releases its inhibition, thus permitting inducible recombination of loxP sites(Meinke 
et al., 2016). In this study we crossed the Rosa-26cre-ERT mouse with a C57/BL6 
mouse carrying a gene of interest flanked by two loxP sites to generate conditional 
knockout mice.  The following primers (forward 5̍- 
AGATGCCAGGACATCAGGAACCTG-3̍ Reverse 5̍-ATCAGCCACACCA 
GACACAGAGATC3̍) binding the Cre coding regions were used on genomic DNA 
isolated from biopsies to detect the Cre-ERT allele, producing a 400bp PCR product.  
The following PCR programme was used: denaturing at 94ºC for 5 minutes, 35 cycles 
of 94ºC for 30 seconds, annealing at 54ºC for 1 minute, extension at 72ºC for 2 






2.2 Vav-cre mice 
 
Vav-cre-mediated recombination occurs in most hematopoietic cells in all 
haematopoietic organs, including the haematopoietic progenitor-rich bone marrow. 
Vav-cre is a non-inducible cre system that is active mainly in the haematopoietic cells 
with limited activity in the vascular endothelium but not in other tissues (Georgiades 
et al., 2002). We crossed a Vav-cre mouse with a C57/BL6 mouse carrying a gene of 
interest flanked by two loxP sites to generate transgenic mice that lose the expression 
of the gene of interest predominantly in the haematopoietic cells. The following 
primers (forward 5̍-AGATGCCAGGACATCAGGAAC 3̍ Reverse 
5̍ATCAGCCACACCAGACAC AGA - 3̍) binding the cre coding regions were used 
on genomic DNA isolated from biopsies to detect the Cre allele, producing a 210 bp 
PCR product.  The following PCR programme was used: denaturing at 94̊C for 10 
minutes, 35 cycles of 94ºC for 40 seconds, annealing at 62ºC for 40 seconds, extension 
at 72ºC for 50 seconds, final annealing at 72ºC for 5 minutes and hold at 4ºC. 
 
2.3 PTENfl/fl Rosa-26cre-ERT and PTENfl/fl   Vav-cre 
 
We generated conditional PTEN knockout mice using the Rosa-26cre-ERT system as 
well as the Vav-cre system. In the PTENfl/fl mice, exon 5(Fig 2.1A) of the PTEN allele 
encoding the phosphatase domain (Fig 2.1B) is flanked by loxP sites. PTENfl/fl females 
were crossed with males that carry a single Rosa-26cre-ERT or Vav-cre recombinase 
to generate first generation progeny PTENfl/wt Cre+. PTENfl/fl Cre+ progeny was 
achievable on second generation and subsequent generation by mating PTENfl/fl with 
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PTENfl/wt Cre+. Both mouse lines were born without any physical deformation. For 
the analysis of the deletion of PTEN gene at the DNA level, genomic DNA was 
extracted from blood and ear biopsy and amplified by PCR. Forward primer (5̍-
GTGAAAGTGCCCCAACATAAGG-3̍) and reverse primer (5̍-CTCCCACCAATG 
AACAAAVAGT-3̍) were used to detect the wild type (WT) and floxed PTEN alleles 
producing a 428 bp product for the wild type and 514 bp product for the floxed allele. 
For detection of the deleted allele, forward primer (5′-
GGCCTAGGACTCACTAGATAGC-3′) and reverse primer (5′-
CTCCCACCAATGAACAAAVAGT-3′) were used producing a 705 bp product. The 
following PCR programme was used: denaturing at 94ºC for 4 minutes, 35 cycles of 
94ºC for 30 seconds annealing at 60ºC for 30 seconds, extension at 72ºC 30 seconds, 
final annealing at 72ºC for 5 minutes and hold at 4ºC. 
 
Figure 2.1: PTEN conditional knock out 
 (A)Targeting strategy for gene deletion as previously described. Black boxes represented exons and 
the triangles represent Lox P sites. The position of the genotyping primers is represented by red arrows 
labeled a,b,c. (B)  Schematic diagram showing the domains of the PTEN protein. The N-terminal region 
comprises of a PIP2-binding domain (PBD) and a phosphatase domain whereas the C-terminal consists 
of the C2 domain and C-tail. 
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2.4 PDK1fl/fl Rosa-26cre-ERT and PDK1fl/fl Vav cre 
 
We generated conditional PDK1 knockout mice using the Rosa-26cre-ERT system as 
well as the Vav-cre system. In the PDK1fl/fl mice, exon 3 and 4 (Fig 2.2A) which 
encode the kinase domain (Fig 2.2B) were flanked by loxP sites. PDK1fl/fl females 
were crossed with males that carry a single Rosa-26cre-ERT or Vav-cre recombinase 
to generate first generation progeny PDK1fl/wt Cre +. PDK1fl/fl Cre+ progeny were 
achievable on second generation and subsequent generation by mating PDK1fl/fl with 
PDK1fl/wt Cre+. Both mouse lines were born without any physical deformation. For 
the detection of PDK1 at DNA level, DNA extracts from ear biopsy and blood were 
amplified by PCR. The presence of the wild-type and floxed alleles was detected using 
two primers, forward primer (p99), 5′-ATCCCAAGTTACTGA 
GTTGTGTTGGAAG-3′; reverse primer (p100r), 5′-
TGTGGACAAACAGCAATGAAC ATACACGC-3 producing products of 203bp 
and 237bp for the wild type and floxed alleles respectively. For detection of the 
deleted allele, forward primer (p80), 5′-
CTATGCTGTGTTACTTCTTGGAGCACAG-3′; and reverse primer (p100r), 5′-
TGTGGACAAACAGCAATGAACATACACGC-3′were used producing a 250 bp 
product. The following PCR programme was used: denaturing at 94ºC for 4 minutes, 
35 cycles of 94ºC for 30 seconds annealing at 63ºC for 30 seconds, extension at 72ºC 
30 seconds, final annealing at 72ºC for 5 minutes and hold at 4ºC. 




Figure 2.2: PDK1 conditional knock out.  
(A) Targeting strategy for PDK1 as previously described. Black boxes represent exons, triangles 
represent Lox P sites and arrow shows primer position labeled p80, p99 and p100 used for genotyping. 
(B)  Schematic diagram of PDK1 protein showing the PH domain in green and kinase domain in red. 
 
2.5 PDK1L155/L155 Rosa-26cre-ERT  
 
The PDK1 L155E mutant is a conditional knock-in, in which the PIF pocket site of 
PDK1 is disrupted by mutation of Leu-155 to Glu after Cre recombination (Bayascas 
et al., 2006). The straight, unconditional PDK1L155/L155 knock-in is embryonic lethal 
(Cordon-Barris et al., 2016) and therefore the conditional knock-in was generated 
using the minigene approach which allowed the mice to express the wild-type PDK1 
until cre activation.  The minigene containing PDK1 exons 3 to 14 and a neomycin 
resistance cassette is inserted between exons 2 and 3 whereas the mutation of L155 to 
Glu is in exon 4 (Fig 2.3).  The minigene is flanked by loxP sites and will be deleted 
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upon cre recombinase activation resulting in the expression of mutant PDK1. These 
mice were generated using the Rosa-26cre-ERT as well as the Vav-cre system. 
PDK1L155/L155 females were crossed with Rosa-26cre-ERT for the detection of the wild 
type allele and floxed allele we used two primers, forward primer Primers P1 (5’-
GGAATACTCTGTAGACCAGGCTG-3’) and P2 
(GACGTGTCCTAATACTACCACAAGTGGC-3’) producing a 171 bp product for 
the wild type and 212 bp for the L155E allele. The following PCR programme was 
used: denaturing at 94ºC for 4 minutes, 35 cycles of 94ºC for 30 seconds annealing at 
63ºC for 30 seconds, extension at 72ºC 30 seconds, final annealing at 72ºC for 5 
minutes and hold at 4ºC. Using these primers could not confirm the excision of the 
minigene. Therefore, our alternative approach to determine the excision of the 
minigene was to use primers that detect to the neomycin resistance cassette which is 
coupled to the minigene. However, the detection of the neomycin cassette was 
achieved but the results remained inconclusive as the mice were crossed with Rosa-
26cre-ERT mice which also contain a neomycin cassette. DNA isolated from the bone 
marrow of leukaemic mice was sent to Transnetyx INC laboratories for genotyping to 




Figure 2.3: PDK1L155/155 mutant 
Targeting strategy for the L155E mutant as previously described (Collins et al., 2003). The minigene 
with neomycin cassette sequence is flanked by Lox p sites and is excised during Cre-mediated 
recombination. An asterisk represents the position of the L155 mutation on exon. Black boxes represent 
exons, triangles represent Lox P sites and the red arrows shows primer position labeled P1, P2 used for 
genotyping The wild type allele produced and171 bp fragment whereas the PDK1L55MG produce a 




The mutant PDK1 MGK465E knock-in mice were also bred and maintained in the 
C57BL6 background. The PDK1 MGK465E knock-in was generated by mutation of 
Lys465 to a Glu residue. The mutation is in exon 12 which encodes for the PH domain 
of the PDK1 protein (Fig 2.4). This mutation is not embryonic lethal and the mice are 
born without any defects except for their small body size. We crossed PDK1MGK465E/+ 
with another PDK1MGK45E/+ to obtain homozygous mutants. For the detection of the 
mutant allele at DNA level, genomic DNA was extracted from ear biopsy and blood 
samples and subjected to PCR with the following primers: Forward primer (5′-
GGGTGAAGCATGGAATCTGTGTCTT-3′) reverse 
(5′GCCAGGATACCTAAGAGTACCTAGAA) producing a 196 bp product for the 
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wild type and 236 bp for the mutated allele. The following PCR programme was used: 
denaturing at 94ºC for 4 minutes, 35 cycles of 94ºC for 30 seconds annealing at 63ºC 
for 30 seconds, extension at 72ºC for 30 minutes, final annealing at 72ºC for 5 minutes 
and hold at 4ºC. 
 
Figure 2.4: PDK1 PDK1MGK465/MGK465 mutant 
(A) Targeting strategy for the MGK465 mutation as described before (Bayascas et al., 2008) Diagram 
depicting the 3′ end of the endogenous PDK1 gene from exons 12 to 14, the targeting construct 
generated, the targeted allele with the neomycin selection cassette still present (NEO), and the targeted 
allele with the neomycin cassette removed by Cre recombinase. The knock-in allele containing the 
Lys465Glu mutation in exon 12 is marked with an asterisk and can be detected by genotyping using 
PCR primers K465E F and K465E R, which are depicted as arrows. 
 
2.7 Breeding strategies for compound knockout  
 
We generated conditional compound knockout PTENfl/fl PDK1fl/fl with Rosa-26cre-
ERT and Vav-cre. The compound knockout PTEN fl/flPDK1fl/fl Rosa-26cre-ERT was 
generated by crossing PTEN fl/fl Rosa-26cre-ERT males with PDK1fl/fl females 
without cre. First generation pups where expected to be all heterozygous for PTEN 
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and PDK1 with 50% of the pups carrying the Rosa-26cre-ERT allele. Second 
generation progeny was generated by crossing a male with cre and a female without 
cre. PTEN fl/fl-PDK1 fl/fl Rosa-26cre-ERT can be obtained from third generation 
progeny. The conditional compound knockout mice were born viable without any 
physical defects. This mouse line was maintained by crossing PTENfl/fl-PDK1fl/fl 
Rosa-26cre-ERT males with PTENfl/fl-PDK1fl/fl females without cre.   To generate the 
compound knockout mice on Vav-Cre we crossed PTENfl/fl females without cre with 
PDK1fl/fl Vav-cre males. First generation pups were expected to be all heterozygous 
with 50% of the pups carrying the Vav-cre allele.  Second generation progeny was 
generated by crossing a male with cre and a female without Cre. When breeding for 
the compound knock out with the Vav-cre system it was imperative that the mouse 
that carries the Cre was a male because  a recombined gene resulting from constitutive 
expression of the Vav-cre could cause adverse effects and lead to death at an early age 
in mice. Thus, in a breeding pair of mice, only the male but not the female giving birth 
to the offspring would be affected.  The compound Vav-cre line was maintained by 
breeding heterozygous males with Vav-cre and homozygous females without cre. To 
generate the compound PDK1 mutant with conditional PTEN knockout we used a 
similar approach to that used to generate PTENfl/fl PDK1fl/fl Rosa-26cre-ERT. 
PDKL155E/L155E or PDK1MGK465/MGK465 females were crossed with PTENfl/fl Rosa-
26cre-ERT. PDK1L155E/L155E PTENfl/fl Rosa-26cre-ERT and PDK1MGK465/MGK465 
PTENfl/fl Rosa-26cre-ERT mice could be generated on third generation and were 





Figure 2.5: Breeding strategy for PTENfl/fl PDK1fl/fl Rosa-26cre-ERT compound knockout 
The compound knockout PTENfl/flPDK1fl/fl Rosa-26cre-ERT was generated by crossing PTENfl/fl Rosa-
26cre-ERT males with PDK1fl/fl females without cre 
 
2.8 Isolation of Genomic DNA and Genotyping 
 
An ear biopsy was obtained for adult mice, whereas a small piece of the tail or lower 
extremities of the embryo was cut and placed into 1.5 ml centrifuge tubes.  For 
isolation of genomic DNA we used the Hot SHOT method. Depending on the size of 
the tissue, about 50 to 75 µl of the Hot SHOT alkaline lyses buffer (Sodium hydroxide 
solution pH 12) was added to each tube containing the biopsy. To disintegrate the 
tissue pieces, the tubes were incubated at 95ºC for 15 minutes. An equal amount of 
neutralising buffer (40 mM Tris-HCL solution pH 5.0) was added to adjust the pH. At 








As a reference 2 µl of DNA was used for each 20 µl PCR reaction contained 1X Dream 
Green buffer supplemented with 2.5 mM MgCl2 (Fermentas), 0.25 mM dNTP mix 
(Roche), 1μM from each primer and 0.5 unit of Dream TaqTM Green DNA 
polymerase (fermentas). Thirty five cycles of amplification were performed. 
 
2.10 Competitive Bone-marrow Transplantation 
 
 In order to distinguish donor from competitor cells upon transplantation, our 
transgenic mice (donor) were always C57BL6 CD45.2 whereas the recipient mice 
were wild type C57BL6 CD45.1 (SJL). We sacrificed PTENfl/fl Rosa-cre-ERT26ER, 
PDKfl/fl Rosa-cre-ERT26ER, PDK1L155E/L155E Rosa-cre-ERT26ER, 
PDK1MGK465/MGK465, compound PTENfl/fl / PDKfl/fl  Rosa-cre-
ERT26ER,PDK1L155E/L155E/PTENfl/flRosa-cre-ERT26E, PDK1MGK465/MGK465/PTENfl/fl 
Rosa-cre-ERT26ER transgenic mice all C57BL6 CD45.2 (donor) and a wild type 
C57BL6 CD45.1  (rescue cells) by CO2 euthanization and prepared the hind limbs 
using forceps and sharp scissors.  The muscle was removed from the tibia and femur 
from both legs by dissection.   The bone marrow was flushed out with suspension 
media (SM; 0.2% sterile filtered foetal calf serum in PBS) using a 21-gauge needle on 
to a 40 μm nylon cell strainer into a 50ml falcon tube.  Any bone marrow aggregates 
were gently pushed through the cell strainer using a plunger.  The cells were pelleted 
by centrifugation at 1300 rpm for 5 minutes at 4°C.  Once the supernatant was 
removed, the cell pellet was resuspended in 2ml of erythrocyte lysis buffer (10 mM 
KHCO3, 150 mM NH4Cl, 0.1 mM EDTA pH 8.0) for each mouse.  Cells were 
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incubated at room temperature for 10 minutes then 10 ml of cold SM was added before 
the cells were pelleted by centrifugation.  Cells were resuspended in 10 ml cold SM 
and counted using an improved Neubauer Haemocytometer. Each recipient mouse 
received 1 mio donor (CD45.2) and 0.2 mio rescue (CD45.1) cells in a volume of 150 
µl. Transplantation was done by tail vein injection. 
 
Figure 2.6 Experimental approaches for competitive bone marrow transplant assays 
We transplanted  the bulk of bone marrow cells (1 Mio cells) from PTENfl/fl Rosacre26ER, PDKfl/fl 
Rosa-cre-ERT26ER, PDKL155E/L155E RosaCre26ER, PDK1MGK465/MGK465, compound PTENfl/fl/PDKfl/fl 
Rosa-cre-ERT26ER,PDKL155E/L155E/PTENfl/flRosacre26E, PDK1MGK465/MGK465/PTENfl/fl RosaCre26ER 
transgenic mice all C57BL6 CD45.2 together with 0.2 Mio cells from wild type SJL mouse (CD45.1) 
into lethally irradiated mice (CD45.1). 
 
2.11 Blood reconstitution analysis  
 
Peripheral blood was collected from the recipient mice at different time points to 
analyse the reconstitution of blood post-transplantation and after treatment with 
tamoxifen (i.e. 4 weeks post- transplant and 4, 8 and 12 weeks after tamoxifen 
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treatment). Blood was drawn from tail vein by punching the vein with a needle. Blood 
was collected into eppendorf tubes pre-coated with 0.01 M 
Ethylenediaminetetraacetic acid (EDTA) (Sigma). A full blood count was performed 
using a full blood analyser (Mythic 18 Vet). For preparation of samples for FACS, 
blood samples were subjected to red cell lysis as previously described (in 2.10). 
Samples were transferred to BD test tubes for staining.  
 
2.12 General stain 
 
All antibodies used were purchased from Biolegend. Antibodies used were CD45.1 
(FITC cat# 110706), CD45.2 (APC cat# 109514), c-Kit (PE cat# 105808), Mac1 (PE-
Cy7 cat#101216), Gr1 (PerCP/Cy5.5 cat# 108428) , CD4  (Alexa Floor 700 cat# 
100430) , CD8 ( APC-Cy7 cat#100714)  and B220 (Pacific Blue cat# 103277). A 
master mix was prepared by mixing of the antibodies at a ratio 1:1.5:0.5 (1 µl of 
CD45.1 + 1.5µl of CD45.2 and 0.5µl for the rest) per sample. Staining was carried out 
in 100µl reaction in BD FACS tubes. Unstained samples were also prepared as 
controls. Unstained and stained samples were incubated at 4ºC in the dark for 30 
minutes followed by washed with SM then suspended in 200 µl of SM with 1 µg/ml 








2.13 Processing of leukemic mice 
 
Mice showing symptoms of disease (i.e. loss of condition, hunched, heavy 
breathing, etc.) were sacrificed as previously described. Bone, spleen, liver and 
thymus were collected from the mice by dissection and weighed. The bone 
marrow was harvested as previously described. The cells from the other organs 
were harvested by grinding a piece of the organ with a plunger through a strainer 
and collecting into a 50 ml tube. Each sample was subjected to red cell lysis as 
previously described. The total bone marrow count was carried out for each 
mouse. General stain using the previously described antibodies was carried out 
for each organ. The CD45.1 and the CD45.2 was used to distinguish between the 
donor cells and the recipient cells. 
 
Figure 2. 7 Analysis of sick mouse 
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2.14 HSC Analysis 
 
HSC analysis was carried out at different time points to determine the reconstitution 
of the bone marrow post-transplantation and after treatment with tamoxifen (i.e. 4 
weeks post-transplant and 4, 8 and 12 weeks after tamoxifen treatment). Three mice 
from each group at all time points were sacrificed as previously described. Bone 
marrow cells were collected from the tibia and femur as previously described. Cells 
were initially stained with primary lineage unconjugated rat IgG (Ter119, Mac1, Gr1, 
CD3e, CD4, CD8 and B220, Biolegend) at a dilution of 1:40 for each mouse and 
incubated at 4oC in the dark for 30 minutes followed by washing with SM. Cells were 
spun down to a pellet by centrifugation and stained with Texas Red diluted with PBS 
(1:100) for lineage selection. Following 30 minutes incubation cells were washed and 
suspended in 70 µl of blocking antibody rat IgG (Sigma) for another 30 minutes at 
4oC. Finally cells were washed with SM then stained with secondary antibodies (Table 
2.1) and incubated at 4ºC for 30minutes. Stained Cells were washed and resuspended 
in SM with 1μg/ml of propidium iodine (PI). HSC analysis was carried out using 
ARIA cell sorter (BD Bioscience). LSK (Lin–/lo Sca1+c-Kit+), LT-HSC (Lin –/lo 
Sca1+c-Kit+CD150+CD48-), ST-HSC (Lin –/lo Sca1+c-Kit+CD150-CD48-),  LMPP 
(Lin –/lo Sca1+c-Kit+CD150-CD48+), CMP (Lin–/loSca1–c-Kit+CD34+CD16/32lo), 













Table 2.1 Secondary antibodies and their dilutions that used to stain 









0.1-1x106 cells were washed twice with cold PBS in FACS tubes and centrifuged for 
5 minutes at 300 g. The supernatant was aspirated and cells were resuspended in 200 
µl of PBS and fixed by 70% cold ethanol for at least 1 hour at 4ºC. The fixed cells 
washed twice with cold PBS and stained with 200 µl of PI stain (PBS: 0.2X FBS, 
40ug/ml RNase (Sigma), 40 µg/ml PI (Sigma) for 30 minutes at 4ºC in a dark place. 




2.16   HSC and Progenitors Sorting 
 
Mice were sacrificed as previously described. Bone marrow cells were collected from 
the tibia and femur as previously described. Bone marrow cells were isolated from 
five wild type C57BL6 CD45.2 mice or transgenic C57BL6 CD45.2 mice after 
treatment with tamoxifen for 5 days to induce gene deletion.  Pooled cells from the 
five mice were initially stained with primary lineage unconjugated rat IgG (Ter119, 
Mac1, Gr1, CD3e, CD4, CD8 and B220, Biolegend) at a dilution of 1:40 and 
incubated at 4oC in for 30 minutes followed by washing with SM. Cells were 
incubated with washed Dynabeads (sheep anti-rat IgG, Dynal, Invitrogen, 120.21D) 
in a 4 ml suspension for 30 minutes at 4ºC on a rotating platform. After incubation, a 
magnet was applied to the cells and beads mixture for 3 minutes. The unbound lineage 
negative cells were transferred to a fresh 10 ml test tube. SM was added to the beads 
again to repeat the separation of unbound linage negative cells from the beads.  Cells 
were spun down to a pellet by centrifugation and transferred to a BD tube for staining 
with Texas Red diluted in PBS (1:100) to exclude cells that escaped lineage depletion. 
Following 30 minutes incubation, cells were washed and suspended in 250 µl of 
blocking antibody rat IgG (Sigma) for another 30 minutes at 4oC. Finally cells were 
washed with SM and stained with secondary antibodies (Table 2.1) and incubated at 
4ºC for 30minutes. Stained Cells were washed and resuspended in SM with 1 μg/ml 
of propidium iodine (PI), and then subjected to sort, LT-HSC (Lin–/loSca1+c-
Kit+CD150+CD48-), LMPP (Lin–/loSca1+c-Kit+CD150-CD48+), CMP (Lin–/loSca1-c-
Kit+CD34+CD16/32lo), GMP (Lin–/loSca1-c-Kit+CD34+CD16/32hi) and MEP (Lin–




2.17 Giemsa Stain 
 
Blood was drawn from tail vein or heart puncture to make peripheral blood smears. 
Bone marrow, spleen and liver cytospins were prepared in a Cytospin™ 4 
Cytocentrifuge (Thermo Scientific™) at 300 rpm for 5 minutes. Staining was carried 
out with May-Grünwald stain (Sigma) for 3 minutes, washed with water followed by 
stained with Giemsa stain (1:20, Sigma) for 20 minutes. Slides were left to dry for 




Biopsy from spleen and liver were fixed in 10% formalin prior to be sent to Propath 
(UK) Ltd histology lab. All samples were paraffin embedded and stained using 
Haematoxylin and Eosin stain (H&E). 
 
 2.19 Generation of Mouse embryonic fibroblast (MEF) 
 
All the mice used were fl/fl for the desired allele and one animal in each mating pair 
also expressed the Rosa-26cre-ERT. Timed mating was set for each mouse line and 
sexual activity was monitored the next morning by checking the vaginal plugs which 
composed of coagulated secretions from the male. This was counted as embryonic day 
0.5 (E 0.5). Mouse embryonic fibroblasts were harvested at day 13-14.5 of pregnancy. 
Mice were sacrificed by increasing CO2 levels until rigor mortis occurred. Uterine 
horns were removed from the mice by dissection and placed in 4°C cooled Phosphate 
buffer saline (PBS).  The uterine membrane, placenta and surrounding embryo sac 
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was removed and each embryo was placed in a well of a 6 well plate filled with PBS. 
The head and tail of the embryo were cut off and used for genomic DNA isolation 
which was used for genotyping each embryo. The fetal liver as well as all the vital 
organs were removed using a pair of forceps. The embryos were then transferred into 
new 6 well plates with cold PBS and grinded using a glass slide into fine slurry of 
tissue that was collected into 15 ml tube and span down at 1300 rpm for 5 minutes. 
After removing the supernatant, 2 ml of trypsin (tissue dissociation grade) was added 
to each tube containing the embryo followed by incubation for 10 minutes at 37ºC 
with vortexing every 2 minutes. Medium containing 10% FBS was used to deactivate 
the trypsin followed by another spin at 1300 rpm for 5 minutes. Each embryo was 
cultured in T175 flask. 
 
2.20 Cell cultures 
 
MEFs were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovin serum. Each flask was coated with 0.1% Gelatin (extract from 
animal collagen that helps the cells to adhere to the flask). Medium was replaced or 
replenished when the colour changed to yellow before cultured cells grew too dense. 
Cell lines were frozen using freezing medium (90% FCS and 10% DMSO) and stored 
in -80°C or in liquid nitrogen after 3 to 5 passages. 
 
Primary cells from leukaemic mice were cultured in R20/20 (RPMI1640, 20% FCS, 
20% WEHI, 100 U/ml penicillin, and 100 μg/ml streptomycin). WEHI is a 
conditioned medium (source of IL-3). Medium was replaced or replenished when the 
73 
 
colour changed to yellow before cultured cells grew too dense. Cell lines were frozen 
using freezing medium (90% FCS and 10% DMSO) and stored in -80°C or in liquid 
nitrogen after 3 to 5 passages. 
 
2.21 PI3K/PDK1/AKT/PKC Inhibitors 
 
MEFs were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovin serum in a six well plate (3x 105 cells per well). Medium was 
removed next and replaced with fresh medium. Cells were treated for 60 minutes with 
increasing dose (0.5 µM to 10µM) of PI3K inhibitor (LY294002 cat# s1105 
selleckchem), PDK1 inhibitor (GSK2334470 cat# s7087 selleckchem) AKT inhibitor 
(AKTVIII gift from Dr. Maria Teresa) and PKC inhibitor (PKC817 gift from Prof. 
Peter Parker). Cells were rinsed 3 x with PBS and extracted for western blot analysis. 
 
2.22 Western Blotting 
 
Immunoblotting was used to confirm the deletion of PTEN and PDK1 as well as to 
investigate the phosphorylation of PDK1 substrates. Cells in culture plate were 
washed with cold PBS after aspiration of the culture medium. PBS was aspirated and 
ice cold NP40 buffer containing Tris-HCL 100 mM, pH 7.4, NaCL 300 mM, NP-40 
2% and EDTA 10 mM was added to the cells then left to lyse for 30 minutes on ice. 
For reference, we used 150 µl of lysis buffer per well in a 6 well plate. The adherent 
cells were scraped off the plate using a plastic cell scraper and gently transferred into 
pre-cold micro-centrifuge tubes then centrifuged at 16000 g for 20 minutes at 4ºC.  
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The supernatant contained the proteins of interest and at this point aliquots were taken 
and frozen down while at the same time 10 µl was also taken for protein quantification. 
Proteins were quantified for each sample using the Pierce 660 nm Protein solution. 
The reagent and the sample were equilibrated to room temperature. Sample and 
reagent were mixed at a ratio 1:15 in a 96 well micro plate and incubated at room 
temperature for 5 minutes. A zero reference was prepared by mixing the lysis buffer 
with the reagent at the same ratio. The absorbance of the sample was measure using 
the Nano Drop 8000 against a standard of known concentrations. As a reference we 
used 20 µg of protein for each western blot.  
Samples were mixed with 2% SDS buffer containing 0.5M Tris pH 6.8, 50% Glycerol, 
10% SDS and bromophenol blue (ratio 1:1). Beta mercaptoethanol was added freshly 
to the buffer and samples were heated to 95ºC for 5 minutes. SDS Page electrophoresis 
was run with 10% gradient SDS polyacrylamide gel (NEXT GELTM) at 140V for 60 
minutes followed by a blotting of the separated proteins onto nitrocellulose membrane 
(Amersham TM Hybond TM ECL) at 110v for 90 minutes.  Blocking was carried out 
using 5% milk in 1% Tween – PBS for 1 hour and the membrane was subsequently 
probed with primary antibodies. Rabbit anti mouse antibodies used were purchased 
from Cell Signalling Technologies. These included PDK1 (cat # 5662S), PTEN (cat 
#9559L) phosphor Akt 308 (cat# 4056S) phosphor Akt 473 (cat# 9271S) pan Akt 
(cat# 4685S). The β-actin conjugated with HRP was purchased from Santa Cruz (cat# 
1-19; SC-1616) as well as phosphor SGK1 256 (cat# 16744R). In general, incubation 
with primary antibody was carried out at 4ºC overnight. Incubation with secondary 
antibody was done at room temperature for an hour after the primary antibody has 
been washed off. The secondary antibody was anti rabbit conjugated with peroxidase 
(Jackson ImmunoResearch Laboratory, INC). In general, washing was done 3 times 
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with 1% Tween- PBS between after each step for 10 minutes each (blocking, primary 
antibody, secondary antibody.)   Proteins were detected using ECLTM Western 




Prior to cell culture, 22 × 22 mm No. 1.5 cover slips from Thermo Scientific (cat# 
CBAD00220RA20MNZ) were sterilized with 70% ethanol and coated with 0.1% 
gelatine. MEFs were cultured in a 6 well plate containing the cover slips until they 
were 90% confluent. Medium was aspirated from the cultures and cells washed with 
appropriate volume of PBS. Cells were fixed for 15 minutes by adding 4% 
formaldehyde to a depth of 2 to 3 mm to cover the entire well. The fixative was 
aspirated and cells rinsed three times with PBS for 5 minutes each. Blocking buffer 
(1x PBS /5% normal serum/0.3% Triton TM   X-100) was added over the cells in each 
well followed by incubation for 30 minute at room temperature. Primary antibody 
(phosphor AKT 308 cat# D25E6 pan AKT cat# 40DA from Cell Signalling 
Technologies) was prepared dilution to 1:200 with antibody dilution buffer (1X PBS/ 
1% BSA/0.3% Triton TM   X-100). After incubation, blocking buffer was aspirated and 
diluted primary antibody was applied. Incubation with primary antibody was carried 
out at 4oC overnight in a humid light-tight box to prevent drying. Plates were rinsed 
three times for 5 minutes each with PBS. The fluorochrome-conjugated secondary 
antibody (ant-rabbit cat# 4412s anti-mouse cat# 4409s from Cell Signalling) diluted 
1:200 was applied and plates incubated at room temperature in humid light-tight box 
to prevent drying fluorochrome fading. Plates were rinsed three times with PBS for 5 
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minutes each. Cover slips were removed from the plate and mounted on a microscope 




            Chapter3 PTEN and PDK1 in normal haematopoiesis 
            3.1 A brief introduction 
 
I previously discussed the role of various signalling pathways involved in sustaining 
normal haematopoiesis.  For instance, the Wnt and Notch pathways support normal 
cell proliferation by promoting normal stem cell self-renewal (Molofsky et al. 2004), 
(Reya et al., 2001).   On the other hand, tumour suppressors such as p53, PML and 
PTEN also regulate cell proliferation.  The role of PTEN on normal haematopoiesis 
has been previously studied and shown to play a fundamental role in maintaining 
normal haematopoietic stem cells. Yilmaz and colleagues demonstrated that deleting 
PTEN in bone marrow cells resulted in exhaustion of normal haematopoietic stem 
cells (Yilmaz et al., 2006b). In this study, they transplanted Ptenfl/fl; Mx-1-Cre bone 
marrow cells or wild-type bone marrow cells both CD45.2 into recipient CD45.1 mice 
along with half as many rescue cells from the bone marrow of a CD45.1 mouse. 
Recipient mice were treated with pIpC 6 weeks after they showed stable chimaerism. 
They demonstrate that 5 to 20 weeks post administration of pIpC, the total number of 
control Pten fl/+; Mx- 1-Cre donor HSCs remained constant over time compared to 
PTENfl/fl; Mx-1-Cre donor HSCs which initially dominated the HSC pool, but dropped 
post pIpC treatment.  At the end of 20 weeks, the proportion of control PTEN fl/+ Mx-
1-Cre HSC donor cells remained at 64% of bone marrow population, whereas 
PTENfl/fl ; Mx-1-Cre donor HSC cells decreased to 15% of bone marrow cells (Yilmaz, 
2006). This study showed that PTEN deletion leads to the depletion of normal HSCs 
while at the same time supporting the production of leukaemia-initiating cells. These 
findings suggest an extraordinary requirement for maintenance of leukaemia-stem 
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cells that might diverge from requirements for maintenance of normal stem cells. 
More importantly, they demonstrated that treatment with rapamycin rescued normal 
HSC function and prolonged the life of PTEN fl/fl; Mx-1-Cre mice when PTEN was 
deleted.   The drug rapamycin inhibits the activity of mTOR kinase, which is one of 
the downstream targets of the PI3K pathway. To gain further insights into the 
molecular pathway regulating PTEN function in normal haematopoiesis, we decided 
to study the role of PTEN and PDK1 using a mouse model where we can 
simultaneously delete PTEN and PDK1 in the haematopoietic compartment.  
 
            3.2 Role of PTEN and PDK1 in normal haematopoiesis  
 
To investigate the functional relationship between PDK1 and PTEN during 
haematopoiesis, we performed bone marrow transplantation experiments using total 
bone marrow cells isolated from PTENfl/fl Rosa-26cre-ERT, PTENfl/fl PDKfl/fl Rosa-
26cre-ERT and normal wild type cells from a C57BL6.  In order to distinguish donor 
from competitor cells upon transplantation, our transgenic mice (donor) were all 
C57BL6 CD45.2 whereas the recipient mice were wild type SJL CD45.1. We 
transplanted 1 mio donor cells (CD45.2) together with 0.2 mio competitor/rescue cells 
(CD45.1) into lethally irradiated SJL mice (CD45.1) (n=12 for each group).  Four 
weeks post transplant, we sacrificed 3 mice from each group to determine if the 
transplant was successful and to perform phenotypic analysis. We show that a stable 
chimaerism was archived four weeks post transplant as demonstrated by the presence 
of both CD45.1 (rescue cells) and CD45.2 (donor cells) in the bone marrow spleen 
and liver. We noticed at 4 weeks post transplant, the proportion of donor cells was 
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higher in the bone marrow compared to other organs in all mice respective of the cell 
type transplanted (Fig 3.1 A to C).   We also compared the weight of the spleen and 
liver among mice that received PTENfl/fl Rosa-26cre-ERT, PTENfl/fl PDK1fl/fl Rosa-
26cre-ERT and normal wild type cells. We observed no significant difference in 




Figure 3.1 Engraftment of PTENfl/fl Rosa-26cre-ERT and PTEN fl/flPDK1fl/fl 
Rosa-26cre-ERT cells four weeks after transplant.  
Total bone marrow cells from PTENfl/fl PDK1fl/fl Rosa-26cre-ERT mouse (1 Mio CD45.2 cells) were 
transplanted into lethally irradiated SJL mice (CD45.1 n=10) and 0.2 Mio CD45.1 cells used for rescue. 
(A) Engraftment of donor cells in the bone marrow. (B) Engraftment of donor cells in the spleen (C) 
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Engraftment of donor cells in the liver at four weeks post transplantation. (D and E) weight of the 
spleen and liver respectively.  
 
3.2.1 Multi lineage reconstitution with donor cells  
 
To determine the ability of PTENfl/fl Rosa-26cre-ERT, PTENfl/fl PDK1fl/fl Rosa-26cre-
ERT and normal wild type cells to fully reconstitute. Recipient mice were sacrificed 
4 weeks post-transplant and analysed by FACS. Using a panel of antibodies 
specifically against myeloid markers Mac1, Gr1, stem and progenitor cell marker c-
Kit, lymphoid markers CD4, CD8 and B220, as well as CD45.2 and CD45.1,  we were 
able to distinguish the donor cells from rescue cells and also assess the lineage 
distribution of haematopoietic cells originating from the donor. We demonstrate that 
a full multi-lineage reconstitution of the bone marrow was achieved in all groups and 
the lineage distribution was comparable in all groups. The double positive Mac1 and 
Gr1 population was slightly higher but not statistically significant in mice that 
received PTENfl/fl Rosa-26cre-ERT and PTENfl/fl PDK1fl/fl Rosa-26cre-ERT cells 
respectively (Fig 3.2). We also noticed a slightly higher but not significant percentage 





Figure 3.2 Reconstitution with PTENfl/fl Rosa-26cre-ERT and PTENfl/flPDK1fl/fl Rosa-26cre-ERT 
cells four weeks after transplant.  
Multi lineage reconstitution of the bone marrow was achieved in all groups and the lineage distribution 
was comparable in all groups. No statistical increase or decrease in the cell lineage was observed in all 
groups. 
 
3.2.2 Distribution of HSC and early progenitors four weeks after transplant 
 
To further analyse the reconstitution of the bone marrow at four weeks post-transplant, 
we determined the distribution of HSC and early progenitors in bone marrow using 
classical LSK and SLAM family markers (CD150 and CD48) (Yeung and So, 2009, 
Oguro et al., 2013).  LT-HSC (Lin –/loSca1+c-Kit+CD150+CD48-), ST-HSC (Lin–
/loSca1+c-Kit+CD150-CD48-), MPP (Lin–/loSca1+c-Kit+CD150-CD48+), CMP (Lin–
/loSca1–c-Kit+CD34+CD16/32lo), GMP (Lin–/loSca1–c-Kit+CD34+CD16/32hi) and 
MEP (Lin–/loSca1–c-Kit+CD34-CD16/32lo).  The distribution of the HSCs and early 
progenitors was comparable at this time point (Fig 3.3A and B). However, in general 
the mice that received wild type cells had slightly higher numbers of MPPs and GMPs 
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compared to the PTENfl/fl PDK1fl/fl Rosa-26cre-ERT and PTENfl/fl Rosa-26cre-ERT 
group. Of note, the analysis of the HSCs and early progenitors was done on the general 
bone marrow cells of each mouse without gating for CD45.2 and CD45.1. Given that 
the earlier analysis of the c-Kit expression in CD45.2 cells gave comparable results 
across all groups, we conclude that any masking effects of the present competitor cells 
will be similar in all groups, suggesting no effects in the CD45.2 LSK compartments 
of the investigated groups.    We also analysed the cell cycle of the bone marrow four 
weeks post-transplant and we found that there was no significant difference in the cell 
cycle status of the whole bone marrow (Fig 3.3 C). 





Figure 3.3 Analysis of HSCs and early progenitors four weeks after transplant.  
(A) Distribution of LT-HSCs, ST-HSCs and MPPs four weeks after transplant. (B) Distribution of early 
progenitors GMP, CMP and MEP four weeks after transplant. (C) Cell circle analysis of total bone 
marrow cells four weeks after transplant. 
 
3.2.3 Impaired engraftment after deletion of PDK1 in PTEN deficient 
haematopoietic cells.  
 
To investigate the role of PTEN and PDK1, we induced gene deletion by treating the 
recipient mice with 120ul of tamoxifen for 5 days to activate cre activity.  Four weeks 
post treatment with tamoxifen, we sacrificed three mice from each group. Deletion of 
PTEN and PDK1 was confirmed by PCR using genomic DNA isolated from the bone 
marrow of recipient mice (Fig 3.4D). We compared the level of engraftment in the 
bone marrow, spleen and liver. As expected, the level of engraftment increased in 
mice that received PTEN fl/fl Rosa-26cre-ERT cells, which was in stark contrast to 
mice received PTENfl/fl PDK1fl/fl Rosa-26cre-ERT cells in the bone marrow, spleen 
and liver (Fig 3.4 A to C).  Engraftment of PTENfl/fl Rosa-26cre-ERT cells was not 
statistically significantly different as compared to engraftment of wild type cells. We 
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also compared the weight of the spleen and liver of mice that received PTENfl/fl Rosa-
26cre-ERT cells with mice that received PTENfl/fl PDK1fl/fl Rosa-26cre-ERT or wild 
type cells. The spleen weight of mice that received PTENfl/fl Rosa-26cre-ERT cells 
were significantly higher compare to spleen weight of mice that received wild type 
cells and to a lesser extent higher that the spleen weight of mice that received PTENfl/fl 
PDK1fl/fl Rosa-26cre-ERT (Fig 3.4 E and F). In overall deletion of PTEN alone 
resulted in increased proliferation of donor cells in all the organs. On the other hand, 
deletion of PTEN and PDK1 resulted in decreased engraftment levels of donor cells, 







Figure 3.4 Engraftment of PTENfl/fl Rosa-26cre-ERT and PTEN fl/flPDK1fl/fl 
Rosa-26cre-ERT cells four weeks post cre activation.  
Total bone marrow cells from PTENfl/fl PDK1fl/fl Rosa-26cre-ERT BM (1Mio cells CD45.2 cells) 
transplanted lethally irradiated SJL mice (CD45.1 n=10) (0.2 Mio CD45.1 cells used for rescue. (A) 
Engraftment of donor cells in the bone marrow. (B) Engraftment of donor cells in the spleen (C) 
Engraftment of donor cells in the liver. (D) PCR confirming deletion of PTEN and PDK1 in the bone 
marrow (E and F) weight of the spleen and liver respectively. Significance (* P <0.05 ** P >0.005 *** 
P > 0.001) 
 
 
3.2.4  PTEN deletion influenced lineage selection 
 
In addition to comparing the engraftment level four weeks post tamoxifen treatment, 
we   analysed the bone marrow to investigate whether the conditional knock out of 
PTEN and PDK1 has an effect on the different haematopoietic populations’ 
reconstituting the recipient mice. Firstly, we investigated the distribution of mature 
haematopoietic cells using a panel of antibodies for mature cells lineage markers 
previously described together with the c-Kit for haematopoietic stem cell and 
progenitors. Deletion of PTEN enhanced the proliferation of myeloid cells while 
virtually depleting the B220 cells (Fig 3.5A).  Concurrent deletion of PDK1 almost 
completely reversed these effects in PTEN null mice and showed a comparable pattern 
to the wild type.  We looked at the distribution of the c-Kit positive cells which is a 
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marker for HSCs and early progenitor within the CD45.2 population (Fig 3.5B). 
Interestingly, the c-Kit positive population in the mice that received PTENfl/fl Rosa-
26cre-ERT and PTENfl/fl PDK1fl/fl Rosa-26cre-ERT cells was slightly decreased 
compared to mice that received wild type cells. However, the reduction was not 
statistically significant at this time point (Fig 3.5 B). 
   
 
 
Figure 3.5 Reconstitution with PTENfl/fl Rosa-26cre-ERT and PTEN fl/flPDK1fl/fl 
Rosa-26cre-ERT cells four weeks post cre activation 
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(A) Deletion of PTEN enhanced the proliferation of myeloid cells while virtually depleting the B220 
cells whereas deletion of PTEN and PDK1 showed a moderate expansion of myeloid cells and decrease 
of B220 cells suggesting a mild delay of lineage selection induced by PTEN deletion. (B) Distribution 
of the c-Kit positive cells within the CD45.2 population. Significance (* P <0.05 ** P >0.005 *** P > 
0.001) 
 
3.2.5 PTEN deletion disturbed normal the distribution of haematopoietic stem 
cells and progenitors. 
 
To further investigate the effect of PTEN and PDK1 on normal haematopoietic 
function four weeks post treatment with tamoxifen, we assessed the composition of 
the bone marrow using a panel of antibodies previously described for the HSCs and 
early haematopoietic progenitors. Four weeks after tamoxifen treatment, the 
proportion of LT-HSC (Lin–/loSca1+c-Kit+CD150+CD48-), ST-HSCs (Lin–/loSca1+c-
Kit+CD150-CD48-) and MPP (Lin–/loSca1+c-Kit+CD150-CD48+) was not significantly 
affected in mice transplanted with PTENfl/fl PDK1fl/fl Rosa-26cre-ERT cells or 
PTENfl/fl Rosa-26cre-ERT cells as well as wild type cells (Fig3.6A).  Interestingly, the 
GMP (Lin–/loSca1-c-Kit+CD34+CD16/32hi) was significantly reduced in mice that 
received PTENfl/fl Rosa-26cre-ERT cells and PTENfl/fl PDK1fl/fl Rosa-26cre-ERT 
cells.  Similarly, the CMP (Lin–/loSca1-c-Kit+CD34+CD16/32lo) was also reduced but 
only in mice that received PTENfl/fl Rosa-26cre-ERT cells (Fig 3.6B).  Cell cycle 
distribution did not show any significant disturbance in mice that received either 
PTENfl/fl Rosa-26cre-ERT cells or PTEN fl/fl PDK1fl/fl Rosa-26cre-ERT cells (Fig 







        
 
Figure 3.6 Analysis of HSCs and early progenitors eight weeks after transplant 
(A) Distribution of LT-HSCs, ST-HSCs and MPPs four weeks after transplant. (B) Distribution of early 
progenitors GMP, CMP and MEP four weeks after transplant. Cell circle analysis of total bone marrow 
cells four weeks after transplant. Significance (* P <0.05 ** P >0.005 *** P > 0.001). 
 
3.2.6 PDK1 controls the phosphorylation of AKT 308 in normal haematopoietic 
cells 
 
To test the effect of PTEN and PDK1 deletion in the in normal hematopoietic cells we 
analysed the phosphorylation of AKT Thr308, AKT Ser473 and SGK1 Thr256.  In 
parallel with HSC analysis we sorted the donor cells from each of the recipient mice 
sacrificed four weeks post tamoxifen. Due to the limited amount of cells we obtained 
after sorting, we grouped cells obtained from mice that received the same type of cells 
together. As expected, cells isolated from the bone marrow of mice transplanted with 
PTENfl/fl Rosa-26cre-ERT  had constitutively high levels of phosphorylated  AKT  at 
Thr308 and Ser473 as well as SGK1 Thr256 (Fig 3.7). Conversely,  we could not 
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detect phosphorylated AKT Thr308 in cells isolated from mice transplanted with 
PDK1fl/fl PTENfl/fl Rosa-26cre-ERT or wild type cells. These result sugget that 
phosphorylation of AKT Thr308 is mediated by PDK1 in the haematopoietic cells as 
deletion of PDK1 in PTEN deficient cells was sufficient to completely inhibit the loss 
of PTEN driven phosphorylation of AKT Thr308 in normal haematopoietic cells. 
               
Figure 3.7 PDK1 is required for Phosphorylation of AKT Thr308 in normal 
haematopoiesis. 
Western blot analysis of AKT Thr308, Ser473 and SGK1 Thr256 phosphorylation in PTENfl/fl Rosa-







3.2.7 Engraftment of PTENfl/fl PDK1fl/fl Rosa-26cre-ERT is restored 8 weeks after 
Cre activation 
 
To investigate the long-term effect of PTEN and PDK1 deficiency in haematopoietic 
cells we analysed mice transplanted with PTENfl/fl Rosa-26cre-ERT cells, PTENfl/fl 
PDK1fl/fl Rosa-26cre-ERT and wild type cells eight weeks after cre activation. Our 
earlier findings showed that engraftment levels of donor cells in mice that received 
PTENfl/fl PDK1fl/fl Rosa-26cre-ERT cells drastically dropped four weeks after cre 
activation compared to loss of PTEN alone (Fig 3.4A). Interestingly, the engraftment 
level at eight weeks post cre activation was restored and rose to over 60% in the bone 
marrow (Fig 3.8A) which is similar to wild type transplanted cells but still lower than 
PTEN transplanted cells. Similarly engraftment of PTENfl/fl PDK1fl/fl Rosa-26cre-
ERT cells was also restored in the spleen and liver (fig 3.8B -C). Mice that received 
PTENfl/fl Rosa-26cre-ERT cells maintained a gradual increase in engraftment level 
over the eight week period post cre activation in the bone marrow, spleen and liver 
(FIG 3.8 A - C). PTEN and PDK1 deletion was confirmed by PCR using DNA isolated 
from the bone marrow of recipient mice. We measured the weight of the spleen and 
liver eight weeks post cre activation and revealed that the mice receiving PTENfl/fl 
Rosa-26cre-ERT cells and PTENfl/fl PDK1fl/fl Rosa-26cre-ERT cells have relatively 
increased spleen and liver weight compared to mice that received wild type cells (Fig 





Figure 3.8 Engraftment of PTENfl/fl Rosa-26cre-ERT and PTENfl/flPDK1fl/fl 
Rosa-26cre-ERT cells eight weeks after transplant 
(A) Engraftment of donor cells in the bone marrow. (B) Engraftment of donor cells in the spleen (C) 
Engraftment of donor cells in the liver. (D) PCR confirming deletion of PTEN and PDK1 in the bone 





3.2.8  PTEN deletion induced myeloid and T-cell proliferation  
 
To gain further insight on the long term effect of PTEN and PDK1 deficiency on 
haematopoietic function, we analysed the composition of the bone marrow to find out 
if the donor cells were able to maintain the full multi lineage reconstitution eight 
weeks post cre activation. Mice transplanted with PTENfl/fl Rosa-26cre-ERT cells and 
PTENfl/fl PDK1fl/fl Rosa-26cre-ERT cells showed an increased proliferation of 
myeloid cells marked by elevated percentage of Mac1-Gr1 double positive cells 
compared to mice that received wild type cells. Moreover, the B220 population was 
virtually depleted in mice that received PTENfl/fl Rosa-26cre-ERT cells and PTENfl/fl 
PDK1fl/fl Rosa-26cre-ERT cells. Interestingly, an expansion of CD4 positive cells was 
observed only in mice that received PTENfl/fl Rosa-26cre-ERT cells eight weeks Cre 
activation.  A similar proliferation of myeloid lineage cells accompanied with 
depletion of B220 cells was also observed when PDK1 was deleted in PTEN deficient 
haematopoietic cells, suggesting that PDK1 has no or only little effect on myeloid 
proliferation and B-cell depletion. Conversely, the expansion of T-cell lineage cells 
was only observed in mice that received PTENfl/fl Rosa-26cre-ERT cells suggesting 
that PDK1 indeed moderates the effects of loss of PTEN on CD4 T-cells (Fig 3.9A). 
It is also worth noting that c-Kit population was significantly reduced in mice that 
received PTENfl/fl Rosa-26cre-ERT cells compared to mice that received wild type 
cells (Fig3.9B) suggesting that the LSK population is decreased. Deletion of PDK1 
reversed some of the phenotypes caused by PTEN deletion such as reduction of the c-
Kit subpopulation and expansion of the CD4 subpopulation. However, it was not able 






Figure 3.9 Reconstitution with PTENfl/fl Rosa-26cre-ERT and PTENfl/flPDK1fl/fl 
Rosa-26cre-ERT cells 8 weeks post cre activation.  
(A) Deletion of PTEN enhanced the proliferation of myeloid cells while virtually depleting the B220 
cells whereas deletion of PTEN and PDK1 showed a moderate expansion of myeloid cells and decrease 
of B220 cells suggesting a mild delay of lineage selection induced by PTEN deletion. (B) Distribution 
of the c-Kit positive cells within the CD45.2 population showing depletion in mice transplanted with 





3.2.9 PTEN deletion mediated depletion of HSCs and early progenitors  
 
We have so far demonstrated the effect of PTEN and PDK1 deficiency on lineage 
reconstitution. To extent this, we investigated the effect of PTEN and PDK1 
deficiency on HSCs and early progenitors eight weeks post cre activation. 
Surprisingly, the MPPs (Lin–/loSca1+c-Kit+CD150-CD48+) population was severely 
depleted in mice that receive PTENfl/fl Rosa-26cre-ERT cells whereas it was increased 
in mice that received PTENfl/fl PDK1fl/fl Rosa-26cre-ERT cells. However, there was 
no statistically significant different comparing MPPs in mice that received PTENfl/fl 
PDK1fl/fl Rosa-26cre-ERT cells to mice transplant with wild type cells (fig 3.10A). 
We also noticed GMP (Lin–/loSca1-c-Kit+CD34+CD16/32hi) population was depleted 
in mice that received PTENfl/fl Rosa-26cre-ERT cells and PTENfl/fl PDK1fl/fl Rosa-
26cre-ERT cells whereas the CMP (Lin–/loSca1-c-Kit+CD34+CD16/32lo) population 
was only significantly  disturbed in mice that received PTENfl/fl Rosa-26cre-ERT cells 
(Fig 3.10B). Together these results suggests deletion of PDK1 can reverse some of the 
phenotypes caused by PTEN deletion such as depletion of MPP and CMP but could 
not reverse the depletion of GMPs. Cell cycle analysis of the total bone marrow did 
not show and significant destruction in mice that received either PTENfl/fl Rosa-26cre-









Figure  3.10 Analysis of HSCs and early progenitors 8 weeks after transplant 
(A) Distribution of LT-HSCs, ST-HSCs and MPPs four weeks after transplant. (B) Distribution of early 
progenitors GMP, CMP and MEP four weeks after transplant. (C) Cell circle analysis of total bone 
marrow cells four weeks after transplant. 
 
3.2.10 Phosphorylation of AKT 308 not required for maintenance of normal 
haematopoietic cells 
 
We have shown earlier that cells isolated from the bone marrow of mice transplanted 
with PTENfl/flRosa-26cre-ERT  have constitutively high levels of phosphorylated  
AKT  at Thr308 and Ser 473 as well as SGK1 Thr256 whereas cells obtained from 
mice that received PTENfl/fl  PDK1fl/fl Rosa-26cre-ERT cells showed inhibition of 
AKT Thr308 phosphorylation after cre activation. We again investigated the 
phosphorylation of AKT Thr308, AKT Ser473 and SGK1 Thr256 eight weeks after 
activation of cre. Interestingly, phosphorylation of AKT Thr308 was still inhibited 
eight weeks after cre activation in mice that received PTENfl/fl PDK1fl/fl Rosa-26cre-
ERT cells (Fig 3.11). These results further support our earlier findings that while 
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activation of AKT Thr308 is dependent on PDK1, it may not be required during 
normal haematopoiesis.  
                                  
Figure 3.11 Phosphorylation of AKt Thr308 not required for maintain normal 
haematopoiesis 
Western blot analysis of AKT Thr308, Ser473 and SGK1 Thr256 phosphorylation in PTENfl/fl Rosa-
26cre-ERT and PDK1fl/fl PTENfl/fl Rosa-26cre-ERT bone-marrow cells. 
 
3.3 PTEN deficient HSCs cannot sustain long term reconstitution in irradiated               
mice 
 
Haematopoietic stem cells are defined by their ability to give rise to all blood cells of 
multiple lineages when transplanted into irradiated mice. We have demonstrated 
earlier that PTEN deletion resulted in depletion of early progenitor populations. To 
functionally confirm the depletion of normal HSCs, we sought to perform 
transplantation experiments. We first administered tamoxifen (120 µl per day for five 
days) to induce cre activation in PTENfl/fl Rosa-26cre-ERT and PTENfl/fl PDK1fl/fl 
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Rosa-26cre-ERT mice (both CD45.2, n=5). Next we isolated bone marrow cells post 
treatment and pooled together cells for each genotype. We then sorted HSC (Lin–
/loSca1+c-Kit+CD150+CD48-), MPP (Lin–/loSca1+c-Kit+CD150-CD48+), CMP (Lin–
/loSca1–c-Kit+CD34+CD16/32lo) and GMP (Lin–/loSca1–c-Kit+CD34+CD16/32hi) from 
the pooled cells. For each genotype we, transplanted 5x102 HSCs (Lin–/loSca1+c-
Kit+CD150+CD48-), 1x104 MPPs (Lin–/loSca1+c-Kit+CD150-CD48+), 1x104 CMPs 
(Lin–/loSca1–c-Kit+CD34+CD16/32lo) and 1x104 GMPs (Lin–/loSca1–c-
Kit+CD34+CD16/32hi) together with 2X105 wild type total bone marrow cells 
(CD45.1) into lethally irradiated mice (CD45.1). Eight weeks after transplantation, we 
performed a peripheral blood analysis to determine the level of engraftment. We 
demonstrate that mice transplanted with progenitors from both PTENfl/fl Rosa-26cre-
ERT and PTENfl/fl PDK1fl/fl Rosa-26cre-ERT lacked engraftment and failed to show 
any donor reconstitution (Fig 3.12). While mice transplanted with HSCs from 
PTENfl/fl Rosa-26cre-ERT showed only a low engraftment level eight weeks after 
transplant, mice transplanted with PTENfl/fl PDK1fl/fl Rosa-26cre-ERT HSCs showed 
good engraftment levels and reconstitution of above 70% of the peripheral blood cells. 
These results reveal that the reconstitution levels of PTEN deleted HSCs is 
significantly lower than that of PTEN PDK1 HSCs, strongly suggesting that PTEN 
HSCs exhaust and that deletion of PDK1 in PTEN deficient HSCs restores normal 




Figure 3.12 PTEN deficient HSCs cannot sustain long term reconstitution in irradiated mice eight 
weeks after tamoxifen treatment. 
For each genotype we, transplanted 5x102 HSCs (Lin–/loSca1+c-Kit+CD150+CD48-), 1x104 MPPs (Lin–
/loSca1+c-Kit+CD150-CD48+), 1x104 CMPs (Lin–/loSca1–c-Kit+CD34+CD16/32lo) and 1x104 GMPs 
(Lin–/loSca1–c-Kit+CD34+CD16/32hi) together with 2X105 wild type cells (CD45.1) into lethally 









The haematopoietic system has to be strictly regulated in order to maintain its self-
renewal capacity to generate progenitor cells while sustaining a reserve of pluripotent 
haematopoietic stem cells (Cheung and Mak, 2006). PTEN has been reported to be 
indispensable in the maintenance of haematopoietic stem cells. A previous study by 
Yilmaz et al demonstrated that when mice transplanted with PTENfl/fl Mx-1-Cre were 
treated with pIpC to activate  Cre, the number of PTEN deficient HSCs decreased over 
time whereas the number of wild type HSCs in the same mice increased (Yilmaz et 
al., 2006a).   Another study by Zhang and colleagues also demonstrated that deleting 
PTEN in the haematopoietic cells resulted in short term expansion of HSCs but long-
term depletion of the HSCs. Moreover, PTEN deficient HSCs could not maintain long 
term reconstitution in irradiated mice (Zhang et al., 2006). Comparable to previous 
studies by Yilmaz and Zhang, we used conditional knock out mouse PTENfl/fl Rosa-
26cre-ERT and   PTENfl/fl PDK1fl/fl Rosa-26cre-ERT mice to investigate the role of 
PTEN and PDK1 in normal haematopoiesis. We transplanted bone marrow cells from 
PTENfl/fl Rosa-26cre-ERT and   PTENfl/fl PDK1fl/fl Rosa-26cre-ERT mice (both 
CD45.2) to lethally irradiated recipient mice (CD45.1) and induce cre activation four 
weeks later when the mice showed successful engraftment and fully reconstitution 
with multi-lineage blood cells. Our analysis was only carried out up to eight weeks 
due early onset of leukaemia in mice that receive PTENfl/fl Rosa-26cre-ERT cre cells. 
Myeloid proliferation as an immediate effect of PTEN deletion has been reported in 
several studies (Kalaitzidis et al., 2012, Magee et al., 2012, Tesio et al., 2013). 
Similarly, we demonstrated that deletion of PTEN in the haematopoietic compartment 
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leads to expansion of double positive Mac1–Gr1 myelocytes while depleting B220+ 
Lymphocytes just four weeks post deletion of PTEN. Furthermore, consistent with 
previous data from other studies we demonstrate that four weeks and eight weeks post 
activation of cre,  PTENfl/fl Rosa-26cre-ERT HSCs and early progenitors gradually 
decrease over time suggesting that the haematopoietic stem cell pool is getting 
exhausted. Interestingly mice transplanted with PTENfl/fl/PDK1fl/fl cells showed a 
slower or lesser degree of HSC and early progenitor depletion (Figure 3.10).  We also 
observed increase in the spleen and liver sizes in mice recipient post cre mediation 
which has also been previously reported as a result of extramedullary haematopoiesis 
(Tesio et al., 2013).   Eight weeks after Cre activation mice that received PTENfl/fl 
Rosa-26cre-ERT cre cells showed a much more drastic reduction in MPPs (Lin–
/loSca1+c-Kit+CD150-CD48+) whereas minimum impact was shown on LT-HSCs 
(Lin–/loSca1+c-Kit+CD150+CD48-) and ST-HSCs (Lin–/loSca1+c-Kit+CD150-CD48-).   
Tesio and colleagues have argued that PTEN deletion has no effect on the number of 
quiescent and dormant HSCs (Tesio et al., 2013) contradicting the finding that Pten is 
important regulator of HSC proliferation and self-renewal (Cheung and Mak, 2006, 
Zhang et al., 2006, Yilmaz et al., 2006b). In addition, we further showed that PTEN 
deletion lead to depletion of GMPs (Lin–/loSca1–c-Kit+CD34+CD16/32hi) and CMPs 
(Lin–/loSca1–c-Kit+CD34+CD16/32lo). Our results are consistent with finding from 
Zhang and colleagues demonstrating a slight decrease in GMP and CMP population. 
We demonstrated that in mice transplant with PTENfl/fl PDK1fl/fl Rosa-26cre-ERT 
cells in contrast to mice transplant with PTENfl/fl Rosa-26cre-ERT cells showed 
comparable MPs and CMP population eight weeks post cre mediation to mice 
transplanted with wild type cells.  In our hands, the ST-HSCs and LT-HSCs did not 
show a statistical significant difference in control mice compared to mice that received 
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PTENfl/fl PDK1fl/fl Rosa-26cre-ERT cells and PTENfl/fl Rosa-26cre-ERT cells.  
Together our results suggest that simultaneous deletion of PTEN and PDK1 may have 
delayed or temporally restored normal haematopoietic function of PTEN depleted 
HSC.  To confirm these claim we demonstrated that HSCs isolated from PTENfl/fl 
PDK1fl/fl Rosa-26cre-ERT mice were able to restore engraftment and reconstitute 
lethally irradiated mice. Consistent with our results, inhibition of mTOR downstream 
of PDK1 has been shown to restore normal haematopoietic stem cell function (Yilmaz 














Chapter 4 PTEN and PDK1 in Leukaemogenesis  
4.1 A brief introduction 
 
The PI3K pathway has been associated with several roles such as proliferation, 
survival and differentiation of haematopoietic cells. Consequently, deregulation of 
this pathway has been associated with development of leukaemia as well as other types 
of cancer. Thus, enzymes involved in PI3K pathway enzymes are frequently mutated 
in cancer (Fransecky et al., 2015). Inhibitors targeting key enzymes such as PI3K, 
AKT and mTOR are being developed for the treatment of several cancers such as 
colorectal cancer (Zhang et al., 2011) and in some cases are endorsed as the standard 
of care. Abnormal activation of AKT and mTOR have long been recognized as key 
downstream effects of mutated PI3K pathway resulting in growth advantage of AML 
stem cells (Vanhaesebroeck et al., 2012). 
PTEN is a key regulator of the PI3K pathway and loss of function of PTEN results in 
increased activation of PDK1 and AKT. PDK1 directly activate Akt and mTOR 
complex 1, both of which have been directly linked to leukaemogenesis. Moreover, 
PTEN deletions or mutation have been reported in about 5% to 10%  of T-ALL  cases 
(Gutierrez et al., 2009) and less than 2% of AML cases (Zeisig et al., 2012) . Most 
studies investigating the PI3K pathway and its relation to cancer used approaches such 
as targeting components of the PI3K pathway using inhibitor or gene silencing. While 
many studies focused on only a single component of the PI3K pathway, I decided to 
investigate the role of PTEN and PDK1 in leukaemia using conditionally knock-out 
mouse models were either PTEN, PDK1 or both simultaneously were deleted in the 
well-defined haematopoietic stem/progenitor cells. Using these mouse models, I can 
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compare the impact of loss of PTEN, PDK1 or both on leukaemogenesis. Given the 
important role of PDK1 in activating the various components downstream of the PI3K 
pathway I further aimed to elucidate the function of PDK1 by using additional specific 
knock-in (KI) mice (PDK1 L155E MG and PDK1 K465E). In these models, PDK1 
L155 mice have disrupted PDK1-PIF pocket domain whereas the PDK1 K465 have a 
defective PDK1-PH domain. These two domains are critical for the distinctive 
function of PDK1 i.e. phosphorylation of AKT Thr308 via the PH domain and 
phosphorylation of SGK1, RSK, S6K and PKC via the PIF pocket.  
 
4.2 Role of PTEN and PDK1 in peripheral blood engraftment and lineage 
contribution 
 
To study the effect of PTEN and PDK1 deletion alone or in combination in 
haematopoietic cells, we performed bone marrow transplantation experiments using 
total bone marrow cells (CD45.2) isolated from PTENfl/fl Rosa-26cre-ERT, PDK1fl/fl 
Rosa-26cre-ERT, PTENfl/flPDK1fl/fl Rosa-26cre-ERT, PDK1L155E/L155EPTENfl/fl Rosa-
26cre-ERT, PDK1MGK465/MGK465PTENfl/fl Rosa-26cre-ERT and PDK1MGK465/MGK465 
Rosa-26cre-ERT.  In order to distinguish donor from competitor cells upon 
transplantation, our transgenic mice (donor) were C57BL/6J (CD45.2) whereas the 
recipient mice were wild type C57BL/6SJL (CD45.1). We transplanted 1 mio donor 
cells (CD45.2) together with 0.2 mio rescue cells (CD45.1) into lethally irradiated SJL 
mice (CD45.1). To determine the ability of the different donor cells to engraft, we 
carried out FACS analysis on peripheral blood samples taken four weeks after 
transplantation. Using a panel of antibodies specifically against myeloid markers 
(Mac1, Gr1), stem and progenitor cell marker (c-Kit), lymphoid markers (CD4, CD8 
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and B220), as well as CD45.2 and CD45.1 allowed us to determine not only the level 
of engraftment but also the lineage distribution of haematopoietic cells originating 
from the donor. 
 
4.2.1. PTEN deletion has no effect on engraftment 
 
As a control, we demonstrated that normal haematopoietic cells harvested from a wild 
type C57BL6 CD45.2 mouse had the ability to engraft in lethally irradiated recipient 
mice (Fig 4.1A).  The percentage of C57BL6 CD45.2 (donor cells) was determined to 
be 70% in the peripheral blood of recipient mice four weeks post-transplant. Analysis 
of peripheral blood in mice transplant with PTENfl/flRosa-26cre-ERT cells also 
revealed engraftment levels around 70% four weeks after transplant comparable to the 
observation with wild type cells (Fig4.1B). To study effect of PTEN deletion in 
haematopoietic cells, we analysed the blood again at four weeks post-treatment with 
tamoxifen. Genotyping PCR on genomic DNA isolated from peripheral blood cells 
revealed a complete deletion of the PTEN floxed allele four weeks after tamoxifen 
treatment (Fig 4.1C). Further analysis of peripheral blood was carried out again at 
eight weeks and twelve weeks after tamoxifen administration. As expected, the 
percentage of donor cells further increased to around 75% and 85% at 4 weeks and 8 
weeks respectively and remained at this level at 12 weeks, which was very similar to 





Figure 4.1 Engraftment of wild type and PTENfl/fl Rosa-26cre-ERT cells 
Total bone marrow from wild type C57BL6 mouse and PTENfl/fl Rosa-26cre-ERT mouse (both 
CD45.2) (1 mio cells) was transplanted into SJL (CD 45.1) recipient mice (n=10) together with 0.2 mio 
CD45.1 wild type bone marrow cells for rescue. (A) Percentage of wild type donor cells before and 
after tamoxifen treatment. (B)Percentage of PTENfl/fl Rosa-26cre-ERT donor cells before and after 
tamoxifen treatment. (C) PCR analysis of blood 4 weeks after tamoxifen treatment (1 to 9 represent 
each mouse transplanted with PTENfl/fl Rosa-26cre-ERT after cre activation). PCR controls are 
indicated.  
 
4.2.2 PTEN deletion has influence on lineage selection 
 
In addition to determining the percentage of engraftment, we also monitored the 
lineage distribution of haematopoietic cells derived from the donor before and after 
cre activation.  We further demonstrate that normal haematopoietic cells did not only 
engraft but also lead to multi-lineage reconstitution of the blood (Fig 4.2A). Although 
the normal cells showed great potential to proliferate as indicated by their increase 
over the twelve weeks period, the cell population distribution remained unchanged 
before and after treatment with tamoxifen. In contrast to the control (wild-type cells) 
transplanted cohort, PTEN deletion resulted in an increase of Mac1 positive myeloid 
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cells at 8 and 12 weeks as well as Mac1/Gr1 double positive myeloid cell at 12 weeks 
after tamoxifen treatment while the proportion of Gr1 positive cells remained 
unchanged (Fig 4.2B). On the other hand, a gradual decrease in B220 B-cells was 
observed from 4 weeks to 12 weeks after tamoxifen treatment, whereas no significant 
changes were observed in CD4 and CD8 T-cells. Together this data indicate that 
PTEN deletion causes hyper-proliferation of myeloid cells while depleting B220 





Figure 4.2 PTEN deletion induces lineage selection 
A) Immunophenotying of wild type donor cells before and after tamoxifen treatment is shown. (B) 
Immunophenotying of PTENfl/flRosa-26cre-ERT donor cells before and after tamoxifen treatment is 
shown. Significance (* P <0.05 ** P >0.005 *** P > 0.001) 
 
4.2.3 Deletion of PDK1 impairs the engraftment 
 
PDK1 contributes to cell growth due to its ability to activate a series of signal 
transducers that are involved in promoting cell proliferation and survival (Bone and 
Welham, 2007). Consequently, it was anticipated that deletion of PDK1 has a negative 
effect on cell proliferation and survival. We demonstrate that the level of engraftment 
of PDK1fl/flRosa-26cre-ERT cells as determined by the percentage of CD45.2 donor 
cells in the blood was around 60% at 4 weeks after transplantation, which was 
comparable to the wild type control. However, the percentage of PDK1fl/flRosa-26cre-
ERT cells dropped to just 2% 4 weeks after tamoxifen treatment (Fig 4.3A).  Due to 
the depleted number of cells after cre activation, I could not confirm the in vivo 
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deletion of PDK1 in this experimental set up. At eight weeks and twelve weeks the 
percentage of donor cells further dropped to almost 0%. These results suggest that 
PDK1 is essential for cell growth and proliferation as suggested by other studies 
(Venigalla et al., 2013, Park et al., 2013).  
 
Figure 4.3 Reconstitution of recipient mice with PDK1fl/fl Rosa-26cre-ERT cells 
Total bone marrow from type PDK1fl/fl Rosa-26cre-ERT mouse (CD45.2) (1 mio cells) was 
transplanted into SJL (CD 45.1) recipient mice (n=10), 0.2 mio CD45.1 bone marrow cells used for 
rescue. % of wild type (CD45.2) before and after tamoxifen treatment. 
 
4.2.4 PDK1 deletion impairs the engraftment levels in PTEN deleted cells 
 
PTENfl/flPDK1fl/flRosa-26cre-ERT cells showed comparable engraftment levels of 
about 70%  four weeks after transplantation. Interestingly, the engraftment levels 
dropped to around 50% four weeks after treament with tamoxifen (Fig 4.4A) and 
remained at this lower level throughout the course of the experiment. This result is in 
stark contrast to the enhanced engraftment observed in PTEN deleted cells and the 
loss of engraftment observed in PDK1 deleted cells, suggesting that deletion of PTEN 
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rescues PDK1 KO engraftment phenotypes.  Genotyping PCR of genomic DNA 
isolated from peripheral blood demonstrated complete deletion of PTEN (Fig 4.4B). 
The deletion of  PDK1 alleles  was to some degree achieved as shown with the 
apperence of the deleted band (Fig 4.4C). However the presence of a floxed band was 
unexpected and therefore it was inconclusive to confim a complete deletion by PCR 
alone.  In order to demonstrate a complete loss of PDK1 protein in the compound KO 
mice, we also performed a western blot using cells isolated form bone marrow, which 
showed that  completed deletion of PTEN and PDK1 was achieved  (Fig 4.4D). 
 
Figure 4.4   Engraftment of PTEN fl/flPDK1fl/fl Rosa-26cre-ERT cells 
Total bone marrow cells from PTENfl/flPDK1fl/fl Rosa-26cre-ERT mouse (1 mio cells CD45.2 cells) 
transplanted lethally irradiated SJL mice (CD45.1 n=10) (0.2 mio CD45.1 cells used for rescue). (A) % 
of CD45.2 Donor cells 4 weeks after transplantation and every 4 weeks after tamoxifen treatment. (B) 
PCR analysis of blood 4 weeks after tamoxifen treatment showing complete deletion of PTEN.PCR 
controls are indicated. (C) PCR analysis of PDK1 allele 4 weeks after tamoxifen. PDK1 deletion 
confirmed by presence of PDK1 null band. 22 to 30 and WT represent samples from each experimental 
mouse. (D) Western blot showing complete deletion of PTEN and PDK1 in PTENfl/fl PDK1fl/fl Rosa-
26cre-ERT cells after cre activation. 
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4.2.5 Simultaneously deleting PTEN and PDK1 influences lineage distribution of 
haematopoietic cells in recipient mice 
 
To determine the effect of simultaneous deletion of PTEN and PDK1 on the 
distribution of myeloid and lymphoid cells, we analysed the distribution of 
PTEN/PDK1 deleted cells in the blood.  Surprisingly we found that the population of 
myeloid cells was increased after tamoxifen treatment whereas the population of B 
cells was reduced (Fig 4.5), a phenotype close to that of mice with PTEN deleted cells. 
However, a closer look at the populations involved and the dynamic of the changes 
revealed significant differences between loss of PTEN and loss of both PTEN and 
PDK1. In the experiment with PTEN deletion, Mac-1 positive cells were increased by 
week 8 and 12 and an increase of Mac1/Gr1 positive cells was only observed at week 
12. Interestingly, while both populations were present at similar levels in the blood, 
no changes were observed for CD4 or CD8 T-cells. In contrast, PTEN/PDK1 deletion 
led to increased Mac1/Gr1 cells in week 4, 8 and 12 and only minimal increase of 
Mac1 positive cells by week 12. Strikingly, more than twice as many Mac1/Gr1 cells 
compared to Mac1 positive cells are present in the blood. Moreover, increases in the 
CD4 and CD8 T-cell populations are present in weeks 4 and 8 and week 4, 
respectively, suggesting that loss of PDK1 in the PTEN deleted background influences 
not only the engraftment properties but also the lineage distribution of haematopoietic 
cells in recipient mice.  Although the PTEN/PDK1 KO mice grossly follow PTEN 




Figure 4.5 Reconstirution with PTEN fl/fl PDK1 fl/fl Rosa-26cre-ERT cells  
Immunophenotying of PTEN PDK1 cells before and after tamoxifen treatment is shown. Significance 
(* P <0.05 ** P >0.005 *** P > 0.001)  
 
4.3 Roles of PTEN and PDK1 in leukaemogenesis 
 
It has been shown before that PTEN deletion in haematopoietic cells lead to leukaemia 
(Guo et al., 2011, Kalaitzidis et al., 2012, Magee et al., 2012, Yilmaz et al., 2006b, 
Zhang et al., 2006). The strength of our experimental model is that we can genetically 
knockout PDK1 in PTEN deleted cells and therefore investigate the role of PDK1 in 
PTEN null leukaemia. While mice tranplanted with PDK1fl/flRosa-26cre-ERT or WT 
cells remained leukaemia free, all mice transplanted with PTENfl/flRosa-26cre-ERT 
cells where the deletion of PTEN had been induced in haematopoietic cells succumbed 
to leukaemia with a latency between 50 days and 140 days after PTEN deletion (Fig 
4.6). Remarkably, mice transplanted with PDK1fl/flPTENfl/flRosa-26cre-ERT showed 
no signs of disease until around 160 days after tamoxifen treatment. More importantly, 
the disease that was oberved from day 160 in these animals showed a different kinetics 
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and indeed 40% of the mice remained disease free beyond 400 days. Taken together, 
our data demonstrate that inhibition of PDK1 significantly delays the onset of PTEN 
mediated leukaemia and suggest that PDK1 is a critical mediator in the loss of PTEN 
mediated  leukaemogenesis. This data is consistant with data from previous studies 
showing that PDK1 has antagonistic effect to PTEN and therefore could potentialy 
offset the effects of loss of PTEN function (Iwanami et al., 2009).  However, the 
simultanious deletion of PDK1 and PTEN did not completely reverse the 
leukaemogenesis suggesting that some unknown mechanism might be triggered in the 
mice that came down with leukaemia to compensate for loss of PDK1. 
 
Figure 4.6 PTEN deletion induced leukaemogenesis 
Graph showing the development of leukaemia in mice transplanted with PTENfl/fl Rosa-26cre-ERT  
cells compared to mice transplanted with  PDK1fl/fl PTENfl/fl Rosa-26cre-ERT cells and mice 






4.3.1. PTEN deletion in adult haematopoietic cells results in ALL and AML 
 
Our previous data from the analysis of blood samples showed that PTEN deleted 
cells were able to produce a short term multi-lineage reconstitution in peripheral 
blood before eventually turning into myeloid proliferation while depleting B cells. 
We previously showed that approximately 50 days after tamoxifen treatment, the 
mice that received PTENfl/flRosa-26cre-ERT cells started to develop leukaemia 
and all thirteen mice died by day 140. Bone marrow, spleen, liver and thymus of 
the all the mice that succumbed to leukaemia were examined. FACS analysis 
using antibodies against a panel of surface markers including Mac1, Gr1, B220, 
CD4 and CD8 showed that these mice developed AML, ALL or biphenotypic 
leukaemia. Our results are comparable to findings from previous studies that also 
reported the AML and ALL phenotypes in PTEN mediated leukaemogenesis 
(Yilmaz, 2006).  The normal phenotype of a wild type mouse showed around 60% 
myeloid cells and 40% lymphoid cell in the bone marrow (Fig 4.7B). The 
distribution of haematopoietic cells in the spleen reveals around 17% are myeloid 
cells and 83% are lymphocytes with majority of cells belonging to B-cell lineage.  
The distribution of haematopoietic cells in the liver showed to be around 30% 
myeloid and 70% lymphoid cells while the thymus showed to compose of only T 
lymphocytes. Five out of thirteen mice transplanted PTENfl/fl Rosa26 cre cells 
came down with AML (Fig 4.7A). FACS analysis of the bone marrow of AML 
mice showed almost a complete infiltration of the bone marrow with myeloid cells 
and in most cases more than 70% the cells were positive for both Mac1 and Gr 1 
suggesting an shift in the turnover of myeloid cells (Fig 4.7C). The spleen and 
liver of AML mice also showed increased proportion of myeloid cells with a 
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majority of the cells again positive for both Mac1 and Gr1. The proportion of 
lymphocytes was shown to be greatly reduced in the bone marrow, spleen, and 
liver. Myeloid cells were not present in the thymus in any of the mice that came 








Figure 4.7 PTEN deletion induced AML 
(A) Graph showing survival of mice after PTEN deletion. Five out of thirteen mice came down with 




 Four out of thirteen mice transplanted with PTENfl/fl Rosa-26cre-ERT cells came 
down with ALL.  All four mice came down with ALL between 100 and 140 days 
(Fig 4.8A).  Mice that developed ALL had a very large thymus while the spleen 
and liver in some of the mice appeared large the majority of ALL mice had normal 
size liver and spleen.  Examination of the bone marrow of a typical ALL mice 
showed an infiltration of T-cells into the bone marrow making over 50% of the 
total bone marrow.   A typical ALL mouse presented with majority of the tumour 
cells double positive for CD4 and CD8 (CD4+ CD8+) (Fig 4.8B). The spleen and 
the liver of ALL mice also showed almost a complete infiltration of these organs 






Figure 4.8: PTEN deletion induced ALL. 
Graph showing survival of mice after PTEN deletion. (A) Four out of thirteen mice came down with 





Interestingly some of the mice that came down presented with both ALL and 
AML phenotypes. The mice had slightly enlarged spleen and liver as well as the 
thymus.  Bone marrow examination showed the presence of both T-cells and 
myeloid cells with the bulk of the myeloid cells positive for both Mac1 and Gr1 
in some of the mice. Four out of the thirteen mice that we examined had the 
presence of both myeloid and T-cells leukaemic cells (Fig 4.9A). The most 
intriguing finding in some of the mice that came down with AML/ALL was that 
each organ presented with a different phenotype i.e. AML phenotype in the bone 
marrow and spleen while the liver presented with ALL phenotype in the same 
mouse (Fig 4.9B). Three out of the four mice presented with close to 20% of T–
cells in bone marrow and more than 50% of T-lineage cells in the liver. One 
mouse presented with a fewer proportion the T lineage cells in the bone marrow 
but the liver presented with more than 90% T-lineage cells while the spleen had 
only 20% T-lineage cells. A classical ALL phenotype was seen in just one mouse 
that presented with more than 80% of T-lineage cells present in the bone marrow, 







Figure 4.9 PTEN deletion induced AML/ALL. 
Graph showing survival of mice after PTEN deletion. (A) Four out of thirteen mice transplanted with 
PTENfl/fl Rosa-26cre-ERT presented with AML/ALL.  (B) FACS analysis of AML/ALL mouse  
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4.4 Simultaneous deletion of PTEN and PDK1 resulted only in AML   
 
Surprisingly, mice that were transplant with PTENfl/flPDK1fl/flRosa-26cre-ERT did 
not develop ALL. To specifically examine the delay caused by deletion of PDK1 in 
PTEN induced AML we show the survival curve for the mice that succumbed to AML 
(Fig 4.10). Out of the thirteen mice that were transplant with PTENfl/flRosa-26cre-
ERT cells, only five came down with AML. Six out of ten mice transplanted with 
PTENfl/flPDK1fl/flRosa-26cre-ERT cells succumbed to AML.  Remarkably, four mice 
from the group that received PTENfl/flPDK1fl/flRosa-26cre-ERT survived passed 400 
day without any symptoms of disease.  
 
 
Figure 4.10 Simultaneous deletion PTEN and PDK1 only results in AML. 
Graph showing the development of AML in mice transplanted with PTENfl/fl Rosa-26cre-ERT  
cells compared to mice transplanted with PDK1fl/fl PTENfl/fl Rosa-26cre-ERT cells and mice 





FACS analysis of the bone marrow of AML mice showed almost a complete 
infiltration of the bone marrow with myeloid cells and in most cases more than 80% 
of the cells were positive for both Mac1 and Gr1 suggesting a shift in the turnover of 
myeloid cells in the bone marrow in both PTENfl/flRosa-26cre-ERT as well as 
PTENfl/flPDK1fl/fl Rosa-26cre-ERT group. The spleen and liver of AML mice also 
showed increased proportion of myeloid cells with a majority of the cells again 
positive for both Mac1 and Gr1 (Fig 4.11A). Cell morphology from blood, spleen and 
bone marrow showed increasing appearance of immature myeloid cells in 
PTENfl/flRosa-26cre-ERT group and PDK1fl/flPTENfl/flRosa-26cre-ERT in all mice 
that came down with AML (Fig 4.11B). However, the frequency of immature cells in 
peripheral blood, spleen as well as in the bone marrow was much higher in the mice 
that received PTENfl/flRosa-26cre-ERT cells when compared to mice that received 
PDK1fl/flPTENfl/flRosa-26cre-ERT cells. Moreover, the size of the immature myeloid 
cells in AML mice that were transplanted with PTENfl/flRosa-26cre-ERT was greater 
compared to the cells in mice transplanted with PDK1fl/flPTENfl/flRosa-26cre-ERT 
cells in peripheral blood, spleen and liver. Histology showed infiltration of the liver 
tissue with blast cells in PTENfl/flRosa-26cre-ERT AML mouse as well as 
PDK1fl/flPTENfl/flRosa-26cre-ERT mouse (Fig 3.11C). Histology of the spleen 
revealed complete disruption of the splenic architecture when normal spleen is 
compared to PDK1fl/flPTENfl/flRosa-26cre-ERT AML mouse or 








Figure 4.11 PTEN induced AML in mice transplanted with PTENfl/fl Rosa-26cre-ERT cells and 
PDK1fl/fl PTENfl/fl Rosa-26cre-ERT cells 
(A) FACS profile from a mouse transplant with PDK1fl/fl PTENfl/fl Rosa-26cre-ERT cells that 
succumbed to AML. (B) Cell morphology from AML mice blood film from PDK1fl/fl PTENfl/fl Rosa-
26cre-ERT mouse group vs blood film from PTENfl/fl Rosa-26cre-ERT mouse group.  Bone marrow 
cytospin from PDK1fl/fl PTENfl/fl Rosa-26cre-ERT mouse group vs bone marrow cytospin from PTENfl/fl 
Rosa-26cre-ERT mouse group. Spleen cytospin from PDK1fl/fl PTENfl/fl Rosa-26cre-ERT mouse group 
vs spleen cytospin from PDK1fl/fl PTENfl/fl Rosa-26cre-ERT mouse group. (C) Infiltration of the liver 
with blast cells (compare WT to PTEN KO and PTEN PDK1 KO).  (D) Complete effacement of the 
splenic architecture (compare WT to PTEN KO and PTEN PDK1 KO).  
 
4.4.1 PTEN loss induced AML is independent from PDK1 signalling. 
 
During normal PI3K pathway signalling, PDK1 is required for activation of several 
effector molecules such as AKT, RSK and PKC fundamental to cell survival, growth 
and migration (Bayascas, 2010, Gagliardi et al., 2015, Hossen et al., 2015). Lack of 
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PDK1 in  mouse embryonic stem (ES) cells resulted in  failure  to activate PKB, S6K 
and RSK  when exposed to stimuli that trigged the activation of these enzymes in 
wild-type ES cell (Balendran et al., 2000). Thus, we aimed to investigate the 
mechanism of leukaemogenesis mediated by loss of PTEN in the absence of PDK1. 
Total bone marrow cells from mice transplanted with PTENfl/flRosa-26cre-ERT and 
PDK1fl/flPTENfl/flRosa-26cre-ERT cells that developed AML were analysed to 
evaluate the role of PTEN and PDK1 in the PI3Kinase signalling pathway during 
leukaemogenesis. We used PDK1 KO cells generated by treating mononuclear cells 
PDK1fl/fl Rosa-26cre-ERT with 300 nM of tamoxifen and wild type cells from a 
healthy C57BL6 as controls to demonstrate the normal function of PTEN and PDK1.  
Bone marrow cells were not exposed to any stimuli to activate PI3K pathway enzymes 
prior to preparing cell lysates. We demonstrate that leukemic cells isolated from the 
bone marrow of mice transplanted with PTENfl/flRosa-26cre-ERT have constitutively 
high levels of phosphorylated  AKT  at Thr 308 and Ser473 as well as SGK1 Thr256 
(Fig 3.12). Interestingly, high levels of phosphorylated AKT Thr308 and SGK1 
Thr256 were observed in leukemic cells isolated from mice transplanted with 
PDK1fl/flPTENfl/flRosa-26cre-ERT. While under normal conditions PDK1 is the only 
known kinase responsible for the activation of AKT at Thr308, our findings suggest 
that PTEN deletion mediated AML cells may possess an alternative pathway that 
bypasses the normal requirement for PDK1 to mediate the phosphorylation of 
downstream kinases. These results suggest that PTEN null leukemic cells can grow, 
proliferate, survive and possess pAKT (Thr308) suggesting an uncompromised PI3K 
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pathway even in the absence of PDK1. This result also suggest that AKT ativation 
may still be a requirement for the survival of AML  cells. 
                                           
 
Figure 4.12 PTEN deleted AML cells by passes the normal requirement of PDK1 to activate 
downstream enzymes.  
Western blot analysis of AKT Thr308, Ser473 and SGK1 Thr256 phosphorylation in PTENfl/fl Rosa-
26cre-ERT and PDK1fl/fl PTENfl/fl Rosa-26cre-ERT bone marrow leukaemic cells. 
 
4.4.2 PTEN deficient AML cells failed to induce leukaemia in secondary recipient 
mice 
  
The functionality of leukaemia stem cells is determined by their ability to induce 
leukaemia in secondary recipient mice. Leukaemia-initiating cells are able to maintain 
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diseases upon serial transplant (Lapidot et al., 1994). To test whether PTEN deficient 
AML cells and PTEN PDK1 deficient AML cells can be transplantable and transfer 
AML to irradiated mice we transplanted bulk  AML cells isolated from mice that came 
down with AML after transplant with PTENfl/flRosa-26cre-ERT cells and 
PDK1fl/flPTENfl/fl Rosa-26cre-ERT cells.  Transplanting the bulk leukaemia cells did 
not transfer the disease to secondary recipient mice with both genotypes in my hands 
and all mice survived past 50 day without any symptoms of leukaemia (Fig 4.13). This 
findings are contradictory to previous finding by Yilmaz that suggested PTEN 
deficient AML can be transplantable in secondary recipient mice (Yilmaz et al., 
2006b).  
 
Figure 4.13 PTEN KO AML cells and PTEN PDK1 KO AML cells failed to transferee disease to 
secondary mice 
Graph showing survival of mice after transplant win PTEN  deficient AML cells vs PTEN PDK1 




4.4.3 PTEN deletion induced T-ALL tumour cells appeared to be at different 
stages in each mouse  
 
As described above, 30 % of mice develop ALL upon PTEN deletion. ALL cells 
showed high expression of CD4 and/or CD8 in the bone marrow, spleen, liver and 
thymus and were accordingly classified as T-ALL. Strikingly, this phenotype was 
found only in mice that received PTENfl/flRosa-26cre-ERT cells whereas none of the 
mice that received PDK1fl/fl PTENfl/fl Rosa-26cre-ERT showed the presence of these 
clonal cells in the bone marrow, spleen or liver of mice that succumbed to illness (Fig 
4.14A). A closer examination of the liver for the origin of the T-lineage cells using 
CD8 and CD4 markers revealed that the tumour cells were at different stages in each 
mouse.  Three out of four (50%) mice with T cell tumour showed to have majority of 
the cells positive only for CD4 (CD4+CD8-) with a small portion of the cells double 
positive CD4 and CD8 cells (CD4+CD8+) (Fig 4.14B). The other two mouse were 
found to have majority of the T cells double positive CD4 and CD8 (CD4+CD8+). We 
further characterised the tumour cells using May Grunwald and Giemsa stain. 
Peripheral blood smear prepared using blood drawn from heart puncture revealed the 
presence of ALL blast in circulation in mice that succumb to T-ALL (Fig4.14C).  
These cells appeared to be larger compared to normal mature lymphocytes. Cytospin 
from bone marrow and spleen from the ALL mice also revealed the presence of ALL 
blast accounting for more than 50% of the total bone marrow and spleen cells.  
Together these data suggest that PTEN deletion might induce T-ALL which can 









Figure 4.14 PTEN deletion induce ALL.  
Graph showing the development of ALL in mice transplanted with PTENfl/fl Rosa-26cre-ERT  cells 
compared to mice transplanted with PDK1fl/fl PTENfl/fl Rosa-26cre-ERT cells and mice transplanted 
with wild type cells (P value > 0.0001 PTENfl/flRosa-26cre-ERT vs PDK1fl/fl PTENfl/flRosa-26cre-ERT). 
(B) FACS profile of ALL liver from mice transplanted with  PTENfl/flRosa-26cre-ERT. 
 
 
4.4.4 PTEN deficient T-ALL cells are able to engraft and induce secondary 
leukaemia 
 
To test the ability of PTEN null ALL cells to engraft and induce secondary leukaemia, 
we set up a secondary transplant experiment using cells isolated from mice that were 
transplanted with PTENfl/fl Rosa-26cre-ERT cells that succumbed to T-ALL.  To 
determine the frequency of PTEN null T-ALL stem cells required to induce a 
secondary T-ALL in recipient mice we transplanted 1 mio, 0.1 mio, and 0.01 mio into 
groups of 5 mice per cohort.  We demonstrate that PTEN null T-ALL cells were able 
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to induce leukaemia in secondary recipient mice in less than 30 days when 1 mio or 
0.1 mio were transplanted whereas mice that receive 0.01Mio  cells where able to 
survive past 60 days without and symptoms of illness. The phenotype of the secondary 
leukaemia showed the presence of double positive CD4 and CD8 lymphocytes similar 
to the primary leukaemia (Fig 4.15). Our findings are consistent with previous data 
from that suggested that PTEN deficient ALL cells are transplantable (Yilmaz et al., 
2006b).    
 
Figure 4.15Limiting dilution transplant of PTEN KO ALL cells  
Graph showing the development of secondary ALL in mice transplanted with different numbers of 
PTEN  null ALL cells (1 mio n=5, 0.1 mio n=5, 0.01 mio n=5).  
 
4.5 PDK1 MGK465 mutation has little influence on the PTEN deletion phenotype 
 
Given that loss of PDK1 rescues or changes the phenotypes observed upon loss 
of PTEN, we sought to investigate which property of PDK1 mediates this 
response. To further elucidate the role of PDK1 in  loss of PTEN mediated 
leukaemogenesis, we induced PTEN deletion in PDK1MGK465/MGK465 cells. 
135 
 
PDK1MGK465/MGK465 mutant bears a mutation that disrupt the normal fuction of the 
PH domain of the PDK1 Protein therefore distorts its ability to phosphorylate 
AKT Thr308. To this end, transplantation experiments with 
PDK1MGK465/MGK465PTENfl/fl Rosa-26cre-ERT cells were carried out.  The 
engraftment levels four weeks after transplantation were around 60% which is 
comparable with other experiments. Interestingly, similar to PTEN deletion, 
deletion of PTEN in the PDK1 MGK465 background led to an increase in 
engraftment levels over time (Fig 4.16C). Moreover, an increase in Mac1/Gr1 
positive cells was observed at week 4, 8, and most dramatically at week 12, 
whereas the Mac1 positive cells were increased at weeks 4, and 8 but not at week 
12. On the other hand, a reduction of B220 B-cells was observed. The observed 
phenotype of the PDK1MGK465/MGK465 PTEN deletion closely resembles that of 
PTEN deletion suggesting that PDK1 MGK465 has little influence on the PTEN 
deletion phenotype (Fig 4.16D). While the  control group with 
PDK1MGK465/MGK465 without PTEN deletion also showed an increase of 
engraftment levels over time, (Fig 4.16A), the distribution of myeloid and 
lymphoid cells also changed over time as an decrease of  both Mac1/Gr1 and 
Mac1 positive myeloid cells and an increase of B220 B-cells as well as CD4 and 
CD8 T- cells was observed (Fig 4.16B) . To confirm the deletion of PTEN and 
presence of floxed mutant allele we isolated DNA from blood samples four weeks 
post cre-activation. We show that PTEN was completeley deleted indicated by the 
absent of the floxed band (Fig 4.16E) . We also confirm the presense of the 





Figure 4.16 Reconstitution with PDK1 MGK465/MGK465PTEN fl/fl Rosa-26cre-ERT 
cells.  
PDK1MGK465/MGK465PTENfl/fl Rosa-26cre-ERT cells and PDK1MGK465/MGK465  (CD45.2 1 Mio cells) were 
transplanted into SJL mice (n=10) (CD 45.1 0.2 mio rescue cells). (A) and (C) The percentage of 
CD45.2 donor cells 4 weeks after transplantation and every 4 weeks after tamoxifen treatment is show. 
(B) and (D) Immunophenotying of donor cells before and after tamoxifen with treatment is shown. 
Significance (* P <0.05 ** P >0.005 *** P > 0.001). (E) PCR showing complete deletion of PTEN. (F) 






4.5.1 PDK1 MGK465 mutation has little influence on the PTEN mediated 
leukeamogenesis 
 
We investigated the specific function of PDK1 by observing the latency of leukaemia 
induced by PTEN deletion in PDK1 MGK465 mutant cells.  Surprisingly, the PDK1 
MGK465 mutation had little effect on the general onset of leukaemia in mice 
transplanted with PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells compared to 
mice that received PTENfl/fl Rosa-26cre-ERT cells. All mice from each group died 
between 100 to 150 days post tamoxifen treatment (fig 4.17A). Consequently, both 
AML and ALL phenotype were observed in mice transplanted with 
PDK1MGK465/MGK465PTENfl/fl Rosa-26cre-ERT cells similar to what was observed in 
mice transplant with PTENfl/fl Rosa-26cre-ERT cells. However, when we assesed the 
latency of AML alone and compared between mice transplanted with 
PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells vs mice transplant with PTENfl/fl 
Rosa-26cre-ERT cells, we noted a slight significant delay on the onset of illness 
between the two groups (Fig 4.17B). Cell morphology from blood collected from the 
heartrevealed the presense of myeloid blast in peripheral blood. An increase in the 
frequency of myeloid blasts was also observed in the bone marrow and spleen (Fig 
4.17C). FACS data showed no difference in the phenotype of AML cells between the 
two groups. AML was characterized by expression of double positive Mac1/Gr1 cells 
making over 80% of the bone marrow population. The double positive Mac1 and Gr1 
phenotype was also found to be the major fractions in the spleen and liver (Fig 4.17D).  
Given that the PDK1 MGK465 mutation disrupts the PH domain responsible for 
recruiting and phosphorylating AKT at the membrane, we therefore speculate slight 
delay on the onset leukamia might be a result deficient or delayed AKT  activation 
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suggestng AKT might have a signicant role in AML cause by loss of function o the 
PTEN protein. These results support data from other studies that showed inhibition of 
AKT inhibited growth and induced apoptosis in AML cell lines and primary AML 









Figure 4.17 PDK1MGK465/MGK465 mutation slightly delayed the onset of PTEN 
deletion mediated AML.  
(A) Graph showing the development of leukaemia in mice transplanted with PTENfl/flRosa-26cre-ERT 
cells compared to mice transplanted with PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells and mice 
transplanted with  PDK1MGK465/MGK465 cells. (B) Graph showing the development of AML in mice 
transplanted with PTENfl/flRosa-26cre-ERT  cells compared to mice transplanted with 
PDK1fl/flPTENfl/flRosa-26cre-ERT cells and mice transplanted with PDK1MGK465/MGK465 cells (P value 
=0.0472 PTENfl/flRosa-26cre-ERT vs PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT). (C) Cell 
morphology from bone marow and spleen of AML mouce transplanted with PTENfl/flRosa-26cre-ERT  
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cells. (D) FACS profile of AML mice transplanted with PDK1MGK465/MGK465 PTENfl/flRosa-26cre-ERT 
cells. 
4.5.2 PDK1 MGK 465 mutation has no effect on AKT signalling in PTEN null 
AML cells 
 
To gain further insight into the function of PDK1 using the PDK1 MGK465 mutation, 
we isolated bone marrow cells from mice transplanted with 
PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells and PTENfl/flRosa-26cre-ERT 
cells. Our earlier data showed that PTEN null AML cells isolated from bone marrow 
of mice transplant with PTENfl/flRosa-26cre-ERT cells had elevated levels of 
phosphorylated AKT  both at Thr308 and Ser473 as well as on SGK1 Ser256.  
Interestingly we observed that elevated levels of phosphorylated AKT  Thr308 and 
Ser 473 were observed in cells isolated from mice transplant with 
PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells (Fig 4.17). We previously showed 
that deletion of PDK1 in PTEN null leukaemic cells failed to inhibit the 
phosphorylation of down stream PDK1 targets. These results further supports the idea 
that deletion of PTEN bypass the normal requirement of PDK1 to activate down 




Figure 4.18 PDK1 MGK465 mutation has no effect on AKT Thr 308 in PTEN 
null AML cells.  
Western blot analysis of AKT Thr308, Ser473 and SGK1 Thr256 phosphorylation in PTENfl/flRosa-
26cre-ERT and PDK1fl/flPTENfl/flRosa-26cre-ERT bone marrow leukaemic cells. 
 
4.5.3 PTEN deletion induced ALL and AML/ALL phenotypes in PDK1 MGK465 
mutant 
 
PDK1 MGK465 mutation did not seem to have much effect on PTEN deletion induced 
ALL as compared to the simultaneous deletion of PTEN and PDK1, which resulted in 
significant delay of leukaemia and complete elimination of ALL. We compared the 
latency of ALL and AML/ALL in mice transplant PTENfl/flRosa-26cre-ERT cells to 
mice transplant with PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells. Mice in both 
groups developed ALL or AML/ALL and died between 100 to 150 days after PTEN 
deletion with no significant difference on the onset of illness. Only two mice out of 
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ten mice transplanted with PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells 
succumbed to ALL while four of the mice succumbed to AML/ALL (4.19 A and B).  
FACS analysis of the liver revealed that the T-lineage leukemic cells found in one of 
the ALL mice were mostly double positive for CD4 and CD8 (CD4+CD8+) (Fig 
4.19D) while the other mouse showed to have majority of the cells positive for CD4 
and negative for CD8 (CD4+CD8-). Cell morphology from peripheral blood revealed 
the presence of lymphoid blasts in circulation. Increased frequency of lymphoblast 
was also observed in spleen and bone marrow (Fig 4.19C). FACS profile of mice that 
came down with AML/ALL showed expansion of double positive Mac1 and Gr1 
myeloid cells (Mac1+Gr1+) in the bone marrow while the liver or spleen showed to 















Figure 4.19 PTEN deletion induced ALL and AML/ALL phenotypes in PDK1 
MGK465 mutant.  
(A) Graph showing the development of ALL in mice transplanted with PTENfl/flRosa-26cre-ERT cells 
compared to mice transplanted with PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells. (B) Graph 
showing the development of AML/ALL in mice transplanted with PTENfl/flRosa-26cre-ERT cells 
compared to mice transplanted with PDK1fl/fl PTENfl/flRosa-26cre-ERT cells. (C) Cell morphology 
from the bone marrow and spleen showing invasion of lymphoblasts.(D) FACS profile of ALL mouse 
transplanted with PDK1MGK465/MGK465 PTENfl/flRosa-26cre-ERT cells. (E) FACS profile of AML/ALL 
mouse transplanted with PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells. 
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4.5.4 PDK1 MGK465 mutation depletes ALL stem cells in PTEN null induced 
ALL 
 
Our earlier data showed that PTEN null ALL primary cells isolated from mice 
transplanted with PTENfl/flRosa-26cre-ERT cells are able to engraft and induce ALL 
in secondary recipient mice. Moreover all mice injected with 1 Mio or 0.1Mio cells 
die within less than 30 days. We investigate the functionality of ALL cells isolated 
from mice transplanted with PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells by 
setting up similar limiting dilution transplant assay (Fig 4.20A).  We observed that 
when we transplant 1 mio of ALL cells isolated from mice transplant with 
PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells only 2 mice died within 60 and 
whereas transplanting 0.1 mio or 0.01 mio cells was not able to induce leukaemia past 
60 days.Our data shows that PDK1 MGK456 mutation significantly depletes ALL 





Figure 4.20 PDK1 MGK465 mutation depletes PTEN null ALL stem cells.   
(A) Graph showing survival of mice transplanted with different number of PTEN null ALL cells compared to mice transplanted with different numbers of PDK1 
MGK465 mutant PTEN null ALL cells. (B) Leukemic stem cells frequency of PTEN null ALL stem cells vs PDK1 MGK465mutant PTEN null ALL stem cells. 
LDA graph showing stem cells frequency of PTEN null ALL stem cells vs PDK1 MGK465 mutant PTEN null ALL stem cells. 
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3.6 PDK1 L155E mutation has little influence on the PTEN deletion phenotype 
 
To investigate the role of the other ‘arm’ of PDK1 , i.e. PIF pocket dependent 
PDK1 signal transduction which  mediates  the phosphorylation of SGK1, RSK, 
PKC and S6K, we analysed the PDK1L155E/L155EPTEN fl/fl Rosa-26cre-ERT 
transplantation experiment. While the initial engraftment levels were very 
comparable to other experiments (70%), we also observed in 
PDK1L155E/L155ERosa-26cre-ERT group a decrease in  engraftment levels after 
tamoxifen treatment over time (Fig 4.21A). Interestingly, the 
PDK1L155E/L155EPTENfl/flRosa-26cre-ERT group showed an increase in 
engraftment over time after treatment with tamoxifen similar to the what we 
observed in the wt or PTENfl/flRosa-26cre-ERT group (Fig 4.21C). Analysis of 
the peripheral blood composition revealed almost identical results that observed 
in the PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT deleted group which closely 
resembles that of the PTEN deleted group (fig 4.21D), suggesting that the 
observed effects of PDK1 on loss of PTEN mediated phenotype require both arms 
of PDK1 signalling, i.e. the active PH domain and PIF pocket for proper AKT and 
SGK activation, respectively. While the  control group with PDK1L155/L155 without 
PTEN deletion showed a decrease of engraftment levels over time, (Fig 4.20A), 
the distribution of myeloid and lymphoid cells also changed over time as a 
decrease of  Mac1/Gr1 positive myeloid cells was observed at 12 weeks while an 
increase of B220 B-cells was observed at 12 weeks (Fig 4.21B). To confirm the 
deletion of PTEN we isolated DNA from blood samples four weeks post cre-
activation. We show that PTEN was completeley deleted indicated by the absent 
of the floxed band (Fig 3.19E). The excision of the minigene could not be 
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detemined using previously decribed primers P1 and P2 (Fig 2.3) hence the 
presense of a floxed band (Fig 4.21F). 
 
 
Figure 4.21 Engraftment and recostitution  of PDK1 L155 mutant cells.  
PDK1L155/L155PTENfl/flRosa-26cre-ERT cells and PDK1L155/L155Rosa-26cre-ERT cells (both CD45.2) 
were transplanted into SJL mice (CD 45.1).  (A) and (C) The percentage of CD45.2 donor cells 4 weeks 
after transplantation and every 4 weeks after tamoxifen treatment is shown.  (B) and (D) 
Immunophenotying of donor cells before and after tamoxifen with treatment is shown. Significance (* 
P <0.05. ** P >0.005 *** P > 0.001). (E) PCR showing complete deletion of PTEN. (F) PCR showing 











Mouse groups that received PDK1L155E/L155EPTENfl/fl Rosa-26cre-ERT cells 
succumbed to leukaemia between 70 and 270 days.  All nine from this group 
succumbed to leukaemia and there was no significant difference when we compared 
the survival transplanted with PTENfl/fl Rosa-26cre-ERT cells of mice that received 
PDK1L155E/L155EPTENfl/fl Rosa-26cre-ERT cells (Fig 4.22A). Moreover, analysis of 
the bone marrow, spleen, liver and thymus carried out carried out revealed that mice 
in this group succumbed to AML, ALL or biphenotype AML/ALL similar to what we 
observed previously in mice that received PTENfl/flRosa-26cre-ERT cells. Similarly, 
mice that came down with AML also presented with enlarged spleen and liver while 
those with ALL presented with a large thymic mass comparable to what we observed 
in mice that received PTENfl/fl Rosa-26cre-ERT cell. Interestingly, when we compared 
the onset of AML in this group to AML in the PTENfl/flRosa-26cre-ERT group, we 
discovered that there was no significant difference on the latency of disease (Fig 
4.22B).  Three out of nine mice in this group came down with AML. Cell morphology 
from bone marrow and spleen revealed increased frequency of myeloid blasts (Fig 
4.22C). FACS analysis revealed that the AML phenotype in this group was 
characterised by expansion of the double positive Mac1 and Gr1 population while 
depleting all other lineages (Fig 4.22D). The phenotype of cells observed in the bone 
marrow spleen and liver was comparable to the observed phenotype found in mice 









Figure 4.22 Deletion of PTEN induces leukaemia in PDK1 L155 mutant cells.  
(A) Graph showing the development of leukaemia in mice transplanted with PTENfl/flRosa-26cre-ERT 
cells compared to mice transplanted with PDK1L155/L155 PTENfl/fl Rosa-26cre-ERT cells and mice 
transplanted with PDK1L1555/L1555 cells. (B) Graph showing the development of AML in mice 
transplanted with PTENfl/flRosa-26cre-ERT cells compared to mice transplanted with  PDK1fl/fl 
PTENfl/flRosa-26cre-ERT cells and mice transplanted with PDK1L155/L155 cells (P value =0.244 
PTENfl/flRosa-26cre-ERT vs PDK1L155/L155PTENfl/flRosa-26cre-ERT). (C) Cell morphology from bone 
marrow and spleen revealed increased frequency of myeloid blasts (D)FACS profile of AML mice 
transplanted with PDK1L155/L1555PTENfl/flRosa-26cre-ERT cell 
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4.6.2 PDK1 L155 mutation has no effect on SGK1 signalling in PTEN null AML 
cells 
 
To gain further insight in the function of PDK1, we isolated bone marrow cells from 
mice that came down with AML from the PDK1L155E/L155EPTENfl/flRosa-26cre-ERT 
group for biochemical analysis. In parallel, we also used bone marrow cells isolated 
from wt and PDK1L155E/L155ERosa-26cre-ERT group. As previously described, cells 
isolated from  PTENfl/flRosa-26cre-ERT AML showed high levels of phosphorylated 
AKT Thr308 , AKT Ser473 and SGK1 Ser206 (Fig 4.23).  As expected, 
PDK1L155E/L155ERosa-26cre-ERT  cells were not able to phosphoprylate SGK1 Ser206 
due to the defective PIF pocket.  PDK1L155E/L155ERosa-26cre-ERT cells also could not 
show phosphorylation of AKT Thr308, which might be due to the fact that normal 
stimulation of the PI3K pathway with IGF was not induced in these cells used in this 
experiment. However, the wild type cells showed baseline phosphorylation of SGK1 
Ser206 without sitmilation, therefore giving evidence that PDK1L155E/L155E Rosa-
26cre-ERT cells are indeed defective in  phosphorylation of SGK1 Ser206. 
Remarkably, PDK1L155E/L155ERosa-26cre-ERT cells regained phosphorylation of 
SGK1 upon PTEN deletion. This is consistent with our earlier findings that deletion 
of PTEN bypasses the normal requirement of PDK1 to activate downstream targets 
such as AKT and SGK1 in leukaemic cells. To futher confirm that expression of the 
mutant allele and excision of the minigene, DNA isolated from the bone marrow of 
leukaemic mice in this group was sent Transnetyx laboratories for genotyping. Their 
result confirmed the expression of the mutant allele (PDK1L155/L155 ) and absence of 
the minigene  (PDK1 TG)  (Table 4.1). Although one of the sample  showed be 
positive for the minigene the signal was lower than the positive control. 
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Figure 4.23 PDK1 L155 mutation has no effect on phosphorylate of SGK1 in PTEN null AML 
cells.  
Western blot analysis of AKT Thr308, Ser473 and SGK1 Thr256 phosphorylation in PTENfl/flRosa-
26cre-ERT and PDK1L155/L155PTENfl/fl Rosa-26cre-ERT  bone marrow leukaemic cells. 
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4.6.3 PDK1 L155 Mutation delayed the onset of ALL   
 
To investigate the impact of PDK1 L155 mutation on ALL phenotype, we compared 
the latency of ALL in mice that received PDK1L155E/L155E PTENfl/flRosa-26cre-ERT 
cells to the latency of ALL in mice that received PTENfl/flRosa-26cre-ERT cells. Two 
out of the nine mice injected with PDK1L155E/L155EPTENfl/flRosa-26cre-ERT cells 
came down with ALL phenotype. Interestingly, we observed that mice that received 
PTENfl/flRosa-26cre-ERT cells and eventually succumbed to ALL died within 120 
days after PTEN deletion, whereas mice that received PDK1L155E/L155EPTENfl/flRosa-
26cre-ERT cells succumb to ALL after 220 days post PTEN deletion. We found the 
difference in latency of ALL between the two groups was significant (Fig 4.24A). 
FACS analysis of the bone marrow, spleen, liver and thymus revealed infiltration of 
these organs with T-lymphocytes that are double positive for CD4 and CD8 markers 
comparable to what we observed in the PTENfl/flRosa-26cre-ERT group. Cell 
morphology from the bone marrow and spleen revealed an increase in lymphoblast 
(Fig 4.24C). Similar to our earlier observation in mice that received PTENfl/flRosa-
26cre-ERT cells and PDK1MGK465/MGK465PTENfl/flRosa-26cre-ERT cells, a fraction of 
mice that received PDK1L155E/L155EPTENfl/flRosa-26cre-ERT cells came down with a 
phenotype we described as AML/ALL biphenotype. Four mice in this group came 
down with this bi-phenotype; however when we compare the latency of disease in 
these mice compared to mice that came down with the same phenotype of disease in 
the PTENfl/flRosa-26cre-ERT group, the similar latency was observed between two 
groups (Fig 4.24B).  The AML/ALL phenotype in these mice showed expansion of 
myeloid cells in the bone marrow comparable to AML phenotype whereas the liver 












Figure 4.24 PTEN deletion induced ALL and AML/ALL phenotypes in PDK1 L155 mutant.  
(A) Graph showing the development of ALL in mice transplanted with PTENfl/flRosa-26cre-ERT cells 
compared to mice transplanted with  PDK1L155/L155 PTENfl/flRosa-26cre-ERT cells. (B) Graph showing 
the development of AML/ALL in mice transplanted with PTENfl/flRosa-26cre-ERT  cells compared to 
mice transplanted with  PDK1fl/fl PTENfl/flRosa-26cre-ERT cells. (C) Bone marrow and spleen cell 
morphology showing increased lymphoblasts. (D) FACS profile of ALL mouse transplanted with 
PDK1L155/L155PTENfl/flRosa-26cre-ERT cells. (E) FACS profile of AML/ALL mouse transplanted with 




4.6.4 PDK1 L155 mutation depletes ALL stem cells in PTEN null induced ALL 
 
To test the functionally of ALL stem cells isolated from mice transplanted with 
PDK1L155/L155PTENfl/flRosa-26cre-ERT cells, we set up an limiting dilution transplant 
assay. We  transplant 1 mio, 0.1 mio and 0.01 mio cells into lethally irradiated mice 
(n=5) together with 0.2 mio wild type cells for rescue.  We observed that when  we 
transplant 1 mio of ALL cells isolated from mice transplant with 
PDK1L155/L155PTENfl/flRosa-26cre-ERT cells only one mouse died within 60 and 
whereas transplanting 0.1 mio or 0.01 mio cells was not able to induce leukaemia past 
60 days (Fig 4.25A). Our data shows that PDK1 L155 mutation depletes ALL stem 




Figure 3.23 PDK1 L155 mutation depletes PTEN null ALL stem cells.  
(A) Graph showing survival of mice transplanted with different number of PTEN null ALL cells compared to mice transplanted with different numbers of PDK1 
L155 mutant PTEN null ALL cells. (B) Leukaemic stem cells frequency of PTEN null ALL stem cells vs PDK1 MGK465 mutant PTEN null ALL stem cells. (C) 
LDA graph showing stem cells frequency of PTEN null ALL stem cells vs PDK1 MGK465 mutant PTEN null ALL stem cells. 
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4.7 Simultaneous deletion of PTEN and PDK1 using the Vav-cre  
 
 
We have established that PTEN deletion in haematopoietic cells using a Rosa-
26cre-ERT system in a transplantation setting causes leukaemia. We further 
showed that deletion PTEN and PDK1 using the Rosa-26cre-ERT system has an 
impact on the latency of leukaemia using transplant studies. To support and 
strengthen our finding, we used another Cre mouse model which utilizes the Vav-
cre sytem to initiate the deletion of PTEN and PDK1 only in the haematopoietic 
cells. To this end, we generated PTENfl/fl Vav-cre, PDK1fl/fl Vav-cre and 
compound knockout PTENfl/flPDK1fl/fl Vav-cre. Single PTENfl/fl Vav-cre mice 
were viable and developed to adult mice. Likewise PDK1fl/fl Vav-cre mice were 
viable and developed to adult mice. Although the compound knockout 
PTENfl/flPDK1fl/fl Vav-cre mice were viable, a few of these mice were born with 
abnormalities such as tiny body size and deformed head. More importantly, the 
breeding of compound knockout mice was very challenging and there seemed to 
be a negative selection against the PTENfl/flPDK1fl/fl Vav-cre genotype. We 
produced more than 200 pups and we were only able to produce 6 mice with 
desired genotype and all of them were females. In addition, these females were 
not able to breed due to early onset of leukaemia which was unexpected if 
compared to the onset of leukaemia in PTENfl/flPDK1fl/fl Rosa-26cre-ERT after 
tamoxifen treatment. We tried different breeding strategies to maximise the 
probability of getting more PTENfl/flPDK1fl/fl Vav-cre.  Surprisingly, 
PTENfl/wtPDK1fl/fl Vav-cre also succumbed to illness making it much more 
difficult to maintain and expand this mouse line. However mice with this genotype 
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were not analysed so I could not confirm leukaemia.  To investigate the 
underlying cause of illness, we bleed PTENfl/flPDK1fl/fl Vav-cre (n=3), 
PTENfl/flVav cre (n=3), PDKfl/fl Vav-cre and PTENfl/fl   (n=3). Similar to our 
earlier finding, deletion of PTEN resulted in positive selection towards myeloid 
lineage and depletion of B-cells in both single PTEN knock-out and compound 
PTEN/PDK1 knockout (Fig 4.26). Surprisingly, we discovered that PDK1fl/flVav 
cre   showed comparable result to PTENfl/fl Vav-cre. 
 
Figure 4.26 Impairment of haematopoiesis in PTENfl/fl Vav-cre, PDK1fl/fl Vav-cre and compound 
PTENfl/fl PDK1fl/fl Vav-cre mice.   
PTENfl/fl  (n=3), PTEN KO (n=3),  PTEN PDK1 KO  and PDK1 KO(n=3). Immunophenotying of 
peripheral blood expansion of the myeloid lineage while depleting B cell lineage. 
 
 
We monitored the PTENfl/flPDK1fl/fl Vav-cre, PTENfl/fl Vav-cre, PDK1fl/fl Vav-cre 
mice until they succumbed to leukaemia. We analysed eight PTENfl/fl Vav-cre 
mice and we show that PTEN deletion resulted in leukaemia between 40 and 110 
days comparable to our earlier findings using PTENfl/fl Rosa-26cre-ERT. 
Surprisingly PTENfl/flPDK1fl/fl Vav-cre mice succumbed to leukaemia between 50 
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and 110 days which is early compared to our findings using 
PTENfl/flPDK1fl/flRosa-26cre-ERT (Fig 4.27A).  FACS analysis revealed that 
some of the mice came down with AML. Two out of eight PTENfl/fl Vav-cre mice 
come down with AML whereas all six out of six PTENfl/flPDK1fl/fl Vav-cre came 
with ALL (Fig 4.27B).  The bone marrow of AML mice showed almost a 
complete infiltration of the bone marrow with myeloid cells and in most cases 
more than 70% the cells were positive for both Mac1 and Gr1 suggesting a shift 
in the turnover of myeloid cells (Fig 4.27C). The spleen and liver of AML mice 
also showed increased proportion of myeloid cells with a majority of the cells 
again positive for both Mac1 and Gr1. The proportion of lymphocytes was greatly 
reduced in the bone marrow, spleen and liver. Myeloid cells were not present in 
the thymus in any of the mice that came down with AML. Interestingly, while the 
FACS profile of AML mice was similar in PTENfl/fl Vav-cre mice and 
PTENfl/flPDK1fl/fl Vav-cre mice, we observed that myeloid cells infiltrated into 











Figure 4.27. Development of leukaemia in PTENfl/fl Vav-cre and PTENfl/fl PDK1fl/fl Vav-cre 
mice. 
(A) Graph showing the development of leukaemia in PTENfl/fl Vav-cre mice compared to 
PTENfl/flPDK1fl/fl Vav-mice. (B) Graph showing the development of AML in PTENfl/fl Vav-cre mice 
compared to PTENfl/flPDK1fl/fl Vav-mice. (C) FACS profile of AML in PTENfl/flPDK1fl/flVav cre 




Similar to our previous finding where we transplanted PTENfl/flRosa-26cre-ERT 
cells, we observed that PTENfl/fl Vav-cre mice came down either with AML or T-
ALL. Moreover, again similar to the earlier Ros26Cre data, none of the 
PTENfl/flPDK1fl/fl Vav-cre mice only came down with ALL (Fig 4.28A). 
Together, these results support that finding that PDK1 might be important in loss 
of PTEN mediated T-ALL.  FACS analysis of the bone marrow, spleen, and liver 
of ALL mice showed infiltration of the bone marrow with lymphoid cells and in 
all cases, more than 50% the cells were positive for both CD4 and CD 8 





Figure 4.28 Development of ALL in PTENfl/fl Vav-cre mice. 
(A) Graph showing survival of mice that succumbed to ALL FACS profile of AML in PTENfl/fl Vav-






4.8 Loss of PTEN induced leukaemia may have arisen from the HSC 
compartment 
 
We have demonstrated that deletion of PTEN in haematopoietic cells led to myeloid 
proliferation that eventually developed to AML or ALL. To investigate the origin of 
the leukaemia in PTEN deleted in haematopoietic cells, we set up transplant using 
different fractions of haematopoietic cells. We administered tamoxifen (120 µl per 
day for five days) to induce cre activation in PTENfl/flRosa-26cre-ERT (CD45.2 
n=10). Next we isolated bone marrow cells post treatment and pooled together. We 
sort LT-HSC (Lin–/loSca1+c-Kit+CD150+CD48-), MPP (Lin–/loSca1+c-Kit+CD150-
CD48+), CMP (Lin–/loSca1–c-Kit+CD34+CD16/32lo) and GMP (Lin–/loSca1–c-
Kit+CD34+CD16/32hi) from the pooled cells. We transplanted 5x102 HSCs (Lin–
/loSca1+c-Kit+CD150+CD48-), 1x104 MPPs (Lin–/loSca1+c-Kit+CD150-CD48+) 1x104 
CMPs (Lin–/loSca1–c-Kit+CD34+CD16/32lo) and 1x104 GMPs (Lin–/loSca1–c-
Kit+CD34+CD16/32hi) together with 2X105 wild type cells (CD45.1) into lethally 
irradiated mice (CD45.1). We observed that only 1 out of 10 mice transplanted with 
HSCs came down with ALL (Fig 4.29A). None of the mice transplanted with MPPs, 
CMPs or GMPs came down with leukaemia. We sacrificed the mice at 20 weeks after 
transplant and discovered that our donor cells were no longer detectable in the bone 
marrow of mice transplanted with MPPs, CMPs and GMPs (Fig 4.29B).  Minimal 
percentage of donor cells was detected in some of the mice that received HSCs. These 
data suggest that deletion of PTEN affects the self-renewal of HSCs therefore 
resulting in stem cell depletion. The origin of leukaemia still remains to be elucidated. 
However, we suspect the leukaemia might have acquired secondary mutations that 
inactivate the senescence response of the few HSCs that remained. Yilmaz and 
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colleagues performed similar experiment, and they demonstrated that when they 
transplanted 15 Flk-2-Sca-1+Lin-c-Kit+CD48- (HSCs) into irradiated mice none of the 
mice came down with leukaemia. They further argued that PTEN deficient HSC were 
able to engraft and initially gave multi-lineage reconstitution, but by eight weeks after 
transplant, none of the mice retained multi-lineage reconstitution. Moreover, the level 





Figure 4.29 Origin of the PTEN deletion induced leukaemia.  
(A) Survival of mice after transplant with different fractions of PTEN deleted haematopoietic cells. (B) 











We have generated single and compound conditional knockout/KI mouse lines with 
PTEN and PDK1 as well as PDK1 mutants (PDK1 L155E MG with disrupted PDK1-
PIF pocket domain and PDK1 K465E a defective PDK1-PH domain) to investigate 
the role of PDK1 in PTEN haematological neoplasms. Understanding the 
consequences of loss of PTEN function at a molecular level and its contribution to 
leukaemia development are critical for cancer biology in general and for development 
of rational therapeutics in particular.  While several studies have reported that PTEN 
is one of the most frequently mutated tumour suppressor genes in human cancers (Guo 
et al., 2011, Fragoso and Barata, 2014); its mutation frequency in haematopoietic 
malignancy is relatively low when compared to other cancers (Denning et al., 2007, 
Chalhoub and Baker, 2009, Barata, 2011). Strikingly, PTEN mutations vary greatly 
in different haematological malignancies with around 2% of AML cases (Zeisig et al., 
2012) and 8-63% of paediatric T-ALL (Gutierrez et al., 2009, Medyouf et al., 2010).  
However, our mouse model shows that AML is more frequent than previously 
reported in PTEN deletion induced leukaemia.  Moreover, earlier studies using PTEN 
mouse models have clearly demonstrated a functional role for PTEN in normal and 
malignant haematopoiesis (Yilmaz et al., 2006b, Zhang et al., 2006). Yilmaz and 
colleagues demonstrated that 6 to 8 weeks old PTEN fl/fl Mx-1-cre mice developed a 
myeloproliferative disease that progressed to acute leukaemia development within 4 
to 6 weeks and exhausted the normal haematopoietic stem cell pool after activation of 
cre with pIpC treatment to delete of PTEN. 
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Similarly, we showed that PTEN deletion seems to preferentially favour the 
proliferation of myeloid cells over lymphoid cells.  It is tempting to speculate that the 
increased proliferation of myeloid cells may have led to development of AML. 
Interestingly, while we could not observe any significant changes in the proportion of 
T cells in the peripheral blood, some of the mice developed T-ALL, despite myeloid 
cell expansion in the peripheral blood suggesting that there could be an underlying 
expansion of T lymphocytes in other organs.  However, it is worth noting that some 
of these mice came down with both AML/ALL. The AML/ALL mice presented with 
different phenotypes of leukemic cells in different organs. We have demonstrated that 
the AML/ALL phenotype could present as AML in the bone marrow whereas the liver 
and spleen revelled a phenotype of ALL. We have shown earlier that deletion of PTEN 
may lead to expansion of CD4+ lymphocytes in the bone marrow (Fig 3.9A) therefore 
speculate that despite the expansion of only myeloid cells in the blood, expansion of 
T- lymphocyte in other organs might have led to development of ALL. We did not see 
an expansion of B-lymphocyte and none of the mice came down with B-ALL. B-cell 
malignancies have not been associated with PTEN deletion or mutation. Moreover, a 
recent study by Shojaee and colleagues demonstrated that, loss of one or both alleles 
of PTEN caused swift cell death of pre-B ALL cells. PTEN deletion was also adequate 
to rescue transplant recipient mice from developing B-ALL (Shojaee et al., 2016). 
Studies using conditional PTEN KO mouse crossed with a Vav-Cre model to generate 
PTEN null mice demonstrated that these mice develop fatal disease with a median 
survival of 82 days (Tang et al., 2013). They further reported that these mice displayed 
a hunched posture, respiratory distress, ruffled fur and weight loss. When the diseased 
mice were dissected, a large thymic mass accompanied by hepatosplenomegaly was 
observed and histological examination of the thymus revealed an infiltration of the 
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thymus by monomorphic lymphoblastic cells. The presence of leukaemic cells in 
organs such as spleen and liver has also been reported. Similarly, our experimental 
mice that succumbed to leukaemia when PTEN alone was deleted in the bone marrow 
had a latency of around 80 days and they also showed comparable symptoms i.e. 
hunched back and respiratory distress. Moreover, FACS analysis of these mice also 
revealed the infiltration of leukaemic cells in the spleen and liver (Fig 4.7B, and Fig 
4.8B). 
The most important finding in the aforementioned studies is that PTEN deletion 
induced leukaemia is dependent on the chronic activation of PI3K/Akt signalling 
pathway. PDK1 controls the activation of substrates such as Akt1 and mTOR1 which 
have been shown to be key regulators in cell metabolism, proliferation, migration and 
survival (Li et al., 2010).  Magee and colleagues compared the activation of Akt1 in 
HSCs/MPPs (CD48-LSK) from E14.5 foetal, 8 weeks old adult wild type bone 
marrow and 8 weeks old bone marrow after PTEN deletion from Mx1 Cre; PTENfl/fl 
mice. They showed that Akt was highly activated in PTEN deleted bone marrow 
compared to the normal bone marrow (Magee et al., 2012). These results suggest a 
different requirement for Akt activation during normal haematopoiesis and leukaemia 
development.  Akt is the main activator of the mTOR complex 1 and it has been 
demonstrated that inhibiting the mTOR complex1 with rapamycin (Sarbassov et al., 
2006, Guertin and Sabatini, 2007) rescued exhaustion of HSC and prevented 
leukaemogenesis upon loss of PTEN (Yilmaz et al., 2006b). Given their central roles 
within the PI3 kinase pathway, it is tempting to speculate that blocking the activation 
of Akt by inhibiting PDK1 could eliminate the development of LSCs and restore 
normal cell proliferation. 
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Interestingly when we conditionally deleted PDK1 alone, the PDK1 null cells failed 
to proliferate and died out in our transplant model suggesting that PDK1 has a critical 
role in cell survival and proliferation. Furthermore, we showed that simultaneous 
deletion of PTEN and PDK1 in the bone marrow impairs engraftment of PTEN null 
cells as demonstrated by a steady rate of proliferation (Fig 4.4A) suggesting a critical 
requirement for PDK1 in loss of PTEN induced proliferation. However, deletion of 
PDK1 was not sufficient to completely suppress PTEN induced leukaemia.  It delayed 
the onset of disease with some of the transplanted mice remained disease free beyond 
400 days. Biochemical testing of bone marrow cells from mice that succumbed to 
leukaemia when PTEN and PDK1 were deleted showed comparable   phosphorylation 
of AKT Thr308, AKT Ser473 as well as SGK1 Ser206 to transplant mice that came 
down when PTEN alone was deleted. In the contrast, we have also shown that before 
the development of leukaemia deletion of PDK1 in PTEN deficient cells completely 
inhibited the phosphorylation of AKT Thr308 suggesting that PDK1 may be bypassed 
during leukaemogenesis leading idiopathic activation of AKT Thr in the absence of 
PDK1. It is also worth noting that when both PTEN and PDK1 were deleted, we only 
observed AML but not ALL. PTEN deletion mediated leukaemogenesis may bypass 
the normal requirement of PDK1 for activation of downstream PI3K pathway 
enzymes as a mechanism of cancer cell survival and growth. Together our finding 
suggest that AKT Thr308 phosphorylation triggered at some point during 
development of leukaemia and it is not mediated by PDK1. AKT functions may not 
be required during normal haematopoiesis but may be a requirement for developing 
leukaemia stem cells.  
However, PDK1 cannot be ruled out as a key mediator of leukaemogenesis as its 
deletion completely cleared transplant mice from ALL and delayed latency of AML 
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induced by PTEN deletion. In another study using the Lck cre system which selective 
induces the deletion of PTEN alone or simultaneously deletion of PTEN and PDK1 
only in T-cell progenitors.  In these mice, the p56lck promoter mediates cre activation 
in T cell precursors at double negative (DN) 3 and 4 stage of lymphoid development 
before expression of the MHC receptor CD4 and CD8 (Finlay et al., 2009). It was 
reported that by deleting PTEN on its own the mice died of lymphoma in about 13 
weeks (Finlay et al., 2009).  Interestingly, when PTEN and PDK1 were deleted 
simultaneously in the lymphocytes, majority of the mice survived with no clinical 
symptoms of lymphoma (Finlay et al., 2009). Only a few mice with combined deletion 
of PTEN and PDK1 developed lymphoma and it was argued that the mice might have 
escaped the deletion of PDK1. Our experimental setup used a conditionally inducible 
Rosa-26cre-ERT system to induce deletion of PTEN and PDK1 in all of the 
haematopoietic cells after transplant. In contrast to Finlay and colleagues data, we 
showed that simultaneous deletion of PTEN and PDK1 did not induce T-ALL in 
recipient mice.  However, the majority of lymphoid cells that caused the disease in 
Finlay’s study originated from the earlier progenitors double positive population DP 
(CD45+CD25+). CD4+ and CD8+ lymphocytes were greatly reduced in 
PTENfl/flPDK1flflLck cre mice. Our data however showed that PTEN deletion in the 
bulk of the bone marrow resulted in T-ALL that was CD4+ and CD8+.  This difference 
could be due to the activation of the Cre in different stages of haematopoietic 
development.   
Surprisingly, mutations in PDK1 such as PDK1 MGK465 and PDK1 L155E 
disrupting the PH and PIF domain, respectively had little impact on loss of PTEN 
mediated cell proliferation. The PDK1 MGK465 mutation which does not allow the 
activation of Akt through PDK1 seemed to slightly delay the on-set of AML induced 
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by PTEN deletion, suggesting that Akt might play a role in leukaemogenesis. In 
contrast, the PDK1 L155 mutation which impairs the phosphorylation of S6K, SGK1 
and RSK does not have any significant impact on the onset of AML induced by PTEN 
deletion but showed a slight delay of ALL onset suggesting that other kinases such as 
S6K, SGK1 and RSK have little or no role in loss of PTEN induced AML while 
contributing to ALL. These results suggest that AML and ALL might have different 
requirement for PDK1 signalling.  In our mouse model, manipulation of PDK1 by 
introducing a mutation had no effect on activation of AKT Thr308 or SGK1 similar 
to what we observe with total ablation of PDK1 further supporting the speculation that 
PTEN deletion by passes the normal requirement for PDK1 to activate downstream 
effectors.   
Chalhoub and colleagues demonstrated that PTEN deficiency caused macrocephaly 
in mice whereas PDK1 deficiency resulted in microcephaly showing an antagonistic 
effect. Interestingly combined deletion of PTEN and PDK1 fully rescued the PTEN 
deficient macrocephaly. Similarly, PDK1 deficiency rescued cell-autonomous 
hypertrophy of PTEN deficient neuronal nuclei and somata.  However, the PDK1 
deficiency did not rescue cerebellar neuron migration in PTEN deficient brains.  
Taken together these results provide evidence that loss of PDK1 reverts many loss of 
PTEN phenotypes in normal and malignant development, suggesting that PDK1 might 
be a starting point in targeting PTEN deficient cancer. However targeting PDK1 on 
its own may not fully restore the spectrum of pathology induced by loss of PTEN as 
PDK1 could not prevent abnormal migration of cerebral neurons nor could it reduce 
the invasiveness of malignant T-cells (Iwanami et al., 2009, Chalhoub and Baker, 
2009).  More importantly, Cantrell and colleagues demonstrated that PTEN null 
lymphocytes can increase in size, proliferate and differentiate without PDK1. This 
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shows that targeting PDK1 alone may not be enough to rescue leukaemic cells which 
may by-pass the normal PDK1 requirements for cell growth and proliferation. One 
important question is whether Akt is still required for maintenance of leukaemic stem 
cells as previously suggested.  Several studies have shown that the expression of 
phosphorylated Akt is increased upon PTEN deletion (Lim et al., 2014, Cai et al., 








CHAPTER 5 PI3K/PDK1/AKT/PKC inhibitors 
 
5.1 Brief Introduction 
 
Targeting the PI3K signalling network has been shown to be of therapeutic value 
in the treatment of cancer (Fransecky et al., 2015). We have demonstrated earlier 
that loss of PTEN mediated leukaemogenesis can be delayed by simultaneously 
silencing PDK1.  Under normal condition, PDK1 is responsible for activation of 
downstream kinases such as AKT, SGK1, RSK and PCK. Noticeably, PDK1 is 
the only kinase known to phosphorylate AKT Thr308. While deletion of PDK1 in 
PTEN-/- cells did initially inhibit phosphorylation of downstream kinases 
including pAKT308Thr, AKT and few other substrates were subsequently 
phosphorylated when compound PTEN /PDK1 KO became leukaemic. This not 
only suggests that AKT Thr308 plays an important role in leukaemogenesis 
mediated by PTEN deficiency, but also demonstrates that leukaemic cells can 
bypass the normal requirement for PDK1 to phosphorylate and activate AKT 
Thr308. Crosstalk between PI3K and MAPK/ERK has been previously reported 
(Zhou et al., 2015, Mendoza et al., 2011). We therefore speculate that AKT 
Thr308 may be activated in response to PDK1 deficiency as a result of novel 
crosstalk with other pathways such as MAPK and ERK in leukaemogenesis. The 
kinase(s) responsible for the phosphorylation of AKT Thr308 in the absence of 
PDK1 has not been documented and remains completely unknown.  
To this end, we sought to set up an in vitro assay to pursue a candidate approach 
and also potentially a high throughput kinase inhibitor screen to identify the 
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kinase(s) that might be responsible for the observed phosphorylation of AKT 
Thr308. As PTEN and PDK1 deficient leukaemic cells do not grow very well in 
in vitro cultures, I decided to use mouse embryonic fibroblasts (MEFs) instead 
and investigated the effects of different inhibitors targeting different components 
of the PI3K pathway in  PTEN deficient MEFs and compound PTEN and PDK1 
deficient MEFs. We generated PTEN MEFs by setting up time matings with 
PTENfl/flRosa-26cre-ERT male and PTENfl/fl female. To produce compound 
PTEN and PDK1 MEFs, we set up time matings with PTENfl/flPDK1fl/fl Rosa-
26cre-ERT male and PTENfl/flPDK1fl/fl female. MEFs were harvested at E13.5 
days and cultured in DMEM medium supplemented with 10% foetal bovine 
serum. We allowed at least 3 passages before treating with 10 µM of tamoxifen 




Figure 5.1 Generation of PTEN and PDK1 null MEFs.  
Timed mating set up with PTENfl/flRosa-26cre-ERT male and PTENfl/flRosa-26cre-ERT to generate 
PTEN KO MEFs. Timed mating set up with PTENfl/flPDK1fl/flRosa-26cre-ERT male and 
PTENfl/flPDK1fl/flRosa-26cre-ERT female to generate compound PTEN and PDK1 KO MEFs. 
 
5.1.1 PDK1 inhibitor (GSK2234470) has no effect on AKT Thr308 
phosphorylation induced by PTEN deletion 
 
We have earlier demonstrated that AKT is phosphorylated at Thr308 in the 
absence of PDK1 in PTEN deficient leuakemic cells (Fig 4.12). To determine if 
we will obtain similar responses in wild type and PTEN KO MEFs, we used a 
PDK1 inhibitor (GSK2234470) mimicking the effects observed in PDK1 KO. 
Wild type and PTEN deleted MEFs were treated for 1 hour in vitro with increasing 
doses of the PDK1 inhibitor, and cell lysates were subsequently prepared and 
subjected to western blot.  As a result, at concentrations as little as 1.0 μM, the 
inhibitor completely inhibited the activity of PDK1 in the wild type MEFs as 
shown by loss of phosphorylation of AKT Thr308 (Fig 5.2A). Interestingly, 
PDK1 inhibitor did not impair the phosphorylation of AKT Thr308 even at the 
highest concentration tested (10 µM) in PTEN deleted MEFs (Fig 5.2B), strongly 
suggesting that deletion of PTEN bypasses the normal requirement for PDK1 to 
activate certain downstream effectors such as AKT Thr308 in the PI3 kinase 
pathway. As expected, the inhibitor did not have any effect on the phosphorylation 
of AKT Ser473, which is mediated by mTOR2 and therefore cannot be affected 
by inhibition of PDK1. Phosphorylation of SGK1 Thr256 was slightly reduced in 
wild type MEFs with doses from 5 µM to 10 µM, but there was no effect on PTEN 
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null MEFs, indicating that SGK1 may also be phosphorylated in the absence of 
PDK1 in the PTEN-/- background. 
 
Figure 5.2 Immuno-blotting of PDK1 down-stream effectors after treatment with GSK2334470 
PDK1 inhibitor.   
The indicated MEFs treated for 1 hour with GSK2334470 PDK1 inhibitor were lysed and subjected 
western blot with antibodies specific for the indicated down-stream effectors of PDK1. (A) Wild type 
MEFs treated with inhibitor. (B) PTEN deleted MEFs treated with inhibitor. (lane 1) DMSO; (lane 2) 
0.5 μM of inhibitor; (lane 3) 1.0 μM of inhibitor; (lane 4) 3.0 μM of inhibitor; (lane 5) 5.0 μM of 
inhibitor; (lane 6) 7.0 μM of inhibitor; (lane 7) 10.0 μM of inhibitor. 
5.1.2 AKT VIII inhibitor has no effect on phosphorylation of AKT Thr308 in the 
absence of PDK1 in PTEN deleted MEFs 
 
Phosphorylation of AKT at the activation loop (Thr308) is mediated by PDK1 through 
the interaction of the PH domain under normal conditions.  To test the possibility that 
activation of AKT Thr308 is mediated by interaction with residual PDK1 protein that 
could have remained after deletion or a conformational change in the folding of the 
AKT enzyme that may lead to auto phosphorylation, we used AKT VIII inhibitor, 
which is a reversible quinoxaline compound that potently and selectively inhibits 
Akt1/Akt2 activity. The inhibition activity of AKT VIII prevents the conformational 
chance of AKT and is PH domain depent therefore has no effect against PH domain-
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lacking Akts, or other closely related AGC family kinases, PKC, and SGK, even at 
very high concentration. Compound PTEN and PDK1 deleted MEFs as well as wild 
type MEFs (control) were treated for 1 hour in vitro with increasing doses of the AKT 
VIII inhibitor and cell lysates were subsequently prepared and subjected to western 
blot. We demonstrate that as little as 0.5 µM of AKT VIII inhibitor was able to inhibit 
the activity of AKT Thr308 in wild type MEFs whereas even at the highest 
concentration of this inhibitor tested (10 µM) did not impair the phosphorylation of 
AKT Thr308 in PTEN and PDK1 deleted MEFs (Fig5.3). These results further 
strengthen the idea that a kinase other than PDK1 may be responsible for the 
phosphorylation of AKT Thr308. As expected AKT VIII inhibitor did not show any 
effect on AKT Ser473, which is mediated by mTORC.  
 
Figure 5.3 Immuno-blotting of PDK1 down-stream effectors after treatment with AKT VIII 
inhibitor.  
Compound PTEN and PDK1 deleted MEFs as well as wild type MEFs (control) were treated for 1 hour 
in vitro with increasing doses of the AKT VIII inhibitor and cell lysates were subsequently prepared 
and subjected to western blot with antibodies specific for the indicated down-stream effectors of PDK1. 
(A) Wild type MEFs treated with inhibitor. (B) PTEN and PDK1 deleted MEFs treated with inhibitor.  
(lane 1) DMSO; (lane 2) 0.5 μM of inhibitor; (lane 3) 1.0 μM of inhibitor; (lane 4) 5.0 μM of inhibitor; 




5.1.3 PKC inhibitor (817) has no effect on phosphorylation of AKT Thr308 in the 
absence of PDK1 in PTEN deleted MEFs 
 
To further investigate the probable cause of phosphorylation of AKT Thr308 in the 
absence of PDK1 in PTEN null MEFs, we used a PKC inhibitor to test if the 
phosphorylation of AKT Thr308 could be a result of feedback loop mediated by PKC. 
Compound PTEN and PDK1 deleted MEFs as well as wild type MEFs (control) 
cultured in a six well plate were treated for 1 hour with increasing doses of the PKC 
inhibitor, and cell lysates were subsequently prepared and subjected to western blot. 
Interestingly, PKC inhibitor was able to impair the phosphorylation of AKT Thr308 
in wild type MEFs suggesting that it has anti PDK1 or AKT activity although directly 
targeting PKC. On the other hand, PKC inhibitor was not able to inhibit the 
phosphorylation of AKT Thr308 in PTEN and PDK1 deleted MEFs (Fig 5.4). These 
results suggest that PKC is unlikely the kinase that mediates the phosphorylation of 






Figure 5.4 Immuno-blotting of PDK1 down-stream effectors after treatment with PKC inhibitor 
(817).  
Compound PTEN and PDK1 deleted MEFs as well as wild type MEFs (control) were treated for 1 hour 
in vitro with increasing doses of the PKC-i inhibitor and cell lysates were subsequently prepared and 
subjected to western blot with antibodies specific for the indicated down-stream effectors of PDK1. 
(A) Wild type MEFs treated with inhibitor. (B) PTEN and PDK1 deleted MEFs treated with inhibitor. 
(lane 1) DMSO; (lane 2) 0.5 μM of inhibitor; (lane 3) 1.0 μM of inhibitor; (lane 4) 5.0 μM of inhibitor; 
(lane 5) 10.0 μM of inhibitor. 
 
 
5.1.4 PI3K inhibitor LY294002 completely inhibited the phosphorylation of AKT 
Thr308 in compound PTEN and PDK1 deleted MEFs 
 
We next tested the effect of PI3K inhibitor LY294002 on compound PTEN and PDK1 
deleted MEFs. LY294002 is a flavonoid derivative reversible inhibitor and has been 
shown to effectively target a wide range of kinases including all isoforms of PI3K. 
We cultured compound PTEN and PDK1 deleted MEFs in a six well plate, and treated 
with increasing doses of the LY294002 for 1 hr once they reached 90% confluence. 
Wild type MEFs were subjected to similar treatments. We observed a decreased 
phosphorylation of AKT Thr308 in wild type MEFs treated with 0.5 µM of LY294002 
inhibitor, and a complete inhibition was achieved with 1 µM. Interestingly, we also 
observed a reduction of phosphorylation of AKT Thr308 in compound PTEN and 
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PDK1 null MEFs treated with 0.5 µM of LY294002 inhibitor and a complete 
inhibition of AKT Thr308 phosphorylation with 1 µM of LY294002 comparable to 
what we observed in wild type MEFs (Fig 5.5). These results suggest that targeting of 
PDK1 together with PI3K or closely related kinases might be required for complete 
inhibition of AKT Thr308 in PTEN-/- cells. Noticeably, LY294002 also slightly 
inhibited the phosphorylation of AKT Ser473 at doses from 5 µM to 10 µM in 
wildtype MEFs and compound PTEN and PDK1 deleted MEFs, suggesting that it has 
effect on mTOR2 activity, which is known to directly activate AKT Ser473. 
 
Figure 5.5 Immuno-blotting of PDK1 down-stream effectors after treatment with Pi3K inhibitor 
LY294002.  
Compound PTEN and PDK1 deleted MEFs as well as wild type MEFs (control) were treated for 1 hour 
in vitro with increasing doses of the LY294002 inhibitor and cell lysates were subsequently prepared 
and subjected to western blot with antibodies specific for the indicated down-stream effectors of PDK1. 
(A) Wild type MEFs treated with inhibitor. (B) PTEN and PDK1 deleted MEFs treated with inhibitor. 
(lane 1) DMSO; (lane 2) 0.5 μM of inhibitor; (lane 3) 1.0 μM of inhibitor; (lane 4) 5.0 μM of inhibitor; 













5.1.5 PI3K inhibitor LY294002 could not completely inhibit the phosphorylation 
of AKT Thr308 in PTEN deleted MEFs 
 
We have shown earlier that targeting PI3K with LY294002 resulted in a complete 
inhibition of AKT Thr308 phosphorylation in PTEN and PDK1 deleted MEFs, 
suggesting that PI3K or closely related kinase sensitive to LY294002 might be 
responsible for the phosphorylation of AKT Thr308 in the absence of PDK1. We next 
would like to test if LY294002 could also successfully inhibit phosphorylation of 
AKT Thr308 when PTEN has been deleted but PDK1 is fully functional in MEFs. We 
set up and dose time response experiment by treating PTEN deleted MEF’ with 50 
µM of LY294002 for 10, 20, 30, 40 and 60 minutes. We demonstrate that LY294002 
partially inhibited the phosphorylation of AKT Thr308 when exposed to treatment for 
10 to 20 minutes (Fig 5.6). Interestingly phosphorylation of AKT Thr308 was 
regained at 30 minutes. The reappearance of phosphorylation could be a result of 
feedback that counteracts the effect of PI3K inhibition. These results suggest that 
targeting PI3K alone is not sufficient to counteract the constitutive activation of AKT 




Figure 5.6 Dose time responses of AKT Thr308 and AKT Ser473 after treatment with LY2942002 
inhibitor.  
PTEN deleted MEFs treated with 50 µM of LY294002 for 10, 20, 30, 40 and 60 minutes.  
 
5.1.7 Activation of AKT Thr308 may be dependent on both PI3K and PDK1 in 
PTEN deleted MEFs 
 
To test if the phosphorylation of AKT Thr308 is dependent on PI3K or PDK1 when 
PTEN is deleted, we set up a dose vs time response using PDK1 inhibitor 
(GSK2234470) after pre-treatment with PI3K inhibitor (LY294002). Firstly, we 
treated PTEN deleted MEFs with 50 µM of LY294002 for 30 minutes, then we 
aspirated the medium and replaced with fresh medium containing 1 µM of 
GSK2234470 for 10, 20, 30, 40 and 60 minutes. Interestingly, treatment with the 
PDK1 inhibitor after pre-treatment with LY294002 inhibited the phosphorylation of 
AKT Thr308 in the first 10 minutes. Phosphorylation was partially regained from 20 
to 30 minutes and fully regained post 40 minutes treatment (Fig 5.7). This suggests 
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that the combined effect of two inhibitors could potentially inhibit the phosphorylation 
of AKT Thr308 in PTEN deleted MEFs. The gradual regain of AKT Thr308 
phosphorylation could be due to recovery from the earlier exposure to LY294002, 
which is reversible upon removal of the inhibitor. Full phosphorylation of AKT 
Thr308 in the presence of PDK1 inhibitor also indicates that inactivation PDK1 is not 
sufficient to inhibit AKT Thr308 phosphorylation when PTEN is deleted in MEFs. 
We did not observe any effect on the phosphorylation AKT Ser473 in this 
experimental set up. 
              
 
Figure 5.7 Dose time responses of AKT Thr308 and AKT Ser473 pre-treated LY2942002 
inhibitor and treated with GSK2234470. 
PTEN deleted MEFs treated with 50 µM of LY294002 for 30 minutes and aspirated to replace with 





5.1.8 Dual treatment of PTEN deleted MEFs with LY294002 and GSK2234470 
inhibitors resulted in short term inhibition of AKT Thr308   
 
We have shown earlier that when we treated compound PTEN and PDK1 deleted 
MEFs with PI3K inhibitor (LY294002), we observed a complete inhibition of AKT 
Thr308 with doses below 10 µM. We further showed that pre-treating PTEN deleted 
MEFs with LY294002 and treating with PDK1 inhibitor (GSK2234470) successfully 
inhibited the phosphorylation of AKT Thr308 in the first 10 minutes. To further 
confirm the effect of dual inhibition of PI3K and PDK1 in PTEN deleted MEFs, we 
set up a dose time response by treating PTEN deleted MEFs with 50 µM of LY294002 
and 1 µM of GSK2234470. In contrast to the pre-treatment strategy, dual treatment 
with LY294002 and GSK2234470 completely inhibited the phosphorylation of AKT 
Thr308 in the observed time frame (10 to 60 minutes). Although low levels of AKT 
Thr308 phosphorylation might be regained past 60 minutes, these results suggest that 
combined treatment of LY294002 and GSK2234470 completely inhibits 
pAKT308Thr for at least 60 minutes.  
                  
Figure 5.8 Dose time responses of AKT Thr308 and AKT Ser473 after dual treatment with 
LY2942002 GSK2234470 inhibitor.  
PTEN deleted MEFs treated with 50 µM of LY294002 and 1 µM GSK2234470.  Analysis was carried 
out at 0, 10, 20, 30, 40 and 60 minutes. 
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5.1.9 Pan-PI3K inhibitor suppresses the activation of AKT Thr308 in PTEN 
deleted MEFs 
 
We have demonstrated earlier that the PI3K inhibitor LY294002 showed some 
effective short term inhibition of AKT Thr308 in the first 10 minutes of treatment. 
Moreover dual treatment with LY294002 and GSK2234470 exhibited very effective 
inhibition of AKT Thr308.  We next tested another PI3K inhibitor (NVP-BKM120) 
which is a pan-PI3K inhibitor capable of inhibiting all isoforms of class 1 PI3K 
(PI3Kα, PI3K, PI3Kβ, PI3Kδ, and PI3Kγ), as well as the individual isoform inhibitors. 
We treated PTEN deleted MEFs with 1 µM pan-PI3K inhibitor and 1 µM of each of 
the individual isoforms inhibitors (PI3Kα inhibitor, PI3Kβ inhibitor, PI3Kδ inhibitor, 
and PI3Kγ inhibitor) for 1 hour prior to preparing cell lysates. Interestingly, we 
observed that the pan-PI3K inhibitor greatly suppressed the phosphorylation of both 
AKT Thr308 and AKT Ser473 (Fig 5.9).  Surprisingly, the individual isoform 
inhibitors had no effect on the phosphorylation of either AKT Thr308 or AKT Ser473. 
The down regulation of AKT Ser473 suggests that the pan-PI3K inhibitor might also 
have effect on mTOR2 similarly to LY294002 inhibitor.  Together, these results 
suggest that a negative feedback loop involving multiple PI3K isoforms, mTOR2 or 
other related kinase might be responsible for the phosphorylation of AKT Thr308 in 




Figure 5.9 Immuno-blotting of PDK1 down-stream effectors after treatment with pan-PI3K 
inhibitors and isoform inhibitors.  
PTEN deleted MEFs with 1 µM pan-PI3K inhibitor and 1 µM of each of the individual isoforms 
inhibitors (PI3Kα inhibitor, PI3Kβ inhibitor, PI3Kδ inhibitor, and PI3Kγ inhibitor) for 1 hour prior to 
preparing cell lysates. Western blot analysis for AKT Thr308/Ser473 and SGK1 Thr256. (lane 1) 
DMSO; (lane 2) 1 µM of pan-PI3K inhibitor; (lane 3) 1 µM of PI3Kα inhibitor; (lane 4) PI3Kβ 
inhibitor; (lane 5) 1 µM of PI3Kδ inhibitor; (lane 6) 1 µM of PI3Kγ inhibitor. 
 
5.2 Analysis of AKT Thr308 activity using immunofluorescence in PTEN MEFs 
and wild type MEFs treated with PDK1 inhibitor 
 
To identify signalling mechanism and the kinases underlying the phosphorylation of 
AKT Thr308 in the absence of PDK1 in PTEN deleted cells, we reasoned that a high 
throughput kinase inhibitor screen may provide an unbiased and global search for such 
kinases/mechanisms.  Due to the complexity of the kinase inhibitor screen, western 
blot cannot be used to identify the potential hits and therefore immunofluorescence 
(IF) staining was to be developed for the screen. After demonstrating by western blot 
that the PDK1 inhibitor (GSK2234470) can effectively inhibit AKT Thr308 in wild 
type MEFs, I tested this PDK1 inhibitor also by IF. To this end, PTEN deleted and 
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wild type MEFs were seeded at 3x105 cells per well in a six well plate with gelatine 
coated round cover slips.  Treatment with 1 µM GSK2234470 (PDK1 inhibitor) was 
administered in half of the wells and the other left untreaded for 1 hour.  We analysed 
the cells growing over the cover slip for expression of AKT Thr308. We demonstrated 
that AKT Thr308 could be detected in both PTEN deleted MEFs and wild type MEFs 
(5.10A). As expected treatment with 1 µM GSK2234470 had no effect on AKT 
Thr308 phosphorylation in PTEN deleted MEFs whereas phosphorylation of AKT 
Thr308 was completely inhibited in wild type MEFs (Fig 5.10B). These results are 
consistent with our earlier experiments using western blot, indicating the validity of 





Figure 5.10 Immunofluorescence for AKT Thr308 and total AKT in PTEN deleted MEFs and 
WT MEFs. 
PTEN deleted and wild type MEFs were seeded at 3x105 cells per well in a six well plate with gelatine 
coated round cover slips.  Treatment with 1 µM GSK2234470 (PDK1 inhibitor) was administered in 
half of the wells and the other left unthreaded for 1 hour. (A) We demonstrate that AKT Thr308 could 
be detected in both PTEN deleted MEFs and wild type MEFs. (B) Treatment with 1 µM GSK2234470 
had no effect on AKT Thr308 phosphorylation in PTEN deleted MEFs whereas phosphorylation of 












Our genetic KO data showed that deletion of PTEN resulted in constitutively activated 
AKT Thr308 that could not be inhibited by deletion of PDK1, suggesting that the 
normal requirement of PDK1 for activation of AKT may be bypassed in the absence 
of PTEN. To support this data, we treated wild type MEFs with PDK1 inhibitor 
GSK2334470, and showed that we can completely inhibit phosphorylation of Akt at 
T308 but not at S473. Interestingly when we treated PTEN null MEFs with PDK1 
inhibitor GSK2334470, we could not inhibit the phosphorylation of Akt at T308 even 
with the maximum dose of 10 µM of the inhibitor, suggesting that PTEN deletion 
might trigger other pathways that might lead to phosphorylation of Akt independent 
of PDK1.  We tested AKT VIII inhibitor which selectively target AKT1 and AKT2 
with a mechanism of action dependent on the presence of the PH domain of the full-
length protein (Calleja et al., 2009). AKT inhibitor VIII targets the AKT inactive 
conformer preventing conformational change of AKT resulting in loss of AKT Thr308 
phosphorylation (Calleja et al., 2009).  We demonstrate that the AKT VIII did not 
have any effect on AKT Thr308 in PTEN and PDK1 deleted cells, suggesting that 
constitutive activation of AKT Thr308 in PTEN-/- cells is not attributed to 
conformational change and therefore rules out the possibility of auto phosphorylation 
or phosphorylation of AKT by residual PDK1. AKT VIII prevents the conformational 
change of AKT therefore preventing phosphorylatyion of AKT via the PH domain as 
well as auto phosphorylation.   The PKC inhibitor (817) did not have any effect on 
phosphorylation of AKT Thr308 ruling out the possibility of a feedback effect that 
might evolve PKC for the phosphorylation of AKT Thr308 when both PTEN and 
PDK1 have been lost.   
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Finally, we tested the PI3K inhibitor (LY294002) and showed that it was able to 
inhibit AKT Thr308 in compound PTEN and PDK1 deleted MEFs. Interestingly, the 
LY294002 showed slight inhibition of AKT Ser473 in compound PTEN and PDK1 
deleted MEFs treated with 10 µM of inhibitor, suggesting that the inhibitor may also 
have effect on mTOR2 which mediated the phosphorylation of AKT Ser473.  
However, LY294002 inhibitor failed to inhibit the phosphorylation of AKT Thr308 
when PTEN alone was deleted in MEFs. We further went on to test another PI3K 
inhibitor and specific PI3K isoform inhibitors. We showed that the specific isoform 
inhibitors (PI3Kα, PI3K, PI3Kβ, PI3Kδ, and PI3Kγ) had no effect on AKT Thr308 
phosphorylation. Intriguingly, the pan-PI3K inhibitor (NVP-BKM120) capable 
inhibiting all class 1 PI3K isoforms greatly inhibited AKT Thr308 as well as AKT 
Ser473 in PTEN deleted MEFs.  LY294002 and pan-PI3K inhibitor have effect on 
wide range of other kinases, and therefore it is inconclusive to pick PI3K as the kinase 
responsible for the phosphorylation of AKT Thr308 in the absence of PDK1. Together 
these results suggest that targeting of multiple different kinases is required for the 
successful reversion of the impacts by PTEN deletion.  
Previous studies have shown that the mTORC1 is an effector of the PI3 kinase 
pathway that promotes cell growth, proliferation and survival. It has also been shown 
that chronic stimulation of the mTORC1 leads to phosphorylation and down 
regulation of IRS1, which in turn impairs the activation of PI3 kinase as a negative 
feedback mechanism (Zhang et al., 2007, Sarbassov et al., 2005, Sabatini, 2006). 
Insight into signal transduction pathways over the past years have shown that no single 
pathway operates in isolation and that pathways are small parts of fully integrated 
networks within the cell (Manning and Cantley, 2007). Therefore it is conceivable a 
functional crosstalk of the PI3 kinase pathway with other pathways that might lead to 
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activation of Akt independent from PDK1 in PTEN deletion mediated cancer. The 
most common pathway known to have cross talk with the PI3 kinase pathway and also 
contribute to cell growth, proliferation and survival is the Ras/Erk/Mek pathway 
(Carracedo and Pandolfi, 2008).  The Ras/Erk/ Mek pathway has been shown to 
activate RSK and S6K1 as well as inhibit the TSC1/2 leading to the activation of 
mTORC1 (Chappell et al., 2011). More research including high throughout screen has 
to be done to investigate these crosstalk mechanisms that might contribute to cancer 












CHAPTER 6  
Conclusions  
 
The PI3K pathway has been associated with many cellular functions such as cell 
metabolism, cell growth, survival, proliferation and drug resistance. Substantial data 
suggest that the PI3K pathway is often perturbed in a number of haematological 
malignancies as well as other forms of cancers (Barrett et al., 2012). Targeting this 
pathway may be of therapeutic value in the treatment of haematological malignancy 
and cancer in general. Many drugs targeting different enzymes of the PI3K pathway 
have been designed and some of them tested in clinical trial (Dancey, 2010). Although 
promising results have been gathered on the effectiveness of these drugs, remission of 
cancer and drug resistance is always almost inevitable. The mechanism of cancer and 
resistance to drug is still not fully understood and therefore further insights need to be 
gathered. The main goal of my PhD was to investigate the role of PTEN and PDK1 in 
leukaemogenesis and normal haematopoiesis using mouse models where I can 
simultaneously delete PTEN and PDK1 in haematopoietic cells. To demonstrate the 
significance of PTEN and PDK1 in haematopoiesis, we showed that deletion of PTEN 
depleted normal haematopoietic stem cells and early progenitors. Simultaneous 
deletion of PTEN and PDK1 in haematopoietic cells was able to rescue some of the 
phenotype cause by PTEN deficiency strongly suggesting inhibition of PDK1 could 
be of therapeutic value in loss of PTEN mediated diseases. 
Loss of PTEN has been shown to cause constitutive activation of the PI3K pathway 
and in the case of haematopoietic cells leads to the development of cancer. We 
demonstrate that loss of PTEN in the haematopoietic compartment results in the 
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development of AML or ALL and in some cases both AML and ALL consistent with 
previous published data. We further demonstrated that ablation of  PDK1 in loss of 
function of PTEN in haematopoietic cells does not completely reverse the 
leukaemogenesis induced by PTEN deletion; however it was able to significantly 
delay the onset of AML. Moreover, deletion of PDK1 in PTEN deficient 
haematopoietic cells rescued the mice from developing ALL in both 
PTENfl/flPDK1fl/flRosa-26cre-ERT mice and PTENfl/fl PDK1fl/fl Vav-cre mice. 
We used distinctive PDK1 mutants to further elucidate the function of PDK1 in 
leukaemogenesis. We demonstrated that the PDK1 MGK465 mutation that disrupts 
the PH domain of PDK1 resulting in deficient activation of the AKT Thr308 slightly 
delayed the onset of AML in PTEN deleted haematopoietic cells and had no 
significant effect on the onset of ALL. On the other hand, the PDK1 L155 mutation 
that disrupts the PIF pocket resulting in deficient activation of S6K, RSK, SGK and 
PKC showed slight delay in the onset of ALL while it had no significant effect on the 
onset of AML. These results signify the importance of PDK1 as a target in the 
treatment of PTEN deletion induced leukaemogenesis. In addition, our data show that 
AML and ALL might have different requirements for downstream PDK1 targets and 
therefore it is important to understand the biology of the underlying pathway 
dysregulation in these conditions in order to decide on the treatment to use in a given 
disease.  We hypothesize that the leukaemia that develop in the absence of PDK1 
when there is loss of PTEN may have resulted from the bypassing the normal 
requirement of PDK1 to activate downstream targets. We use MEFs deficient for 
PTEN or deficient for both PTEN and PDK1 to investigate the underlying mechanism 
for the phosphorylation of AKT Thr308 in the deficiency of PDK1. We demonstrated 
that inhibitors such as LY294002 that target multiple kinases in combination with 
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inhibition of PDK1 are more efficient in inhibiting the phosphorylation of AKT 
Thr308.  These results suggest targeting multiple kinase maybe the best approach to 
prevent drug resistance due to feedback or bypassing of the targeted kinase by other 
mechanisms. PIK3K pathway was previously shown to crosstalk with other pathways 
such as MAPK and ERK/Ras pathways which may contribute to the bypassing of 
PDK1 in PTEN deficiency.  An important future step will be to carry out a high 
throughput kinase inhibitor screen to narrow down the kinases that might be 
responsible for the phosphorylation of AKT Thr308 in the absence of PDK1 when 
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